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Summary 
 
The aim of this thesis was to investigate the impact of the Managed Clinical 
Network (MCN) for colorectal cancer in the West of Scotland on outcomes for its 
patients. The alternative hypothesis was that greater changes to patient 
outcome had occurred over time than those that would have been expected in 
the absence of a Managed Clinical Network service structure. 
 
The study was a retrospective cohort study merging locally derived clinical audit 
and nationally held Cancer Registry datasets. This facilitated a comprehensive 
examination of patient characteristics and survival outcomes in varied cohorts of 
patients suffering from colorectal cancer in the West of Scotland.  
 
I employed longitudinal, cross sectional, univariate and multivariate methods of 
data analysis. Following a review of the current literature a baseline 
demographic summary of the population was produced. This allowed an 
examination of temporal changes in both survival and practice in the region in 
order to evaluate the key determinants underpinning differences before and 
after the inception of the new service structure. I went on to study specific 
aspects of patient management on outcome including effects of surgeon 
specialisation, effects of mechanical bowel preparation on short and long term 
outcomes and degree of equity of surgical provision for patients with rectal 
cancer. These aspects of care are thought to be measures of quality in patients 
with colorectal cancer and could be influenced by the inception of a Managed 
Clinical Network 
 
Evaluation of the current literature regarding effects of Managed Clinical 
Network on outcomes for colorectal cancer patients demonstrated a paucity of 
studies investigating our alternative hypothesis. 
Overall it appears that the introduction of the MCN has lead to improvements in 
survival for particular groups of patients only. We analysed the records of 37,890 
colorectal cancer patients in the West of Scotland over a 25-year period and 
confirmed expected proportions of colonic to rectal lesions as well as equal sex 
distribution. We also report a higher ascertainment for data regarding Dukes’ 
stage when compared to other published series. 
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Trends in relation to volume of work undertaken by surgeons on colorectal 
cancer patients in the West of Scotland demonstrate that there was increasing 
specialisation over the period under study. This is evidenced by the increase in 
proportion of resections performed by higher volume surgeons and is 
encountered in both colon and, to a lesser extent rectal cancer surgery. It seems 
that increasing specialisation has had resultant effects on overall survival for 
colon cancer patients but not for rectal cancer patients thus far. 
 
With regard to specific aspects of patient care we were able to show that 
specialisation has increased with time in our region and that mechanical bowel 
preparation has no effect on either immediate or long-term outcome in patients 
undergoing surgery for colon cancer. We also showed that in the West of 
Scotland we provide a surgical service to rectal cancer patients that is unbiased 
with regard to sex and degree of socioeconomic deprivation. This contrasts to 
previous findings in England. 
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1 Introduction and Literature Review 
Specialist care is associated with better survival from cancer.  This observation, 
along with evidence of geographical inequities in the quality of cancer care led 
to reorganisation of cancer services into Managed Clinical Networks throughout 
the United Kingdom, which began in the late 1990s.  However, there is a lack of 
evidence that the reorganisation of services has resulted in either improvements 
in survival or a reduction in inequities of care, over and above those that would 
have occurred without reorganisation.  Colorectal cancer is the second most 
common cause of cancer deaths in the United Kingdom and much of the 
evidence that led to service reorganisation came from analyses of colorectal 
outcomes.  The aim of this thesis is to describe the impact of Managed Clinical 
Networks on colorectal cancer outcomes in the West of Scotland.  However, 
before any evaluation of the effects of service reorganisation can be made - 
either temporally or geographically – other potential confounding factors that 
affect colorectal cancer survival need to be taken into account.  These include 
patient characteristics, such as demographic and socio-economic factors, and 
disease factors, such as cancer site and stage.  The West of Scotland has a high 
incidence of colorectal cancer, diverse socio-economic conditions, and high 
quality clinical information systems that make it useful for understanding 
determinants of cancer outcomes.   
This chapter begins by describing colorectal cancer care in the context of the 
West of Scotland.  A review of literature on the effects of patient and disease 
factors is then presented.  Next, the effectiveness of the major treatment 
modalities is reviewed.  Lastly, a review of literature on specialist care is made.  
This explores definitions of what constitutes specialist care and includes a 
systematic review of literature on the impacts of Managed Clinical Networks on 
patient outcomes. 
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1.1 Colorectal Cancer and its care in the West of Scotland 
Background to development of managed cancer services in Scotland 
 
Inevitably when development of cancer services in Britain is considered, the 
Calman-Hine report is cited. It is widely regarded as the piece of work that lead 
to the restructuring of cancer services in England from 1995 (7). The report 
followed 20 years of similar restructuring of cancer services in other countries.  
It was in 1974 though that Sweden took the lead when their Minister for Health 
introduced a care programme for cancer (SNAP 1996). In Denmark, a prototype 
version of the current SIGN guidelines for breast cancer has been in use since 
1977. The Dutch and Americans have been using cancer care systems 
implemented as far back as 1995 (8). The fact that both Calman and Hine had 
backgrounds in cancer and with patient groups meant they were acutely aware 
of the needs of both service providers and potential service users.      In England 
and Wales the Calman Hine report produced the initial impetus for reforms in 
cancer services (7). Although it was neither specific nor outlined any objective 
way of measuring improvement in cancer services, it led to a shift toward 
integrated cancer services. It was followed by a Scottish version less than a year 
later (Scottish Office Department of Health 1996) that outlined seven principles 
for integrated cancer care services throughout Scotland (see extract below). A 
review commenting on the evidence base for this reform followed the report (9). 
It outlined a broad scope for the reform and highlighted the differences in 
outcomes for patients suffering from different cancers. Emphasis was placed on 
the growing body of evidence for organised networks producing better outcomes 
although the authors recognised the disparity between different types of cancer. 
A further project in East Anglia agreed with the Selby review. It supported the 
Calman-Hine strategy but recognised that certain cancers were in need of 
priority change as opposed to an overhaul of all cancer services (10). 
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EXTRACT FROM A POLICY FRAMEWORK FOR COMMISSIONING CANCER 
SERVICES 
 
GENERAL PRINCIPLES 
The principles which should govern the provision of cancer care are: 
 
All patients should have access to a uniformly high quality of care in the 
community or hospital wherever they may live to ensure the maximum 
possible cure rates and best quality of life. Care should be provided as close 
to the patient’s home as is compatible with high quality, safe and effective 
treatment. 
 
Public and professional education to help early recognition of symptoms of 
cancer and the availability of national screening programmes are vital parts 
of any comprehensive programme for cancer care.  
 
Patient, families and carers should be given clear information and assistance 
in a form they can understand about treatment options and outcomes 
available to them at all stages of treatment from diagnosis onwards.  
 
The development of cancer services should be patent centred and should 
take account of patients’, families’ and carers’ views and preferences as 
well as those of professionals involved in cancer care. Individuals’ 
perceptions of their needs may differ from those of the professional. Good 
communication between professionals and patients is especially important.  
 
The primary care team is a central and continuing element in cancer care 
for both the patient and his or her family from primary prevention, pre-
symptomatic screening, initial diagnosis, through to care and follow up or, in 
some cases, death and bereavement. Effective communication between 
sectors is imperative in achieving the best possible care. 
 
In recognition of the impact that screening, diagnosis ad treatment of 
cancer have on patients, families and their carers, psychosocial aspects of 
cancer care should be considered at all stages. 
 
 Cancer registration and careful monitoring of treatment and outcomes are 
essential. 
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With these principles in mind, clear roles were set out for the first time in 
Scotland for interregional, regional, local and hospital-specific members of 
cancer centres. 
 
The aforementioned framework reform was in response to the United Kingdom 
National Health Service Cancer Services Collaborative / Improvement 
Partnership. 
 
The Cancer Services Collaborative programme commenced in 1999, before the 
publication of the National Health Service Cancer Plan. It built on the pioneering 
approach to service improvement developed by Don Berwick and colleagues at 
the Institute for Healthcare Improvement in the USA. In essence the Cancer 
Services Collaborative is applying lessons learned about process re-engineering in 
industry to the context of cancer care. It provides the model through which the 
principles from process re-engineering manifest in hospital medicine. It is then 
hoped that application of these principles will translate into improved quality of 
care and outcomes (11). 
 
The principles were to initiate a paradigm shift in three ways. Firstly, the overall 
organisation of services would move from being general to specialised. Secondly, 
patients would be referred to specialists directly. It was envisioned that this 
would provide more uniform access for patients (12). Finally, to facilitate a 
more streamlined management plan the clinicians who previously were more 
autonomous would work within a multidisciplinary model of care (8). This, it was 
hoped, would make optimal use of resources resulting in optimal benefit to 
patients in terms of outcomes. 
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The following figure represents the points in the patient journey where the MDT 
is thought to exert an effect. 
 
Figure 1 - Points of Influence of the MDT process 
 
 
 
Figure adapted from Freeman and Chu (13). 
 
Before drawing conclusions from the population as a whole it is important to 
have a degree of understanding of the pathological processes leading to 
development of colorectal cancer. A grasp of the current prognostic indicators is 
also important to allow us to draw sensible conclusions from results. 
 
Within each region are a number of Health Boards. Within each Health Board are 
a number of MDTs. Using the West of Scotland as an example, there are a total 
of 11 MDTs operating in five Health Boards, covering 17 hospitals. This ranges 
from one MDT in the smallest three Health Boards to six MDTs in the largest (14). 
The population of the West of Scotland numbers 2,488,000. The Greater Glasgow 
and Clyde Health Board covers 1.2million people (15). 
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Managed Clinical Networks and Multi-Disciplinary Teams 
 
There is a continuing body of evidence to support the treatment of colorectal 
cancer in high volume institutions where specialist colorectal surgeons are 
available (16). The impact of MCNs has been described for various conditions and 
locations outside the West of Scotland so a full assessment of the effects of 
treatment for colorectal cancer in all units in the West of Scotland is wanting 
(17,18).  
 
Published data regarding the management of colorectal cancer throughout 
Europe (EUROCARE) resulted in Scotland fairing badly when compared to its 
European neighbours in terms of survival outcomes (19). This review of current 
literature provides an opportunity to explore more fully the impact that the 
Calman-Hine report has had in the West of Scotland with regard to colorectal 
cancer. 
 
This review of current literature attempts to answer 4 questions:  
 What is the current structure of MCNs with regard to colorectal cancer?  
 Are they effective?  
 What is known about the effects of either MDTs or MCNs on the outcomes 
of patients with colorectal cancer? 
 What is known about the effects of specialisation and volume on outcome 
for colorectal cancer patients? 
 
  
In order to manage effectiveness there generally has to be objective evidence to 
facilitate comparison between groups. Various papers report on whether or not 
recommendations are followed up or adhered to. These are usually in relation to 
guidelines or therapies (20). Measuring outcome following this (e.g. survival) 
remains less well reported. 
 
Previous work evaluating impact of the MDT on patient survival in lung cancer 
patients demonstrated encouraging results (21). However, this was a single-
centre experience and was not reporting on effects of a larger MCN setup. It is 
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hoped that larger networks should be able to replicate the outcomes of a single 
MDT.  
 
Objective measures of outcome are generally sought to provide a means of 
comparison between populations. They are also widely employed and quoted for 
the purposes of audit thus upholding one of the tenets of Clinical Governance. In 
relation to colorectal cancer, 5 year survival is currently the gold standard 
objective measure (22). Any further attempts to tease out the weight added by 
each component of the MCN and MDT to patient survival outcomes increases the 
complexity of analysis. In the initial few years following Calmanisation articles 
relating to MCNs tended to be single centre reports or editorials with no 
objective, thus comparable, outcomes (17,23). MCN and MDT performance are 
thought to influence patient outcome positively so various attempts have been 
made to assess this in an objective way. 
Most recently and most comprehensively, Hong and co-workers performed a 
wide-ranging literature review examining the potential relationship between 
multidisciplinary care and patient survival (24). Despite identifying 12 of 21 
studies for review reporting statistically significant associations between MDT 
care and patient survival, only three of these were in colorectal cancer patients. 
The heterogeneity of study methodology and range of outcomes measured meant 
that a meta analysis was not possible. Only one study provided a before-after 
comparison in colorectal cancer patients. This study was limited to a single 
surgeon in a single hospital (25). Their final conclusion was that for all cancers, 
a causal relationship linking MDT care with improved patient survival could not 
be affirmed. 
 
The factors that may affect outcome of cancer care can be divided into three 
categories. Firstly, patient characteristics. Secondly, characteristics of the care 
providers and thirdly, the structure of the care system. Table 1 summarises the 
areas where differences between hospitals or MDTs can arise. It is the aim of the 
NHS and cancer reform strategies to minimise these differences thus creating a 
service with equitable entry, treatment, and long-term outcome for all 
colorectal cancer patients. We are currently able to assess many of the patient 
characteristics. It would be additionally advantageous to measure co-morbid 
conditions.  
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Most consultants operating on colorectal cancer patients in the West of Scotland 
are declared specialists. The only exception to this is when an emergency 
resection is required. A further level of complexity is added when one considers 
that often there is more than one hospital contributing cases to a single MDT 
forum. 
 
Table 1 - Factors that may affect access to and outcomes from colorectal cancer care 
services 
Patient characteristics Health care provider 
characteristics 
Structure of the care 
system 
Clinical – tumour stage 
and tumour morphology 
Case volume MDTs 
Co-morbid conditions Experience, training / 
certification 
Case volume 
Socio-economic status  Type – teaching vs. DGH 
Age, sex, race Age, sex, race 
 
Location – urban vs. rural 
Educational background  Facilities / design 
Healthcare beliefs, 
attitudes, practices 
 Hospital characteristics 
 
  Type and number of staff 
  Quality assurance 
programme 
Adapted from table 3 in (5) 
 
 
Methods of measuring outcome 
 
It should be noted that long-term outcomes can be assessed by regular follow-
up. Strategies for this have been recently assessed but opinion remains divided 
in the field of colorectal surgery as to what represents an optimum follow-up 
strategy for colonic and rectal cancer patients. There remain several unresolved 
issues that lie outside the scope of this thesis (26).  
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An early attempt at measuring MDT performance in 2002 demonstrated that 
although MDT activity was widespread for colorectal cancer, a wide variation 
existed regarding its full implementation (27). Various problems were described 
therein. The authors’ main conclusion was that a dedicated MDT clerk is 
essential to ensure smooth running of MDTs. The main drawback of this study is 
that it was a questionnaire. The vast majority of MDTs in the West of Scotland 
now have dedicated MDT clerical support staff, in line with QIS.  
 
The most comprehensive report on outcomes in British colorectal cancer 
patients so far comes from Yorkshire (28). Morris et al also concluded that there 
is a variable extent to which Calman-Hine recommendations have been 
implemented. They employed the Kelly et al questionnaire approach to assessing 
growth of MDTs and their adherence to national criteria for the ideal team. This 
was done over a far wider population though. They then improved upon the Kelly 
approach by employing multilevel binary logistic regression models to their 
population based longitudinal study (n= 11548). They concluded that where 
institutions had followed Calman-Hine recommendations (i.e. had more surgical 
site specialisation), there was evidence of increased use of preoperative 
radiotherapy and increased proportion of anterior resections in rectal cancer 
patients     
 
The paradigm shift in cancer care brought about by the Calman-Hine report 
should have affected public awareness. Whether or not this evolution would 
have happened without Calmanisation will never be known. For now though, we 
are concerned with ascertaining what definite changes in outcome have 
occurred since its inception. 
 
An in depth analysis on a par with that performed by Morris and co-workers is 
wanting in Scotland. This would not only provide an almost direct comparison 
with their work but it would offer a unique glimpse into the current performance 
of the MCN for colorectal cancer and outcomes for its patients. This then 
provides a benchmark for future studies in Scotland, where a separately 
managed healthcare system exists compared to England. 
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Effective MDT working has various requirements. Leadership and team dynamics 
are considered imperative for the MDT to function optimally. Administrative 
support has also been highlighted in the past as an essential element in the 
smooth operation of an MDT. Protected time is a further issue that has been 
highlighted. Many MDTs operate over lunch hours, with no timetable slot 
devoted to the important decisions being made regarding patient management. 
Funding is the essential element that provides all of the aforementioned 
requirements. Under funded units will find it hard to adequately staff and 
resource an MDT that is to function optimally. 
 
Certain aspects of the MDT are inherently harder to measure. Nonetheless they 
have been suggested as influencing the team dynamic and therefore potentially 
influencing patient outcome. These include more psychological and sociological 
areas such as communication between health professionals, job satisfaction, and 
psychological well-being of team members and patients alike. It is difficult to 
ascertain whether changes in these parameters translate into improved patient 
outcome. 
 
On the other hand, there are more objective measures in the MDT environment 
that can act as benchmarks from which to compare performance. These 
encompass clinical outcomes, preoperative assessment, and recruitment into 
clinical trials. Frequency and results of audit remain important too. The 
following points summarise the aims and outcomes of the National Cancer Peer 
Review Programme 
 
The National Cancer Peer Review Programme aims to improve care for people 
with cancer and their families by: 
 Ensuring services are as safe as possible  
 Improving the quality and effectiveness of care 
 Improving the patient and carer experience  
 Undertaking independent, fair reviews of services  
 Providing development and learning for all involved  
 Encouraging the dissemination of good practice 
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The outcomes of National Cancer Peer Review Programme are: 
 Confirmation of the quality of cancer services 
 Speedy identification of major shortcomings in the quality of cancer 
services where they occur so that rectification can take place  
 Published reports that provide accessible public information about the 
quality of cancer services 
 Timely information for local commissioning as well as for specialised 
commissioners in the designation of cancer services  
 Validated information which is available to other stakeholders 
 
Taken from www.cquins.nhs.uk (29). 
 
As previously mentioned, the gold standard objective measure of outcome for 
colorectal cancer patients is survival at five years. There are currently no 
published data demonstrating an improved survival following treatment for 
colorectal cancer in an MDT. The most encouraging results to point towards this 
come from Paisley. MacDermid et al recently published outcomes on a series of 
patients who have an increased survival having been treated in an MDT versus 
those who have not been treated in an MDT. They looked only at the effect of 
chemotherapy and not at the entire MDT management process (25). Ideally, a 
before and after MDT comparison should be made. This is the case for a 2006 
study by Stephens et al. They compared a group of 77 oesophageal cancer 
patients from 1991-1997 i.e. pre-MDT to a group of 67 MDT managed patients 
between 1998 and 2003 (30). They found the most important predictors of 
increased survival to be MDT management, lymph node metastases and ASA 
grade. The operating surgeon was not found to be significant. They did not 
adjust for the year of incidence. 
 
McCarthy et al provide evidence of improvements in 1 year survival for breast 
and colorectal cancer in an MDT environment. Their wide-ranging study of 
compliance to current MDT standards revealed that compliance with certain 
tumour-specific clinical guidelines and cancer quality standards translated into 
survival gain at one but not five years. This was not the case for general 
standards relating to service coordination and service provision (31). 
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Recording of data 
 
Quality outcome measures rely upon the completeness and quality of the original 
patient data. The data from the MCN represent a rich source of information on 
emerging and evolving practice patterns. 
  
Ideally the precise objective measures used to produce the most meaningful 
results would guide the type of information collected. In the pragmatic world 
however, the situation is more likely to be that we tailor the outcomes measures 
to the available data. In essence we have to make do with what we have. 
 
As will be outlined in the methods section, merging local West of Scotland MCN 
audit data with centrally held death records and Scottish cancer registry data 
created a novel dataset. Firstly, however, it is important to understand the 
origins of these data and how they are recorded, as the process of data 
collection and collation in itself is relatively new. 
 
Managed Clinical Networks 
 
Managed Clinical Networks (MCNs) have been variously described. A generally 
held definition is that they represent linked groups of health professionals and 
organisations from primary, secondary and tertiary care, working in a co-
ordinated manner, unconstrained by existing professional and Health Board 
boundaries, to ensure equitable provision of high quality clinically effective 
services throughout Scotland (32).  They aim to reduce the critical disconnect, 
cited as existing between the development of treatments and their translation 
to patients with colorectal cancer. Collaboration exists at different levels. 
Firstly, between government and the profession as a whole. Secondly between 
government and those who set the standards that MCNs are to achieve. Thirdly, 
between the standard setters and the managed networks themselves. The 
advantage of these various collaborations is that information is shared across a 
large population base affecting a maximum number of patients. Similarly, the 
network audit process enables far more detailed research to be conducted with 
far more numbers than would have been possible previously. A main 
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consideration is how much of this is translated into clinical practice in order to 
improve patient outcome. 
 
The following figure highlights where the critical disconnection lies. 
 
Figure 2 - Schematic representing the perceived point of critical disconnection 
between development of treatments and translation into patient benefit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Chu and Freeman in (33). 
 
MCNs were first introduced as a result of a Scottish Executive medical executive 
letter (MEL) in 1999(32). At that point there were pre-existing networks in the 
Highlands and Islands as well as the diabetes network in Tayside. The label MCN 
was therefore introduced as an umbrella term for similar collaborations spanning 
the NHS whilst including the existing units. Existing services considering 
themselves as functional MCNs sought formal approval from their local Trust and 
Health Board. 
This contrasted to the implementations in England and Wales where the 
centralised Cancer Centre model was adopted. Both models were introduced to 
DISCOVERY 
DEVELOPMENT 
DELIVERY 
CRITICAL 
DISCONNECTION 
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be more functional with regard to spread of population and location of services 
throughout their respective countries. 
The overhaul of cancer services was underpinned by a set of principles. It was 
agreed that MCNs should have a set of principles to comply with too. These are 
contained within the MEL (32).   
 
The need for a uniform set of standards was addressed by the Clinical Standards 
Board for Scotland (CSBS). They were also responsible for developing the key 
clinical and organisational performance indicators relevant to the service. The 
CSBS was responsible for developing minimum clinical standards for the 
management of the common cancers. The colorectal cancer standards were 
published in January 2001 but have now become part of Quality Improvement 
Scotland (QIS). The latest set of Clinical Standards were published in March 2008 
(34). 
 
A further HDL in 2002 re-stated the commitment of the executive to MCNs in 
terms of both funding and regular review. They were to draw on experiences to 
date and implement any necessary change. Focus was made on 11 key areas 
where clarification of roles was needed. These ranged from patient involvement 
to assistance available from the Health Department (35). 
 
By their very nature and concept, MCNs are flexible and dynamic entities. They 
have been created for maximising patient care worldwide in areas ranging from 
home parenteral nutrition (HPN) and paediatric liver disease to cardiac services, 
breast cancer and paediatrics (18,36-38). MDTs for patients with learning 
disabilities have been around since at least 1983 (39). A formal preliminary 
evaluation of the development of cancer networks was published in 2002. This 
described swift organisational change within the NHS with regard to Cancer 
Services. It was confined to England and further limited by response rates as low 
as 33% to the survey questionnaire (40).  A commentary on the survey remarked 
that it appears that implementation of the ground-breaking Calman-Hine report 
has been patchy, incoherent and incomplete (41). With this in mind it seemed 
more sensible to base further studies on objective measures at the MDT level 
before attempting to evaluate MCN function. 
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Current Structure 
 
In Scotland there are currently three regional colorectal MCNs, namely the West 
of Scotland Cancer Network (WOSCAN), North of Scotland Cancer Network 
(NOSCAN), and South East Scotland Cancer Network (SCAN). The concept of 
coordinated care is promoted by each of these MCNs. Submission of all cases of 
colorectal cancer to MDT review is now considered mandatory but variation in 
attendance and process between MDTs still occurs despite their inception more 
than eight years ago. Most recent reports suggest continued heterogeneity across 
our region in terms of MDT coordinators, oncologists and clerical or audit staffing 
(42). It is the role of each MCN to audit this. 
 
Variation in and reorganisation of rectal cancer services 
 
A growing body of evidence exists to suggest significant variation in the type of 
rectal surgery performed across England and Wales (43-45). This variation has 
also previously been demonstrated to affect outcome (46). To date, this has not 
been investigated in any entire regional population. 
A number of important studies provide relevant background to this piece of work 
as well as prompting numerous research questions and potentially influencing 
further reform of surgical service provision. There have been numerous 
important series pertaining to quality of rectal surgery and outcome published in 
the last six years. Two large retrospective population-based analyses highlight 
the large variation in ratio of APE to AR in the UK, following examination of a 
huge population of rectal cancer patients numbering 83,866 (43-45). They point 
to a decrease in APE with time and a statistically significant likelihood of 
receiving an APE for rectal cancer if the patient is male and / or 
socioeconomically deprived. Morris and co-workers also comment on the 
significant variation in type of major resection used between individual surgeons 
and hospital trust. This is independent of case-mix. 
 
A prospective, randomised controlled trial looking at outcomes in rectal cancer 
patients in Holland quotes an improvement in survival for AR patients of 19.1% at 
seven years compared to APE (p = 0.008). They do not state if survival is overall, 
relative, or cause specific. They also state that 30.4% of APE patients had 
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positive circumferential margins compared to 10.7% in the AR group (p=0.002)  
(47). An advantage of their study is that they report results with tumours divided 
into different groups according to the tumour height from the anal verge. This 
very useful information is omitted from other major studies.   
A large descriptive multicentre study of 1036 patients looks in particular at 
circumferential margin involvement (CMI) in restorative (i.e. AR) and non-
restorative (i.e. APE) procedures (48). The conclusion is that APE is associated 
with a significantly higher CMI than AR. 
 
Marr et al have also published data regarding a series of 561 rectal cancer 
patients demonstrating a statistically significant 11% reduction in cancer specific 
survival for patients undergoing AR compared to APE. Whilst affirming previous 
results from Tekkis et al regarding higher rates of CMI in APE patients, they also 
state that APE patients have a higher rate of local recurrence (LR). Their results 
stated a LR rate of 22.3% in APE patients versus 13.5% in AR patients, (p = 0.002; 
cancer specific survival 52.3% versus 65.8%, p = 0.003). There is however no 
mention of assessment of the case mix between the two groups under study. 
This could potentially explain some of the differences found (49). 
 
 The final important study in recent years is a prospective observational national 
cohort study involving 2136 rectal cancer patients and their oncological 
outcomes when comparing APE with AR for resections in the lower rectum. The 
main aim was to be able to select patients that would be suitable for 
radiotherapy (50). They examined various putative negative prognostic 
indicators concluding that if surgery is optimised; preventing intraoperative 
perforation and involvement of the circumferential resection margin, the 
prognosis for cancers of the lower rectum seems not to be inherently different 
from that for tumours at higher levels. 
 
Rates of APE are slowly dropping with time in England, Canada and mainland 
Europe  but there remains concern that some surgeons may still overuse this 
procedure thus resulting in some patients not only receiving an avoidable 
colostomy but also undergoing a more deforming operation (43)(51,52). Overall 
rates in the West of Scotland have not yet been ascertained to compare to 
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English figures (7). We aimed to perform this comparison, both with previous 
published data and nationally agreed standards. 
 
Since 1995 the UK Government has undertaken wide scale reform of UK cancer 
services to ensure a ‘‘high quality of cancer care for all’’ and improve cancer 
survival in the UK (7). Quantifying and addressing variations in surgical practice 
is a key component in trying to achieve this. The Department of Health has 
published guidance stating that, wherever possible, surgeons should try to 
ensure anal sphincters are preserved (53). 
 
Recently, there has been a growing appreciation of the importance of 
undertaking national comparative audit to monitor performance and outcomes 
across the NHS and realisation of the potential for routinely available health 
datasets to achieve this (54) (55). In consequence, this retrospective regional 
population based study sought, via linkage of cancer registry and routine, 
centrally collated clinical audit data, to examine variation in rectal cancer 
surgery throughout the West of Scotland between 2000 and 2005. We wanted 
principally to determine rates of use of APE and other rectal cancer operations 
across the region at a population level to determine if any significant variation 
could be explained by differences in patient characteristics such as Dukes’ stage 
of disease, age, gender, type of admission or socioeconomic deprivation level. In 
addition we sought to quantify the extent of variation in practice between MDTs, 
Health Boards and surgeons according to the volume of their practice. Although 
not a novel approach, this is the first time these aspects of rectal cancer surgery 
have been investigated at this level in our region (44). 
 
In summary, the last six years have provided a number of large studies closely 
examining the variation in surgical practice for treating rectal cancer. The key 
findings are that the rate of APE resections is reducing with time. The two 
largest published studies to date have noted that men are more likely to undergo 
APE than women. Being both male and socioeconomically deprived are 
predictors of APE for a rectal tumour. There also exists significant variation, 
independent of case mix, in the rate of APE resections for rectal tumours 
between both individual surgeons and hospital trusts. 
 
  36 
 
1.2 Colorectal cancer epidemiology 
Colorectal cancer is currently the second most common cause of cancer death in 
the Western world (56). The age-standardised incidence rate for colorectal 
cancer in Scotland is around 64.3 per 100,000 in men and 41.5 per 100,000 in 
women. This is greater than the UK average of 52.9 per 100,000 for men and 
34.9 per 100,000 in women (22). See figure three below. In contrast, the age-
standardised European incidence rates for bowel cancer, EU-27, by sex are 60.5 
per 100,000 for men and 37.2 per 100,000 for women. It therefore represents a 
significant health problem for the general population. The USA incidence per 
100,000 and are age-adjusted to the 2000 USA standard population and were 
54.43 in 2000 and 45.51 in 2007 (57). 
 
In the West of Scotland the EASR incidence of 56.5 per 100,000 in 2008. The 
European Age Standardised Mortality Rate (EASR) was 20.6 per 100,000 in 2008 
(58). 
The 5 year relative survival for all colorectal cancer patient of both sexes in 
Scotland from 1998-2002 is 54.2% (58). 
This compares to a 64.7% 5 year relative survival for all ages, all races and both 
sexes of patients with colorectal cancer in the USA from 1998 (57). 
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Figure 3 - Higher incidence of colorectal cancer in Scotland compared with England for 
males by health authority UK and Ireland 1991-2000 when comparing ratio of directly age-
standardised rate in health authority to UK and Ireland average. 
 
 
 
*Ratio of directly age-standardised rate in health authority to UK and Ireland 
average. Taken with permission from chapter 7 of (59). 
   
A similar picture exists for females. 
 
There are likely to be a variety of ethnic, genetic and environmental causes for 
colorectal cancers. The fact that populations moving from one region to another 
adopt the new areas incidence for colorectal cancer points to an environmental 
aetiology. Indeed this is the case in around 80% of colorectal cancer patients. 
Increased intake of fruit, fibre and vegetables are all considered protective in 
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the risk of developing colorectal cancer. This contrasts with increased red meat 
intake and increased dietary fat both being implicated in increased risk of 
colorectal cancer.  
Increased physical activity has been found to be protective whereas increased 
BMI (Body Mass Index) and centripetal obesity are now considered risk factors for 
developing the disease (60) (61). 
Hormones are alternatively thought to have protective or causative roles in 
colorectal cancer patients. 
 
An important consideration for many public health and large population studies 
documenting healthcare inequalities in the West of Scotland is socio-economic 
inequality and its translation into outcomes. Age, sex, geographic residence may 
be other markers or cofactors for underlying behavioural and genetic 
determinants of cancer incidence and survival (62-66). The West of Scotland has 
a larger proportion of deprived areas than the rest of Scotland.  Figure four 
illustrates the distribution of Carstairs scores in Greater Glasgow NHS Board 
overlaid with the distribution of scores in the rest of Scotland. The distribution 
of socio-economic deprivation in Scotland is approximately normally distributed 
with a small right tail of more deprived populations. It is measured using the 
Scottish Index of Multiple Deprivation (SIMD).  
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Figure 4 – Distribution of deprivation scores within the Greater Glasgow NHS Board area 
and the rest of Scotland 
 
 
 
Prognostic factors in colorectal cancer patients 
 
As with many cancers, colorectal cancer in Scotland demonstrates an increased 
incidence with time from 50.2 per 100,000 in 1990 to 54.3 per 100,000 in 2008 
EASR (European Age Standardised Rates) (58). At present men are more likely to 
be diagnosed with colorectal cancer than women (67). EASR 66.1 and 42.6 for 
men and women respectively in the West of Scotland in 2008 (58). 
It is generally held that patients presenting as emergency admissions have 
poorer survival compared to elective cases. This outcome holds true following 
adjustment for age, stage, and socioeconomic circumstances (SEC) (68). Despite 
the introduction in 2000 of UK government rules for patients with suspected 
malignancy to be seen by a hospital specialist within two weeks of referral there 
have been challenges to the effectiveness of these guidelines (69) (70). To date 
there is also no published evidence that reducing the time to first treatment to 
60 days reduces overall survival.   
Urgency of admission has previously been correlated with increased proportions 
of postoperative complications. In the first nationwide population based survey 
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of colorectal cancer treatment McGrath et al reported the numbers of patients 
suffering from postoperative complications in emergency cases and elective 
cases respectively (71). 69.9% of 1311 patients had no post-operative 
complications. Surgery-related complications were recorded for 10.8% of 
patients. There was however, no attempt to assess whether the differences 
were statistically significant or not between the two groups. 
 
Colorectal cancer incidence is higher and survival poorer in more deprived 
populations, and as a result overall mortality is higher (72). The poorer survival 
in patients from more deprived backgrounds was initially ascribed to a more 
advanced stage at presentation in more deprived patients (73). More recently 
two large studies have stated that the type of curative operation offered to 
patients suffering from colorectal cancer can differ according to their 
socioeconomic status (62)(44). This has not been examined across an entire 
region, inclusive of all hospital providers.  
 
The incidence of colorectal cancer remains skewed towards a higher incidence in 
more deprived patients (72). Also across the deprivation categories there is a 
continuing trend for patients from more deprived backgrounds to exhibit 
decreased survival when compared with their more affluent counterparts 
(64,65,74). As a determinant of poor outcome in colorectal cancer patients, 
deprivation is thought to exert its effect in many ways. These are variously 
defined as lack of resources, inadequate information and knowledge, 
substandard living conditions, risk-promoting lifestyle, attitudes and behaviours, 
and poor nutrition. Many of these aspects of deprivation then contribute to 
increased incidence of co-morbid conditions such as COPD, diabetes and 
hypertension. 
The pervading stoical West of Scotland culture may augment or diminish the 
expected negative effects of poor socioeconomic circumstances. 
In the West of Scotland it can be argued that an overriding fatalistic or stoical 
culture exists to some degree. That is to say, there is an ingrained tendency for 
the majority of the population not to seek or accept cancer screening or care. It 
may be that given time, education and public health campaigning will result in a 
change in this attitude.  
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A number of studies point to differences in long-term outcome for patients with 
colorectal cancer according to their socioeconomic background. Most recently, 
Harris and co-workers performed a retrospective analysis of relationships 
between deprivation and survival in 486 rectal cancer patients (63). They 
demonstrated that despite a non-significant difference in stage at presentation, 
those from a deprived background had poorer overall survival compared to their 
affluent counterparts. Their study was confined to patients diagnosed with 
rectal cancer in a single hospital.  
 
In the West of Scotland, Hole and colleagues have shown that cancer specific 
survival is better in more affluent patients even after adjustment for both stage 
of disease and mode of presentation(65). This was a retrospective study 
involving 2269 patients undergoing both palliative and curative resection for 
colorectal cancer. The excess mortality was confined to those patients 
undergoing apparently curative resection. No distinction was made between 
colonic and rectal cancers so that it is not possible to say whether the 
socioeconomic effects on survival were different between anatomical sites.  
A study by Byers and co-workers in the USA concluded from their collaborative 
state registries study of 4422 colorectal cancer patients that patients from areas 
of low socioeconomic status have more advanced disease at time of presentation 
for breast and prostate cancers but not colorectal cancer (75). Colorectal cancer 
patients are liable to receive less aggressive therapy (adjuvant chemotherapy) if 
they have lower socioeconomic circumstances (SEC). This results in greater all 
cause mortality for colorectal cancer patients. They also found that low SEC was 
not a risk factor for mortality across all ages, only those patients aged <65 years.  
They suggest this may be as a result of medical insurance service provision 
changing around the age of retirement. 
Other groups have studied the influence of deprivation on the postoperative 
phase of treatment for colorectal cancer. Smith and colleagues performed an 
analysis of a surgical association database of 7290 colorectal cancer patients, 
concluding that being more deprived was an independent risk factor for longer 
postoperative stay and is associated with higher postoperative mortality (64). 
One of the principles of an MCN is to provide equitable care throughout the 
network. Assessing if this is happening in Scottish practice is an aim of this 
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thesis. The ethos linked to MDT care for colorectal cancer patients would be 
expected to reduce, if not eliminate, this inequality. This will be examined. 
 
Novel prognostic indicators 
 
As with many other cancers, researchers in the field of colorectal cancer strive 
to elucidate more accurate methods of stratifying prognosis according to 
reproducible, objective measures. One topical area of research is inflammation. 
It is now well recognised that patients with the same stage of disease mount 
differing local and systemic inflammatory responses to the presence of 
colorectal cancer (76). Of particular note is the modified Glasgow Prognostic 
Scale (mGPS). It is now a validated tool for gauging prognosis in curative 
resection colorectal cancer patients based on serum levels of inflammatory 
proteins (77). One further validated scoring tool combines four known prognostic 
indicators to derive a cumulative score for patients with node negative disease. 
The so called Petersen Index (PI) is not widely employed at present but 
represents a potential area in which to further tailor specific treatments to 
patients with the same TNM stage (77,78). The prognostic significance of 
peritoneal tumour cells has previously been tested in gastric cancer. This has 
now been demonstrated to be of strong prognostic significance in stage III 
colorectal cancer patients also (79). 
 
Pathology - related prognostic factors 
 
Pathology plays an important part in diagnosis and prognosis. The pathologist is a 
key member of the core multidisciplinary team and its approach to colorectal 
cancer patient care. A recent review by Quirke and Morris discusses the 
particular facets of the reporting process that are important to the MDT. They 
also make a clear point that recording data accurately in the national minimum 
core dataset could lead to improved outcomes for colorectal cancer patients 
(80). 
It is worth taking some time to explore those aspects of the pathological process 
deemed important to the MDT as well as those features that have evolved to be  
important prognostic indicators. This will begin with an overview of the current 
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thinking regarding the pathogenesis of colorectal cancer and followed by a 
description of the pathological assessment made after resection of a tumour. 
 
Adenoma – carcinoma sequence 
 
The fact that 70% of colorectal cancers develop from adenomatous polyps and 
that the incidence of adenomas is 30-40% in Western populations is reason 
enough to justify government funding of a screening service given that a 
proportion of these adenomas will transform into carcinomas with time (67). Flat 
adenomas are more difficult to detect; they may have a higher rate of malignant 
change and can also develop into a more aggressive phenotype but only account 
for 10% of all polyps. The overall process of transformation from normal gut 
epithelium to malignant neoplasm is now well understood. A number of key 
molecular events have now been elucidated. These help to explain the 
adenoma-carcinoma sequence (81). 
 
Diagnosis 
 
The majority of patients with colon cancer will have the diagnosis confirmed 
histologically prior to consideration of surgical intervention. In contrast, all 
cases of rectal cancer require to be confirmed histologically before proceeding 
to surgical or neoadjuvant therapy (82). Biopsies are normally taken at time of 
sigmoidoscopy or colonoscopy. A small percentage of patients will have the 
diagnosis made from a metastatic deposit biopsy. This would be the case in a 
patient with an undiagnosed primary where biopsies are taken from liver lesions. 
Confirmation of the diagnosis is usually uncomplicated however confirmation 
may not be possible when samples are too superficial. In this case dysplasia or 
adenoma may be confirmed but not frank invasion. 
 
Staging 
 
Accurate staging is essential in formulating a management plan for all colorectal 
cancer patients. The relationship between pathologist, radiologist and surgeon is 
therefore necessarily close, as accurate staging is one of the main determinants 
of subsequent management. 
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The most common process occurs in three stages. Firstly a preoperative 
histological diagnosis is arrived at if possible; this comes from biopsy results. 
Secondly, the pathological staging is confirmed from the resected surgical 
specimen. Finally there is confirmation where an agreed stage of disease is 
recorded at a post-operative MDT meeting. This is the stage recorded in the 
regional MCN dataset. 
 
Pre-Operative radiological staging is undertaken using CT scanning to assess both 
the anatomical location of the primary lesion and its relationship to adjacent 
structures. An assessment of distant spread to lungs or liver is also made. In 
addition MRI is employed for staging or rectal tumours.  
 
Spread 
 
There are generally four ways in which a cancer can spread: 
 Directly into adjacent structures 
 Via the lymphatic system 
 Haematogenous spread 
 Transcoelomic spread 
 
There are various staging systems in use for assessing colorectal cancer. They all 
aim to be able to objectively assess degree of spread via the different routes 
outlined above thus arriving at an objective measure. This is then used to act as 
a guide to further management. Modified Dukes’ staging for colorectal cancer 
was previously the accepted and most widely employed staging system in the 
UK. It is the system used to record stage for the majority of patients in this 
thesis (80). 
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Table 1 - Modified Dukes' Classification for staging of colorectal cancers 
Stage Description 
A Growth of primary tumour does not penetrate beyond muscularis 
propria; no nodal metastases 
B Growth of primary tumour extends beyond muscularis propria; no 
nodal metastases  
C1 Lymph node metastases but apical lymph node free of tumour 
C2 Metastases within apical lymph node(s) 
D Distant metastases 
 
 
The alternative to Dukes’ classification is the TNM staging system. It is the 
favoured method of colorectal staging in most countries outside of Britain and 
has been developed by the International Union Against Cancer (UICC) in 
Switzerland over the last 40 years. TNM allows for greater subdivision of patient 
groups. This is especially true of the T stage. More detailed comparisons can 
then be made with more equally matched patients in terms of treatment and 
outcome. There are three basic elements to the classification, namely tumour 
stage, nodal stage and presence of metastases. A summary can be found on the 
American Cancer Society website (83).  
 
It is imperative that patients have their disease clinically staged at time of 
diagnosis as this then ensures correct treatment, thus optimising survival. It also 
acts as an objective research tool for assessing outcome. If a universally agreed 
staging system is employed it is far easier to make comparisons between 
populations in different countries. 
 
The TNM classification has a number of recognised advantages over Dukes’ 
classification. These include better global communication and objectivity and 
thus improved management of patients (80). In the United Kingdom there has 
been a gradual move towards the use of the TNM classification. Although it has 
been recorded on RCPath datasets since 1996, the vast majority of patient stage 
data in this thesis are recorded using Dukes’ stage. This is as a result of the 
delayed and sporadic adoption of RCPath guidelines by pathologists across the 
UK (84). 
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Extramural vascular invasion 
 
Extramural vascular invasion (EVI) is defined as tumour found within blood 
vessels located outside the muscular wall of the gut. These are almost always 
veins and are located within the fat surrounding the gut. EVI usually only occurs 
in T3 or T4 tumours. Courtney et al reported that EVI is an adverse prognostic 
indicator of survival in colorectal cancer patients whereas the presence of this 
finding was previously thought not to have independent prognostic value (85) 
(76). Talbot et al (1980) correlated EVI with development of hepatic metastases 
(86). Since EVI is now considered a variable in the joint national guidelines 
minimum data set for colorectal cancer histopathology reporting it will be 
interesting to note whether it holds prognostic significance in our dataset. 
 
Lymph node metastases 
 
There is a strong correlation between number of lymph node metastases and 
colorectal cancer patient survival (87). In addition, the presence of tumour 
within the apical node of the resection is consistent with an additional degree of 
adverse outcome (88). A more recent approach to assessing lymph node 
harvesting is to calculate the lymph node ratio of total nodes sampled to number 
of positive nodes. A higher ratio equates to a worse prognosis. This method also 
helps to overcome some of the inherent problems with simply assessing overall 
numbers of nodes harvested or nodes positive which can vary according to site of 
lesion and extent of exposure to preoperative chemotherapy and radiotherapy in 
colonic and rectal lesions respectively (89). A median of 12 harvested and 
analysed nodes is now considered important (82). 
 
A variety of novel techniques exist to detect lymph node metastases, including 
genetic and epigenetic DNA analysis (90). They are not yet used routinely either 
intraoperatively or in NHS laboratories but could improve detection rates in 
future if validated. 
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Local Recurrence 
 
Local recurrence (LR) is defined either as regrowth of tumour in or around the 
tumour bed after previous removal of all macroscopically visible tumour, or if 
tumour returns after inadequate resection. This includes regrowth within the 
suture or staple line of an anastomosis, the adjacent mesocolon or adjacent 
lymph nodes (88). 
 
The significance of local recurrence is that it dramatically reduces survival. If a 
patient is found to have local recurrence, they have a 90% chance of death as a 
result.  
A 1996 MRC trial reported a 33% local recurrence rate at five years in patients 
with Dukes’ B and C rectal lesions (91). This is in stark contrast to the 6% local 
recurrence rate quoted by Heald et al (1998) in their single centre results from 
19 years’ experience of the total mesorectal excision (TME) for rectal cancer 
(92). 
 
Circumferential resection margin 
 
The involvement of the circumferential resection margin (CRM) with tumour is a 
further risk factor for local recurrence. Quirke demonstrated in his classic 1986 
work that the rate of local recurrence is directly related to the positivity of the 
CRM (93). It therefore aids in the decision as to whether or not a patient with 
rectal cancer is a candidate for postoperative radiotherapy. It is defined as the 
area of a rectal tumour not covered by a serosal surface, a non-peritonealised 
surgical resection margin (84). In contrast, involvement of a serosal surface by 
tumour is a risk factor for intraperitoneal spread of tumour. This influences 
staging and subsequent treatment. Current RCPath guidelines state a margin of 
<1 mm is regarded as an involved margin. It is not possible to say that a margin 
of >1mm ensures a disease free margin but it is currently recorded as a clear 
margin in the dataset (84). 
 
 
Resection margins and local recurrence tend to be of more relevance to rectal 
resections as it is often harder to obtain sufficient clearance when operating in 
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the cramped anatomy of the pelvis compared to colonic resections in the 
abdominal cavity.  
 
Clinical management and survival 
 
It is now common to consider the stages in a patient’s progression from diagnosis 
through treatment to recovery as part of a continuous pathway or journey. With 
this in mind, a sensible approach is to break down the pathway and examine 
each individual step in isolation. This can help to pinpoint distinct areas in the 
pathway that may be deficient.  
As with any medical problem, the process begins with the patient seeking 
medical advice with a view to reaching a diagnosis. 
 
Diagnosis, screening and primary care referral 
 
The aim of screening is to enhance the pick-up rate of patients with colorectal 
cancer as a whole. It also aims to diagnose patients at an earlier stage of their 
disease. The Scottish bowel cancer screening programme will be fully 
implemented by the end of 2010. It is estimated that 160 lives per year will be 
saved as a result. Two published papers from different phases of a bowel 
screening pilot study have postulated that following introduction of screening, 
mortality rates from colorectal cancer could start to show a stronger socio-
economic gradient than currently exists (94,95). This introduces the important 
point of lead time bias. Lead-time bias is the perceived improvement in survival 
for patients due to earlier diagnosis from screening, since screening adds a 
variable amount of apparent survival to all people who are diagnosed in the 
asymptomatic state, compared to symptomatic patients (96). A larger socio-
economic gradient in diagnosis following screening goes against the ethos of 
both the NHS and Multidisciplinary team (MDT) care and will be discussed. Since 
screening is currently being rolled out across Scotland this thesis will offer a 
potential benchmark for future studies. 
In relation to the West of Scotland there is also a need to scrutinise data prior to 
the inception of the National Colorectal screening programme. This will allow for 
future assessment of its effectiveness. From 2009 it is estimated that mortality 
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from bowel cancer will decrease by 16% thus saving approximately 150 lives per 
year (97). 
Results have also been published from another European pilot study that justifies 
its expansion throughout the country. They demonstrated that 38693 (49·6%) of 
78083 patients had an FOBT, with 2392 (6·2%) having a positive result.  Positive 
predictive values were 4·0% for cancer, 28·1% for advanced adenoma and 36·6% 
for any adenoma (97).  
Simultaneous work in developing countries has concluded that despite the clear 
benefits of screening for colorectal cancer, the cost of implementation has to be 
taken into account. In India and some African countries where there is already a 
less developed healthcare system, the creation of a screening service is far too 
expensive to implement. It is argued that the portion of the health care budget 
that would be devoted to screening could have quicker and further reaching 
effects upon a wider population if spent in other areas. 
It has recently been concluded by Sankaranarayanan et al (2009) that screening 
is not cost effective and cannot be justified for most developing countries (98). 
Primary care referral is an area of interest to patients and politicians alike. 
Again, waiting times issues are outwith the scope of this thesis. The process of 
referral from a GP to hospital remains a dynamic one. This is due both to the 
changing nature of the NHS and to the perceived speed at which patients can be 
assessed if referred along different pathways. Colorectal cancer patients can 
now be referred by genetic clinics, screening services; GP to clinic, GP to A&E, 
and an increasing proportion are being referred by NHS 24 to A&E. This last 
route has not yet, been assessed with specific regard to colorectal cancer 
patients. 
 
Following diagnosis, it is imperative that patients undergo a thorough and 
uniform preoperative assessment. This includes staging of disease, general 
physical examination, measurement of routine biochemical and haematological 
parameters, and informed consent for intervention. Recently published work has 
confirmed that substantial variability exists in the preoperative evaluation of 
patients with colorectal cancer (99).  
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Patient selection 
 
Recent surgical and anaesthetic techniques have improved the number of 
adequate oncological resections in the elderly. Patients must be deemed fit for 
surgery. Previously this may have been a single decision by the operating 
surgeon based on his previous experience. It would take into account their age, 
stage and comorbidity. Now, however, patients where there is a potential 
operative risk tend to be selected more on an aggregate of objective measures. 
These include cardiopulmonary tests (such as echocardiogram) and pulmonary 
function tests.  
 
General preoperative considerations 
 
Staging by CT and MRI is one of the most important preoperative considerations. 
It has already been discussed above in relation to all colorectal lesions but for 
rectal lesions ultrasound can be useful. Trans Rectal Ultrasound (TRUS) or 
Endoanal Ultrasound (EUS) is the most common technique for assessing the 
extent of invasion of the rectal wall. It is ideal for staging smaller superficial 
tumours (T stages T0, T1, T2) being considered for local resection and non-
radical surgery. It is only good at estimating the lower so is helpful in selecting 
patients who may be suitable for local, endoanal or transanal excision. It is now 
considered accurate in staging gastro-intestinal tract tumours to allow an 
ultrasound staging system analogous to the pathological TNM system with a 
prefix ‘u’ denoting that this is an ultrasound rather than a pathological staging 
(100). The main determinant of LR is an involved CRM. EUS is poor at assessment 
of the CRM due to the inability to delineate the mesorectal fascia (101). MRI 
remains the investigation of choice for assessment of CRM. Tissue reaction in 
larger more locally invasive tumours makes EUS less reliable. It is also less 
reliable for assessing nodal metastases due to its reduced specificity at 
detecting the differences between benign nodes and those containing metastatic 
deposits.  
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Computed Tomography Staging 
 
Computed Tomography (CT) scanning is inferior to both Magnetic Resonance 
Imaging (MRI) and TRUS in relation to accuracy in local staging of rectal 
carcinoma. This is due to its inability to adequately differentiate between the 
soft tissue planes in the rectal region. CT scanning remains of prime importance 
for global assessment of distant metastases in colorectal cancer patients. It 
remains the gold standard for assessment of hepatic and pulmonary metastatic 
deposits. 
  
MRI staging  
 
The current surgical strategy for all locally advanced rectal carcinomas is to 
attempt down staging prior to surgery.  This treatment strategy is based on the 
relationship of the tumour to the mesorectal fascia, the optimal surgical 
circumferential resection margin that can be achieved by total mesorectal 
excision. MRI has been recognised as being useful in the ability to identify the 
CRM and accurately predict involved, threatened and clear margins and thus 
determine the MDT treatment decision. All patients who appear to have a 
threatened margin (<1mm) should be considered for preoperative neoadjuvant 
treatment in the form of short or long course chemoradiotherapy, whereas 
patients with clear margins can be treated by optimal surgery alone (101). 
 
FDG PET Scanning 
 
F-fluorodeoxyglucose (FDG) Positron emission tomography (PET) has been used 
for detection, staging and surveillance of disease in colorectal cancer patients 
and is considered a modality with emerging applications.  FDG is a biological 
tracer that allows the evaluation of glucose metabolism. Elevated uptake of FDG 
has been shown in several types of malignant primary tumours thus highlighting 
tumour activity. FDG scanning also has the potential for demonstrating tumour 
metabolic activity before structural changes can be shown by CT imaging.  In 
particular, FDG PET may be potentially useful for distinguishing local 
recurrences from postoperative scarring, for detecting hepatic and extra-hepatic 
metastases prior to any surgery or chemo-radiotherapy and for assessing 
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recurrent colorectal cancer when there are no indicators other than rising 
carcionoembryonic (CEA) levels. (102) 
A systematic review by Patel et al (2011) concluded that combination PET/CT 
has a higher accuracy for detection of extra-hepatic and hepatic metastases 
than CT alone. These results were based on a small number of studies though 
(103).  
 
 
The limitations of PET scanning include poor anatomic delineation, the fact that 
tumours <5mm cannot be detected, and high false negative results in patients 
who have had chemotherapy <1 month before the scan (104). 
Normal physiologic and metabolic activity in the gastrointestinal tract can also 
be problematic and careful correlation with fused CT images is now 
recommended to improve specificity.  
There is insufficient data at present to justify the routine use of FDG-PET in 
detecting recurrence in patients with colorectal cancer, mainly due to the lack 
of large randomised trials. In areas such as post-operative surveillance of 
colorectal carcinoma where the surgical treatment options and chemotherapy 
strategies are being constantly redefined, PET/CT may find additional future 
applications, particularly with the development of new, more specific 
radiotracers. 
 
Antibiotic and DVT prophylaxis 
 
Both antibiotic and Deep Venous Thrombosis (DVT) prophylaxis are considered 
standard measures in the pre-operative preparation of any colorectal cancer 
patient for surgery. Major abdominal surgery on a mitotic lesion is deemed an 
infection risk. SIGN 104 states that antibiotic prophylaxis is highly recommended 
for colorectal surgery, quoting an odds ratio of 0.24 and Number Needed to 
Treat (NNT) of 4 at a 1+ level of evidence (105). 
Cancer is also a recognised risk factor for DVT. Both have been adopted as 
surrogate markers for quality of care by NHSQIS (34). 
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Bowel Preparation 
 
Traditionally, preparation of the bowel for all elective and some emergency 
surgery was considered mandatory. Use of Mechanical Bowel Preparation (MBP) 
prior to large bowel surgery has been recommended since 1945. This dogma has 
been challenged in recent years. It is now considered normal practice in Europe 
to electively resect a colonic lesion without the requirement of bowel 
preparation (106-109). North American surgeons however, persist with 
preparation with MBP prior to surgery. Bowel preparation is still generally 
administered for resections of rectal tumours worldwide. It has been used with 
the aim of reducing postoperative complications.  Early observational studies 
and subsequent decades of clinical experience indicated that preoperative bowel 
lumen cleansing was associated with decreased patient morbidity and mortality 
(110). It was hypothesised that bowel preparation acted by both reducing faecal 
bulk - and therefore mechanical stress on anastomoses – and by reducing colonic 
bacterial load (111) (112). However, several recent systematic reviews and 
meta-analyses of randomised controlled trials of mechanical bowel preparation 
have been carried out and all consistently found no convincing evidence for its 
short term benefits and some evidence for lower postoperative cardiac events 
among non-MBP patients (111,113-115) (116) (117).   
 
A recent Cochrane review of 14 randomised controlled trials of mechanical 
bowel preparation concluded that there was no evidence it improved either 
morbidity or post-operative mortality (116). However, after the first update of 
the Cochrane review, the incidence of anastomotic leakage was observed to be 
significantly higher among patients treated with mechanical bowel preparation 
and a trend toward poorer short term outcomes remains in the latest update 
(111)(116). The primary outcome for the Cochrane review was anastomotic 
leakage and the majority of included studies followed patients for the post-
operative period (30 days after surgery) only, with the longest follow-up being 
about two months (118). 
 
There is evidence that some operative complications predict long-term 
outcomes, specifically survival, among colorectal cancer patients. Anastomotic 
leak is an independent prognostic indicator of poorer cancer-specific survival in 
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patients having had potentially curative resections and remains significant after 
exclusion of deaths within the postoperative period (119) (120)(121).  
 
Stoma Nurse  
 
It is hard to assess the individual influence of a stoma nurse’s input into 
outcomes but there is no doubt that their role is important in the psychological 
preparation and well being of the patient in the perioperative period. A stoma 
nurse is recognised as integral to the MDT (34). They are involved in the 
education of the patient regarding stomas and potential complications. This was 
concluded in a randomised trial comparing 42 patients seen preoperatively in the 
community by a stoma nurse versus those seen postoperatively in hospital. 
Statistically significant results were obtained in favour of the intervention group 
for time to stoma proficiency, hospital stay and unplanned stoma-related 
community interventions per patient. No adverse effects of the intervention 
were noted. The average cost saving per patient was £1,119 for the study group 
compared with the control group (122). 
 
In the postoperative period stoma nurses ensure that either the patient or their 
main carer is able to cope with changing the stoma bag. They also clarify 
situations where the patient or carer should seek further help. 
 
Intent of operation 
 
It is the aim of any MCN to ensure a common approach to these decisions and 
would therefore be interesting to study these in a regional, i.e. MCN, context. 
Prior to the inception of MCN (Managed Clinical Network) care for colorectal 
cancer patients the decision as to whether a resection was deemed curative or 
palliative was based on the surgeon’s impression at the time of surgery.  
 
Currently, more advanced preoperative assessment modalities in conjunction 
with the MDT process mean that the decision regarding therapeutic intent is 
more informed. Decisions regarding downgrading of tumours in order that they 
may become resectable now require consideration. This is particularly relevant 
for preoperative radiotherapy in rectal cancer. 
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Surgery in the management of colorectal cancer 
 
 Patients with colorectal cancer undergo either a laparotomy or a laparoscopic 
procedure to resect the tumour. In cases of advanced disease with involvement 
of adjacent organs an en bloc resection may take place. This employs the 
principles of total tumour clearance following known routes of lymphatic and 
haematogenous spread of tumours. The likelihood of lymph node involvement 
increases with depth of tumour invasion so the lymphovascular pedicle draining 
the tumour site is resected. If the tumour has spread directly into neighbouring 
organs they are either completely removed (e.g. spleen) or a wide margin of 
clearance is attempted. En bloc resection, coupled with the no-touch technique 
are methods first described by Turnbull et al in 1967. The no-touch technique 
minimises tumour shedding cells into the circulation as it is manipulated (123). It 
is now possible to detect these cells in draining vessels or intra-peritoneally 
using Polymerase Chain Reaction (PCR) technology. Both techniques remain 
strictly adhered to in the operating theatre. In fact, size of en bloc resection has 
been used as a surrogate marker of specialisation in colorectal surgery. 
 
Resection of colonic tumours and high rectal or rectosigmoid tumours is normally 
completed with either a hand sewn or stapled anastomosis. With the advent of 
reliable, efficient and ergonomically designed stapling devices it is now possible 
to resect tumours and staple anastomoses deep in the pelvis.  Surgery in the 
rectal area is regarded as requiring more skill as there is the potential for anal 
sphincter involvement and the related complication of rendering the patient 
incontinent. Operating deeper down in the pelvis is also technically more 
demanding as a result of lack of space. The Department of Health has published 
guidance suggesting that the sphincter should be retained in as many cases as 
possible. As a result the rates of abdomino-perineal excision (APE) have 
gradually been dropping over the years. Historically, 50% of patients with rectal 
cancer would normally require an APE (124). This drop has been mirrored by a 
similar rise in the number of rectal cancers being resected via the abdomen - an 
anterior resection (AR). Low or even ultra-low anterior resections are now 
performed routinely by colorectal surgeons for tumours close to the anal margin 
to allow sphincter preservation. This results in a higher objective quality of life 
for patients postoperatively (125). 
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Surgery is the mainstay of curative treatment for Dukes’ A, B and C patients. 
This ranges from endoscopic polypectomy to mulitmodal treatment of advanced 
and disseminated disease. As a single treatment modality this is true for all 
Dukes’ stage A and most stage B disease.  
 
With regard to rectal tumours the popularisation and dissemination of the total 
mesorectal excision (TME) has standardised treatment for the vast majority this 
group of patients (92). 
 
Heald recognised that the midline hindgut (rectum) and its mesorectum were 
embryologically derived together as a single unit. TME involves en bloc resection 
of the rectum and mesorectal tissue to the level of the levator ani muscles 
through sharp dissection through the avascular plane between the mesorectum 
and surrounding tissues (126). 
 
Nerve preserving rectal resection 
 
Preservation of the autonomic plexuses in close relation to the rectum 
(hypogastric, inferior hypogastric and pelvic splanchnic) became possible 
following initiation of novel resection techniques by the Japanese surgeons Hojo 
and Moriya (127). These techniques have been incorporated into the TME 
programme to allow lower rates of urogential nerve dysfunction.  
 
The principles of embryological gut development have now been applied to 
resections of colonic tumours. A German group, describing their technique as the 
Complete Mesocolic Excision (CME) report increased five year survival. The 
technique has now been replicated in another centre and verified in a third 
(128). 
 
Patients lower on the socio-economic scale have been found to be more likely to 
undergo APE than AR for cancer (43,44). This goes against the high quality of 
cancer care for all ethos proposed by MDTs and the government cited in the 
Cancer Plan 2000 (129). Similarly, another finding reported by Morris et al is that 
throughout England males were significantly more likely to receive an APE than 
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females. This finding was mirrored by the significant result that women were 
more likely to receive an anterior resection than men (44). This group found no 
significant differences between type of operation and age or stage at 
presentation. Stage at presentation was a statistically significant factor for 
patients admitted as emergencies only. These latter patients were also more 
likely than average to undergo a Hartman’s procedure or an anterior resection. 
 
There is evidence that rates of circumferential resection margin positivity vary 
between surgeons. So far, this has been shown to be able to predict outcome in 
rectal cancer patients (130). 
 
 
Since the first recorded colonic resection in the early 1990s, laparoscopic 
colorectal surgery has become well established and validated as a suitable 
alternative to open colonic resection. It offers advantages in terms of reduced 
hospital stay, reduced postoperative pain, shorter time to return of bowel 
function, and improved abdominal aesthetics with regards to scar size. Its 
disadvantages include the steep learning curve to attain proficiency and the 
need to be willing and able to convert to an open procedure. 
 
In its infancy, there was concern that laparoscopic resections lead to port site 
metastases and an increased frequency of intraperitoneal seeding of tumour. 
With the evolution of this technique various groups have now demonstrated no 
significant differences between open and laparoscopic methods (131). Other 
concerns regarding adequacy of resection margins, yield of lymph nodes and 
length of resected bowel with laparoscopic resections have all been 
demonstrated to be unfounded in randomised controlled trials (132,133). 
 
Current guidelines suggest that any patient requiring removal of a colorectal 
neoplasm can be offered the option of an open or laparoscopic resection (82). 
 
Current role of chemotherapy 
 
Standardised regimes of neoadjuvant and adjuvant chemotherapy according to 
stage of disease continue to evolve. They have been adjuncts to surgery for over 
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25 years. Research efforts continue to be directed towards compounds with low 
side effect profiles that remain cytotoxic, antiproliferative and orally 
administered. 
 
Capecitabine is one of the newer oral chemotherapeutic agents to have received 
a lot of trial attention in the last few years. Its effects have been studied in 
various phase I and II trials (134). 
Current recommendations in Scotland date from 2003. They recommend that 
adjuvant chemotherapy should be considered for all Dukes’ C patients unless 
contraindicated. The favoured regimen is bolus fluorouracil and low dose folinic 
acid (FUFA). This is given over five days, every month for six months (135). More 
recent evidence published in Col Dis indicated that following the introduction of 
MDT in one district general hospital, there was an improvement in the survival of 
patients due to optimal oncological input into their management plan (25). 
 
Current role of radiotherapy 
 
As rectal tumours tend to be more fixed in their location they are amenable to 
treatment with ionising radiation. The first successful radiotherapy for rectal 
cancer was administered in 1914 (126). 
 
Radiotherapy regimes continue to evolve. It can be administered in a number of 
ways; preoperatively or postoperatively, over a short or long period, and in high 
or low doses. 
 
The aim of preoperative radiotherapy is to downstage the tumour. This may then 
facilitate clear resection margins thus reducing the likelihood of local recurrence 
in future. These benefits were first demonstrated in the Swedish rectal cancer 
trial in 1997 however they did not translate into long-term survival advantages 
(136). 
 
Adjuvant radiotherapy is now a standard part of the management bundle for 
selected rectal cancers. These groups include all stage II and stage III patients in 
North America. In some European countries a short 1-week course of radiation is 
employed in all cases of rectal cancer (137).  
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Two broad categories of radiotherapy treatment are currently favoured in the 
UK. Firstly, a dose of 45Gy in 25 fractions over five weeks is given to fixed rectal 
lesions. This is in an attempt to render lesions resectable. The second commonly 
administered course is 25Gy in five Gray fractions given the week before 
surgery. This is given to patients with resectable lesions with the intention of 
reducing local recurrence. The evidence base for these regimens comes from the 
Stockholm 2 trial and has been adapted by SIGN for the current Scottish 
Recommendations (136). 
 
Evidence continues to accumulate towards further sub-selection of patients for 
radiotherapy, administered only to those patients with threatened or involved 
mesorectal margins. This theoretically decreases the chance of the surgeon 
breaching the tumour margin. It may also result in fewer complications from 
patients receiving radiotherapy unnecessarily (138). 
 
 
Management of advanced disease 
  
Around 33% of colorectal cancer patients will develop synchronous or 
metachronous hepatic metastases (139). One area of treatment for advanced 
stage colorectal cancer disease that has seen recent advances is resection for 
hepatic and lung metastases. Hepatic metastases occur before other distant 
metastases because the venous flow from the bowel passes to the liver via the 
portal system before entering the systemic circulation. Seeding therefore tends 
to occur here first. Operations that were previously deemed palliative are now 
potentially curative. As the resolution of computed tomography and ultrasound 
scanners improves so can both the selection of patients for resection of their 
metastases and their outcomes. Intraoperative ultrasound scanning of the liver is 
another technique employed to detect occult metastases at operation. This may 
result in the altering or abandoning of the resection if occult metastases are 
found to involve other lobes. There is now a tendency to assess patients for 
potential resectability of their metastases in terms of resection margins and 
having two contiguous segments of liver disease-free, rather than overall tumour 
size (140). 
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Radiofrequency ablation (RFA) is a further, adjunctive tool employed by 
surgeons. It uses high frequency alternating current to direct high temperature 
to localised areas. Coagulative necrosis and tissue dessication follows. RFA is 
reserved for regions of hepatic tissue which are not amenable to resection. This 
is usually due to proximity of the resection margin to vital blood vessels. RFA is 
used either as a single treatment or in conjunction with resection. 
 
In patients with responsive tumours, chemotherapy is known to cause tumour 
shrinkage. Its use can therefore convert a patient with an unresectable liver 
lesion into a potentially resectable lesion (140). 
 
Metastases to the lung are the second most common following the liver. As no 
satisfactory regimen of chemotherapy exists at present, surgery is the only 
chance for a potentially curative result. Again, high resolution CT imaging has 
aided in the earlier detection of previously occult pulmonary metastases. This 
has resulted in a reported five year survival rate of 24% to 63% for lung 
metastatectomy.  
 
Lizasa and coworkers have shown that the two most important prognostic 
indicators in advanced disease are a high Carcinomatous Embryonic Antigen 
(CEA) and number of metastases (141). 
 
The evaluation of long-term outcomes in this unfortunate group of colorectal 
cancer patients has now been published (142). Encouraging improvements in 
outcome following treatment in the MDT setting are also now coming to light in 
high impact journals. Lordan and colleagues have also shown in their 10-year 
study of outcome following hepatic resection for colorectal liver metastases that 
an MDT with a liver surgeon can positively and significantly influence the 
outcome of patients referred with hepatic metastases from colorectal cancer 
(56).  As this is a specialist hepatobiliary unit the number of patients is 
comparatively small (n=331) but nonetheless offers an interesting insight into 
differences in survival benefit when a specialist liver surgeon is involved in the 
referral of patients from MDT for resection of tumour.  
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Post operative care and ERAS 
 
Traditional barriers to rapid postoperative recovery following colorectal surgery 
are pain, paralytic ileus, and other organ dysfunction. 
 
A modern multimodal approach involving a pain team, physiotherapists, 
occupational therapy and dieticians has generated the global term enhanced 
recovery. This results in a less protracted hospital stay for an increasing number 
of colorectal cancer patients. Enhanced Recovery After Surgery (ERAS) is the 
multidisciplinary and multimodal approach to enable rapid recovery and 
improved outcome for surgical patients by attenuating the stress response to 
surgery. 
 
The most recent meta analysis of six randomised controlled trials with a total of 
452 patients by Varadhan (2010) used outcome measures of length of hospital 
stay, complication rates, readmission rates and mortality in 452 patients. (143) 
Although the number of individual ERAS elements ranged from 4 to 12, with a 
mean of 9 they concluded that ERAS pathways appear to reduce the length of 
stay and complication rates after major elective open colorectal surgery 
compared to conventional perioperative care. There was no statistically 
significant difference in readmission and mortality rates between the two 
groups. 
 
Palliation 
 
A recent publication by SIGN outlines the current palliative management 
strategies for pain control in colorectal cancer patients deemed not suitable for 
resection of their tumour(s) (144). 
At a recent meeting of the Scottish Managed Clinical Networks for Colorectal 
cancer it was indicated that there still remains a degree of heterogeneity in the 
representation of palliative care nurses or physicians at MDT meetings. This has 
implications for both blocking of beds in hospital and adhering to patients wishes 
when faced with a diagnosis of unresectable tumour and end of life care. A 
recently published abstract demonstrated that a community based palliative 
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care register can positively and significantly influence this. However, the 
presence of a palliative care representative at the MDT would be required for 
this to happen (145).  
 
Follow-up and trials 
 
Follow-up remains a controversial area. The reasons for following patients after 
treatment for colorectal cancer are early detection of recurrence for salvage 
surgery or palliative treatment, psychological support, the detection of 
metachronous tumour and research or quality assurance of treatment. What 
remains unanswered is duration and intensity of follow-up. Of these the most 
important is how long follow-up is needed.  It appears to be the case that more 
intensive may be better than less intensive follow-up. Jeffrey et al (2007) 
concluded from eight studies in their Cochrane review that an overall survival 
benefit at five years exists for patients 
undergoing more intensive follow up where the OR was 0.73 (95% CI 0.59 to 
0.91). This benefit could be explained by the mortality benefit for performing 
more tests versus fewer tests (OR 0.64 (95% CI 0.49 to 0.85)), and liver imaging 
versus no liver imaging (OR 0.64 (95% CI 0.49 to 0.85)), or because there were 
significantly more curative surgical procedures attempted in the intensively 
followed arm (OR 2.41(95% CI 1.63 to 3.54)) There was significant heterogeneity 
between the studies though (146). 
 
Renehan and coworkers (2004) have shown that follow-up is cost effective (147). 
What is not known is what exactly should be done, when and for how long. 
Results of three large ongoing randomized prospective trials are eagerly 
awaited. These are the Italian GILDA trial, the UK FACS trial, and the 
Scandinavian-based COLFOL trial (148). Furthermore, knowledge of long-term 
side-effects of adjuvant treatment is limited so longer follow-up should help to 
identify any that have not come to light thus far. 
 
Patients entered into clinical trials have been shown to produce better outcomes 
than those not entered into trials (149). It is logical then that MDTs should 
endeavour to attain as high a trial inclusion rate as possible.  
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Schofield and Steele state that “it is reasonable to offer liver imaging to 
asymptomatic patients under the age of 70 in order to detect operable liver 
metastases once during the ﬁrst two years after resection. (Recommendation 
Grade:A) Although there is no evidence that colonoscopic follow up improves 
survival, it does produce a yield of treatable tumours. It is recommended that a 
“clean” colon is examined by colonoscopy ﬁve years after surgery and thereafter 
at ﬁve yearly intervals up to the age of 70. (Recommendation Grade:B)” (150)   
 
Future direction 
 
Combined genetic and epigenetic analysis of sporadic colon cancer suggests that 
it can no longer be viewed as a single disease entity. There are at least three 
different subsets with distinct clinico-pathologic features, with important 
implications for prevention, screening, and therapy (151). 
 
The MCN dataset 
 
The analyses are based initially on a large clinical audit dataset as part of the 
MCN for colorectal cancer. These data are summarised then scrutinised in more 
detail in order to address the aims of the thesis and answer the research 
questions. This population includes patients from the 30 different hospitals in 
the West of Scotland region. 140 consultants were identified as being responsible 
for the patients in the MCN. Both hospital and consultant details were 
anonymised to ensure lack of bias when analysing results. 
 
The general process of audit data capture is as follows: 
Each local unit records data relating to their own direct input to the treatment 
and care of colorectal cancer patients.These data are recorded on separate, 
standardised MCN proformas, namely clinical, pathological and 
chemotherapeutic. This information is then added, at a local level, to an 
existing database of all colorectal cancer patients. See copies of these in the 
appendix.  
 
Periodically, the MCN staff request a copy of these data in order that 
performance against the recognised QIS Standards of care can be measured (34). 
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The practicalities of audit data collection vary across the West of Scotland 
region.  In some units the main clinical/surgical forms are filled in by the 
surgeon, the pathology form by the pathologist and the chemotherapy form 
filled in by the oncologist. Clinical audit staff support this process by ensuring 
that the various component audit forms are completed. They then attempt to 
fill-in the blanks from case notes or by referring back to the relevant clinician to 
attempt a higher rate of completeness. The data are then entered on to the 
local database.  Previously the database was a Microsoft Access application 
developed by the MCN and installed locally within each unit. This was 
superseded by a web-based application whereby all data from the region (and 
potentially the entire nation) are recorded on a centralised MCN database 
directly by the staff in each unit. Audit staff at the MCN headquarters work to 
support the MDTs and increasingly are present at MDT review meetings - this is 
unlikely to be the point at which the audit process is initiated. It is more likely 
an opportunity for audit staff to 'fill in the blanks'.  Nursing staff have their own 
component data set to complete but are not responsible for completion of other 
component parts e.g. clinical, surgical, etc 
A number of patients may, for various reasons, evade enrolment into the MCN 
despite a diagnosis of colorectal cancer. These patients may have migrated out 
of the region, been diagnosed in a private hospital, or be death certificate only 
(DCO) patients. 
The centrally held Scottish Cancer Registry dataset 
 
The Scottish record linkage system was created in the late 1950s. Prior to this it 
was always recognised that the nation held a vast number of potentially useful 
computer records for each member of the population (152). These records had 
never been collated for research or administrative purposes. There were 
however multiple records for each person (153). 
 
The increase in computational power allowed for a permanent, retrospective 
and prospective dataset to be created that could potentially link all records for 
each resident in Scotland. This would then help serve the requirements of larger 
epidemiological research studies. 
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There now exist numerous sets of Scottish Morbidity Record (SMR) data that span 
the entire spectrum of healthcare specialities. Those of relevance to this piece 
of work are SMR1 and SMR6. SMR1 records pertain to all hospital discharge 
records for non-psychiatric and non-gynaecological incidences whereas SMR6 
records are incidences of cancer. 
 
When linking any two records the crux lies in identifying that both relate to the 
same individual. To that end there are a set of five core items of identification 
used during the initial matching process; surname, first initial, year, month, and 
day of birth. Each of these core items carries a discrepancy rate of 3% for pairing 
records. The implication therein is that 15% of true links could be missed. 
 
To allow for this probability matching is employed. A computer algorithm 
calculates a score that is proportional to the likelihood of two different records 
belonging to the same person. Records are then deemed to either match or not 
match based on the score. To further facilitate the matching process all 
surnames have a common phonetic algorithm (soundex) applied to avoid the 
most commonly confused sets of letters causing needless mismatches. 
Current computational power limitations and the sheer number of records 
involved means that comparing each individual record with each other individual 
record remains impossible. To that end records are checked in blocks. Linkage is 
then carried out in two passes. This results in less than 0.5% of true links being 
missed (154).   
 
Quality of care 
 
It is important to consider exactly what is meant by quality and how it can be 
measured in the context of MDT care. Maxwell, in his seminal 1984 BMJ paper 
suggested six dimensions to be borne in mind when assessing quality in 
healthcare. These are access to services, relevance to need, effectiveness for 
patients, equity in service provision, social acceptability, and efficiency and 
economy (155). 
 
Lohr proposed the following definition in 1991: “Quality of care is the degree to 
which health services for individuals and populations increase the likelihood of 
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desired health outcomes and are consistent with current professional 
knowledge” (156) 
 
Access to care 
 
If access to care is compromised or biased towards particular groups of patients 
based on either their location or socioeconomic circumstances this can 
potentially affect patient outcome.  The underlying structure of the healthcare 
system is therefore relevant. The Government and their influence is also 
relevant as they can dictate changes that ultimately affect quality of care. 
Finally, both physician and patient characteristics are known to affect access to 
care. A general practitioner facilitates appropriate access for patients from 
primary to secondary and tertiary care. Then in secondary care, the consultant 
screens referrals in order to prioritise their access to services. 
Patients can affect their own access to care by leading chaotic lifestyles. This 
often leads to delays in attendance at hospital, delays in treatment, then 
compliance issues with treatment. 
 
Processes of care 
 
Screening and diagnosis are two processes of care known to affect quality. Full 
discussion of these topics falls outwith the remit of this thesis however potential 
effects of screening are discussed in chapter 8. 
 
Treatments are a further important process of care. Whether it be single 
modality or a combination of chemotherapy, surgery, or radiotherapy, treatment 
is a large determinant of quality. Supportive care and follow-up are also 
processes of care where debate continues as to what represents best quality 
within a cost-effective environment. Finally, end of life care is a process that 
can be deemed as a contributory factor to overall quality in colorectal cancer 
patients. 
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Outcomes of care 
 
Morbidity, mortality and cost of care are all objective measures and as such are 
used frequently as proxy measures of quality in colorectal cancer patients. 
Mortality can be measured in terms of both postoperative death and long-term 
mortality. Postoperative deaths are generally those occurring within thirty days 
of surgery and are usually considered as being deaths attributable to surgery 
rather than the underlying disease process. 
 
Morbidity is harder to measure as there is no agreed or objective measure for a 
patient’s degree of morbidity. If a patient’s clinical status and/ or quality of life 
are improved by the process of care then they have had an improvement in their 
morbidity. Also, by performing an operation on a cancer the patient is 
benefitting by removing the potential for their cancer to lead to increased 
morbidity in future. 
 
Cost is widely employed as an outcome measure, especially in the NHS. Patient 
length of stay and number of readmissions in a set time period are both used as 
measures of cost to the healthcare system and as outcomes of care and hence 
quality of care. Number of readmissions has also been employed as a proxy 
measure for comorbidity in some studies.   
 
Measuring quality of care 
 
There are both subjective and objective measures of quality. Objectively we can 
make an assessment of outcomes. These are primary or secondary and can be 
applied to all cancers. Primary outcome measures are recurrence and death. 
These are often thought of as being insensitive and somewhat impractical as 
there is a long time delay before meaningful information can be captured and a 
change in the system effected. 
 
Quality can also be measured in the context of care processes. These directly 
affect patients so can be measured more quickly by assessing quantity of 
patients receiving given services such as adjuvant chemotherapy, rectal sparing 
surgery, or CT colonography. These are secondary measures. 
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There are also disease specific measures. These tend to address screening or 
therapy issues relating to a single disease. This contrasts to other aspects of care 
that transcend the disease barriers for example palliative care and pain 
management along with services offering care in the community.  
 
Quality measures are by nature dynamic. They should reflect the current clinical 
climate based on best clinical evidence. They should therefore be revised over 
time. This thesis looks at data before the influence of screening will affect 
survival thus demonstrating the need to perform an analysis now and later 
following the impact of screening. 
 
Measurements of quality can be assessed in relation to the extent to which 
guidelines are followed. Ideally guidelines should be evidence-based but the 
nature of some therapies for colorectal cancer is such that many 
chemotherapeutic agents are on trial. To that end, it is often expert committee 
opinion that leads to guideline formation in colorectal cancer care. Current 
attempts to measure quality of care in this country are limited to audit of 
adherence to clinical standards. This thesis will add to these findings as well as 
addressing other useful measures of quality pertaining directly to colorectal 
cancer care. 
 
Stages in patient care can be identified where decisions to follow a certain line 
of treatment are made. If concordance with guidelines can be measured at each 
stage where a guideline is available then there is a basis for comparison between 
different Health Boards, hospitals or MDTs.  
 
Evaluating quality in any study of healthcare generally requires four prerequisite 
elements: 
 Identification of patients with the disease in question 
 Reliable sources of data 
 Data collection strategies 
 Quality of care measures 
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The methods used to ensure all four of these prerequisites are attained will be 
outlined in the method chapter. 
 
 
 
1.3 Surgeon Caseload, hospital volume and Sub specialisation 
The past decade has generated a myriad of publications reporting on the 
relationships between surgeon caseload, hospital volume, subspecialisation, 
their interrelationships, and putative influence upon outcomes for patients 
requiring operations for cancer. It is now generally held that various factors 
relating to volume and specialisation can be positively associated with improved 
outcome for surgical patients. These include a higher surgeon caseload, a higher 
hospital volume, and surgeon subspecialisation (157). These influences have 
been reported on for a number of surgically resectable cancers including 
pancreatic cancer, breast cancer and colorectal cancer.  
With reference to colorectal cancer a number of groups have confirmed a 
positive relationship between hospital volume and patient outcome (158) (159). 
Much less attention has been given to the effect of surgeon case volume, and to 
survival and long-term mortality outcomes although some studies confirm a 
positive relationship between surgeon caseload and improved outcome 
(16,52,160). The common adage underlying these findings is that practice makes 
perfect – more cases per surgeon in a hospital dealing with higher volume 
produces better outcomes (161,162). 
 
Debate continues in three main areas though. Firstly, what threshold should be 
considered standard for distinguishing a low volume surgeon from a high volume 
surgeon? Arbitrary values for this range from seven to 25 cases per year (44,163).  
Some groups have also measured three levels of volume reporting outcomes in 
terms of low, medium, and high volume surgeons (164). 
Secondly, when should a hospital be designated as a high volume hospital? (157). 
Finally, how should subspecialisation be defined? This can vary from a surgeon 
declaring a specialist interest or being a member of a Society of 
Coloproctologists to a surgeon being declared specialist by a group of his peers 
(162).  
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The most recent systematic review and meta-analysis relating to gastrointestinal 
cancers was an objective review of the reported associations between hospital 
volume, surgeon caseload and mortality. It involved more than one million 
patients with a range of cancers of the GI tract. Of the 135 identified and 
analysed studies, only 42 pertained to colorectal cancer patients. The authors 
concluded that most studies addressed the issue of hospital volume as opposed 
to surgeon caseload. They found a signiﬁcant volume effect was evident for the 
majority of gastrointestinal cancers; with each doubling of hospital case volume, 
the odds of perioperative death decreased by 0.1 to 0.23. They calculated that 
between 10 and 50 patients per year, needed to be moved from a “low-volume” 
hospital to a “high-volume” hospital to prevent an additional volume-associated 
perioperative death. This was dependent upon cancer type. They also called into 
question the validity of hospital surgical case volume as a reliable proxy marker 
for care quality as roughly 33% of all studies failed to demonstrate a significant 
hospital volume effect on mortality (165). 
 
Also of note is the 2010 publication by Borowski and colleagues. They have 
added to the UK evidence base by publishing outcomes on hospital volume and 
surgeon caseload on short-term outcomes and five year survival from a large, 
population-based data set of patients with colorectal cancer. They concluded 
that medium and high volume surgeons were associated with signiﬁcantly better 
operative mortality (odds ratio (OR) 0·74, P = 0·010 and OR 0·66, P = 0·002 
respectively) and survival (hazard ratio (HR) 0·88, P = 0·003 and HR 0·93, P = 
0·090 respectively) than low-volume surgeons. They found that rectal cancer 
survival was signiﬁcantly better in high-volume versus low-volume hospitals (HR 
0·85, P = 0·036), with no difference between medium- and low-volume hospitals 
(HR 0·96, P = 0·505). The benefit of this study was that it addressed both 
surgeon caseload and hospital volume however volume was split into three 
groups as opposed to two. They also highlighted that the volume-outcome 
relationship is not linear (164). 
 
Changes in outcome relating to surgeon caseload and hospital volume are 
therefore likely to cause their effects via different mechanisms. Surgeon 
caseload (or experience) is more likely to affect preoperative and intraoperative 
decision making, patient selection, and choice of resection technique. The 
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influence of hospital volume involves systems and health service components of 
care including the way in which the MDTs function along with the pervading MCN 
or nationally agreed protocols for best quality of care, particularly in the 
postoperative period. A correlation between the two is also likely since the 
presence of a higher caseload surgeon (or surgeons) in a unit will usually lead to 
a hospital being classiﬁed as high volume. Studies should necessarily be designed 
to account for and adjust accordingly for these effects. 
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1.4 Aims of this thesis 
i. To review current literature regarding the functioning and outcomes of 
Multidisciplinary Teams.  
ii. To ascertain whether patients who receive MDT care in the West of 
Scotland for colorectal cancer have better survival than those who do not. 
iii. To assess the influence of socioeconomic circumstances on casemix and 
survival. 
iv. To describe temporal trends in the provision of specialist care for 
colorectal cancer patients in the West of Scotland. 
v. To assess effects of specialist care on complications and overall survival 
following resection of colonic cancer. 
vi. To describe patterns of surgical approaches to rectal cancer resection by 
surgeon and hospital. 
vii. To describe socio-economic patterns in operative complications and 
overall survival in patients receiving surgical intervention for colorectal 
cancer both in a temporal manner (before and after MCN inception) and in 
a cross sectional way with MCN and non-MCN patients. 
 
 
1.5 Objectives of this thesis 
i. To perform an original, contemporary, wide-ranging, and 
methodologically rigorous literature review. 
ii. To complete a linkage of an existing MDT clinical audit database with the 
patient-based linked Scottish cancer registry, General Register Office 
death records and acute hospital discharge data on colorectal cancer 
deaths thus creating a novel dataset.  
iii. To compare two contemporaneous groups’ survival outcomes, namely 
those who had entered an MDT care pathway and those who had not. 
iv. To understand the variables conferring a survival advantage to colorectal 
cancer patients. 
v. To investigate the effects of surgical specialisation in hospitals. 
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2 Methods 
2.1 Literature Search 
A systematic review of the literature was undertaken in October 2007. The 
timing of this was important, as enough time had elapsed from the inception of 
MCNs to allow results, opinions, and outcomes to come to light in the published 
literature. 
The following search strings were used in Medline, Pubmed, Embase, All EBM 
reviews, the Cochrane database, ISI Web of Knowledge, CINAHL, HMIC (Health 
Management Information Consortium), HealthSTAR (Health Services Technology, 
Administration, and Research), and SIGLE (System for Information on Grey 
Literature): cancer, colorectal neoplasm, cancer policy, cancer policy 
implementation, Calman-Hine, specialisation, multidisciplinary team, Managed 
Clinical Network, program development, managed care program. 
The overall yield using the above strategy was 381 abstracts. Two independent 
reviewers David Morrison and Gary Nicholson (DM and GN) then selected the 
abstracts they deemed to be relevant to the thesis topic. This resulted in a 
shortlist of 130 abstracts. The full text for each of these was obtained and 
entered into an online reference management database (Refworks, 
www.refworks.com). Copies of the search strategies for the main searches are 
available in the appendix. 
 
The Department of Health, Scottish Executive and key government agency 
websites were also investigated for relevant titles. 
Finally, searching of reference lists in obtained papers was performed to extract 
a further level of information. The references were imported into Refworks in 
order to remove duplicate records and record ordering of articles and reports. 
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2.2 Study Design 
The study was a retrospective cohort study analysis of data merging locally 
derived (MCN clinical audit) and nationally held (Cancer Registry) datasets. This 
facilitated an examination of patient characteristics and survival in all patients 
suffering from colorectal cancer in the West of Scotland.  
Two main precautions were taken against possible researcher bias. Firstly, all 
hospitals were given a unique hospital identifier. This information was held 
centrally in the MCN office and never disclosed to the author. When hospitals 
were grouped for analysis it was impossible for the author to know which 
hospitals were which. Similarly, each consultant surgeon was given a unique 
identifier. Again, the consultants’ identity was kept from the author to avoid any 
possible bias in interpretation of results.  
 
2.3 Study Population 
Inclusion and exclusion criteria 
 
The inclusion criteria were to have been diagnosed with colorectal cancer in the 
West of Scotland from 1st January 1980 to December 30th 2005. Diagnosis of 
colorectal cancer was based on the ICD (International Classification of Diseases) 
-9 (pre-1999) and ICD-10 classification system. Patients between the ages of 16 
and 99 at diagnosis were included in the analysis; older patients were excluded 
as the quality and completeness of cancer registration data are poorer in this 
age group than for younger cases (166). It is also thought that patients at 
extremes of age display atypical pathophysiological responses to malignancy. 
 
Individuals registered with more than one primary malignant tumour were 
included only once in the dataset, from the date of the diagnosis of their first 
tumour. A small number of registrations which could not be traced through the 
ISD or MCN datasets due to failed linking were also excluded. Cases registered 
only from death certificates and for whom no information was traced on the 
diagnosis of cancer during life (‘death certificate only - DCO’ registrations) were 
excluded. It has been recognised that the validity of the diagnosis is less in such 
cases (167). DCO registrations are more likely to arise in older age groups and, 
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since these cases tend to have a poorer prognosis, their inclusion in survival 
analyses may reduce survival estimates (168) (169). 
The main issues regarding DCO cases are that i) there is no survival time for DCO 
registrations and ii) it is not reasonable to suggest anything about clinical care if 
a diagnosis was not made during life. 
 
2.4 Originality 
This work is original in that it is the first attempt to statistically analyse survival 
outcomes in a clinical audit dataset of this size in Scotland in relation to 
colorectal cancer. It covers a geographical area larger than most published UK 
studies of this type. Performance is known to differ between hospitals, between 
surgeons and between Health Boards. This thesis will take an original look at 
these areas in relation to colorectal cancer patients in the West of Scotland. The 
linkage of MCN audit data to the Cancer Registry is original but some of the work 
uses routinely-available CR data. The results hope to assess whether established 
quality indicators and clinical practice guidelines are effecting a change in 
colorectal cancer patient outcome.   
 
Previous work in this area in the West of Scotland has been of an audit nature 
only. Whilst valuable in its own right, audit does not assess outcomes in terms of 
patient survival. This thesis adds this vital dimension, and lays the foundations 
upon which further work regarding the West of Scotland MCN outcomes can be 
based. 
 
This work is not original in the sense that it is looking at outcomes of MDT 
patients with colorectal cancer. The MDT process has been validated in other 
cancers such as breast as a vector for improved survival of patients with cancer. 
Many of the variables examined have been studied individually in the past. It is 
already known that the baseline survival for colorectal cancer patients is 
increasing with time.  
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2.5 Ethics approval 
Permission to use the linked SMR06 data was obtained from the Caldicott 
Guardians of each of the five West of Scotland Health Boards.  The ISD Privacy 
Advisory Committee also gave permission to supply the WoSCSU (West of 
Scotland Cancer Surveillance Unit) with linked, patient-identifiable data.  Full 
patient identifiers were required to allow linkage to other datasets.  The linked 
cancer registry dataset was supplied by the Scottish Cancer Registry by 
permission of its Director, Dr. David Brewster. The Director of the WoSCSU (Dr. 
David Morrison), as the Data Controller, gave permission for extracts of the data 
to be used for this thesis.  The Lead Clinicians of the West of Scotland colorectal 
cancer MCN gave permission on behalf of the MCN to supply the author with all 
necessary patient-identifiable records from the MCN dataset. Data release forms 
were completed and approved by the regional cancer MCN audit team who 
supplied the data. A copy of the agreement can be found in the appendix.  
 
2.6 Study period 
The data were analysed retrospectively. This took place during the period of 
dedicated MD research, namely August 2007 to August 2009. 
 
2.7 Data - procurement, handling, validation, linking & missing data 
Data were procured from two sources: 
 
i. The West of Scotland MCN team at the MCN department of Glasgow Royal 
Infirmary. 
ii. ISD Scotland provided all SMR06 (Scottish Morbidity Records) pertaining to 
cancer patients along with General Registry Office for Scotland (GRO (S)) 
data on registered deaths. This allowed comparison of data existing 
before the MCN database with that contemporaneous to it. 
 
Data Handling and security 
 
All versions of the dataset were password protected with TrueCrypt version 6.0a 
256bit encryption (Copyright © 2008 TrueCrypt Foundation, www.truecrypt.org).  
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At no time did patient identifiable data leave the West of Scotland Cancer 
Surveillance Unit to be analysed. This was in agreement with locally held data 
security protocols. These were read and signed in accordance with the Data 
Protection Act 1998. Caldicott Principles were adhered to throughout. 
A copy of the data security protocol is contained in the appendix. 
 
Data Validation and linking 
 
Linking initially validated the data. SMR06 contains details on all patients with a 
diagnosis of cancer.  The search was confined to those patients attributed with 
an ICD (International Classification of Disease) C18, C19 or C20 diagnosis viz., 
colorectal cancer. The SMR06 dataset was matched with the MCN dataset on 
three main index variables - forename, surname and date of birth. This 
automatic match of patients was then added to with further patients found 
through a manual process for those patients where the automatic process had 
not worked. 
 
Manual linking of patients was performed using further identifiers such as CHI 
(Community Health Index) number, postcode, or by simply checking for 
forename and surname transposition or unusual names which are not readily 
recognised by the soundex system, e.g. O’Boyle. 
 
The following, table 2 shows current ICD-10 codes for colorectal cancer. All but 
C181 were used for inclusion into this study. It is generally felt that appendicular 
tumours are too histologically and pathologically distinct from other neoplasms 
of the colon to be included in analysis. 
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Table 2 - ICD-10 definitions 
 
Code Definition included or not  
C180 Malignant neoplasm of caecum                                                       
C181 Malignant neoplasm of appendix                                                   x  
C182 Malignant neoplasm of ascending colon                                              
C183 Malignant neoplasm of hepatic flexure                                              
C184 Malignant neoplasm of transverse colon                                             
C185 Malignant neoplasm of splenic flexure                                              
C186 Malignant neoplasm of descending colon                                             
C187 Malignant neoplasm of sigmoid colon                                                
C188 Malignant neoplasm overlapping lesion of colon                                     
C189 Malignant neoplasm of colon  unspecified                                                
C19X Malignant neoplasm of rectosigmoid junction                                        
C20X Malignant neoplasm of rectum                                                       
 
 
Missing Data 
 
A number of strategies exist to deal with missing data. These are summarised by 
Katz in Multivariable Analysis: A practical guide for clinicians (170). 
 
 Delete cases with any missing data 
 Create variables to represent missing data 
 Make additional effort to obtain data 
 Decrease the number of independent variables in the analysis 
 Estimate the values of the missing cases 
 
This final suggestion has been considered in more detail and was employed 
recently in a study by Nur et al regarding socioeconomic inequalities in 
colorectal cancer survival. The missing values were arrived at by using multiple 
imputation (171). 
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2.8 Definitions 
Survival time was defined as the time from date of incidence to date of death or 
date of censor. Censoring is the method used to quantify survival time up to the 
point when a patient does not experience the outcome and stops being followed-
up – either because the subject drops out or because the study ends. Drop out 
from study was not applicable in this thesis.   
For example, in this thesis patients who are still alive on 30th September 2007 
were censored on that date because death data are not complete on the cancer 
registration file after that date. In our population we were unable to assess how 
many people emigrated. Date of censor was 31st September 2007 for all survival 
analyses unless otherwise stated. In this study survival time is the entire time 
that the patient was followed-up. Throughout this thesis it is measured in years, 
as this is most appropriate and commonest unit used when describing survival in 
colorectal cancer patients. 
 
30 day mortality 
 
This represents the mortality within 30 days of surgical intervention and is 
synonymous with postoperative mortality. It is widely regarded as the time after 
which mortality is attributable to the disease process and not surgical 
intervention. It is of particular interest as it is seen as an opportunity for other 
parts of the MDT to influence postoperative care and recovery. 
 
Survival 
 
Convention for studies of clinical outcome in cancer patients has been to 
measure either overall, cause specific or relative survival at 3 months, 1 year, 3 
years or 5 years. This can vary depending on type of cancer. 5 year survival is 
widely employed to compare outcomes in colorectal cancer from different 
populations. 5 years is deemed enough time to confidently assess the long-term 
effects of any treatment that the patient might be given.  
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Overall and cause-specific survival 
 
The simplest estimate of survival is observed survival, which is an estimate of 
the probability that a group of patients with a given disease will be alive at a 
specified time-point after diagnosis, irrespective of the cause of death. As 
colorectal cancer generally affects older people, there are more likely to be 
more competing causes of death. This makes this method more inaccurate in 
older populations.  In cause specific survival deaths attributable to the cancer of 
diagnosis are treated as deaths whereas deaths due to other causes are censored 
at the time of death. 
Some confusion arises when certain loosely related causes of death are treated 
as being the specific cause. For example, ISD cite 15 different causes for 
colorectal cancer specific death, including “secondary malignant neoplasm”, 
“benign neoplasm of colon” and “neoplasm of uncertain behaviour, site 
unspecified” among their primary causes of death regarded as ‘cause-specific’. 
(Appendix 7, ISD Scotland: Scottish Cancer Intelligence Unit. Trends in Cancer 
Survival in Scotland 1971-1995, {{8854 ISD Scotland 2010}} 
 
This contrasts with a Dundee group where colorectal cause-specific survival was 
calculated only for patients with a signed pathology report confirming they had 
an adenocarcinoma of either the colon or rectum (172). 
 
Deprivation Category (DEPCAT) and Carstairs Scores  
 
DEPCAT is a widely used proxy measure of socio-economic circumstances  
derived from the Carstairs score, postcode, and local council area. The Carstairs 
score is a z-score transformed (standard score) weighted sum of four separate 
variables that are thought to represent an objective measure of a postcode 
sector’s socio-economic deprivation level. These are; degree of overcrowding; 
level of male unemployment; proportion of all householders from social classes 
four and five, and level of car ownership. The z-score systems used to generate 
Scottish Index of Multiple Deprivation (SIMD) by definition create a normal 
distribution.  In contrast, residents of Greater Glasgow NHS Board area are found 
in a minority of the most affluent areas but represent the majority – and in many 
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cases the entirety – of the most deprived areas of Scotland.  The West of 
Scotland thus has the scientific advantage of being able to generate large 
populations of both affluent and deprived patients with which to compare and 
contrast health outcomes.  
The SIMD 2009 combines 38 indicators across seven domains namely: income, 
employment, health, education, skills and training, housing, geographic access 
and crime. The overall index is a weighted sum of the seven domain scores. The 
weighting for each domain is based on the relative importance of the domain in 
measuring multiple deprivation, the robustness of the data and the time lag 
between data collection and the production of the SIMD. The domain weightings 
were subject to sensitivity analysis to assess the effects of any changes in 
weights on the overall index ranks (173). 
 
Each DEPCAT was calculated using an individual’s postcode sector and their local 
council area (LCA) before cross-referencing this with the Carstairs 2001 table to 
arrive at a value between 1 (most affluent) and 7 (most deprived) for every 
patient. The standardised table is available for download as an SPSS or Excel file 
at (174). For example, the geographical area covered by G71 spans three 
different council areas. It is therefore possible for a person residing in G71 to 
have one of three different DEPCATs. Given that the population is not equally 
distributed throughout each deprivation category and that larger proportions 
occupy the middle 3 DEPCATs, it was agreed to further regroup the DEPCATs into 
3, as follows: DEPCATs 1 and 2 were regrouped into an affluent category. 
DEPCATs 3, 4 and 5 were regrouped into an intermediate category and DEPCATs 
6 and 7 were regrouped into a deprived category. 
 
It has been considered that DEPCAT is not a true representation or objective 
measure of deprivation and that it gives way to the ecological fallacy. When 
interpreting results regarding socio-economic deprivation one must always 
consider that deprivation measurement and categorisation could be introducing 
a source of error. By categorising patients into distinct groups according to their 
socio-economic status we introduce a source of error. This is due to the fact that 
we are making aggregate measures of socio-economic status across geographical 
areas. We are not assessing each individual objectively. The error therefore is to 
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assume that any individual in any given area (or postcode in our case) has the 
average socio-economic deprivation score of that area when in fact he or she 
could have a worse or better than average socio-economic status. The inference 
of this is that some patients classed as one category on the socio-economic scale 
could in fact belong to another category. In the absence of any better method of 
making this difficult assessment we make do with depgroup (modified DEPCAT) 
in this thesis. Currently there is no better way of assessing degree of 
socioeconomic circumstances. This point should be borne in mind when 
interpreting results that rely heavily on DEPCAT as a prognostic indicator.  
 
Definition of specialist 
 
Debate continues as to the definition of what constitutes a specialist in the field 
of colorectal surgery. Currently, various definitions have been applied. 
Membership of the Association of Coloproctologists of Great Britain and Ireland 
(ACPGBI) has been used as a proxy measure for being a specialist. Regional peer 
opinion has also been employed to determine which consultant surgeons should 
be considered specialist (175).  More objective measures have also been sought. 
If a surgeon is undertaking more than 20 colorectal operations per year then he 
can be said to have enough expertise be called specialist according to the 
ACPGBI (82). Similarly, for rectal cancer, a threshold of seven resections per 
year has previously been quoted for declaring a surgeon specialist (44). This is 
based on the fact that a third of colorectal cancer operations are rectal and 
seven is approximately a third of 20. 
In this thesis we have used seven resections per year as the threshold for rectal 
cancer. We have then used both seven and a further division at ten resections 
per year for colon cancer surgery. This is firstly to be able to compare colon 
cancer outcome with rectal cancer at the same volume and secondly, to assess if 
the higher threshold of ten cases per year yields better outcome than seven, 
thus supporting the argument for specialisation in colonic surgery as well as 
rectal. Furthermore we decided that due to paucity of consultants performing 
greater than 20 resections per year, that this higher threshold would not include 
enough data to provide meaningful interpretations relating to our region. A  
lower threshold of 10 cases is therefore employed herein.  
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2.9 Analysis and Statistical Methods 
Data were supplied from Glasgow Royal Infirmary’s Managed Clinical Network 
office in Microsoft Excel format. This was imported into SPSS format for the 
purposes of data analysis. SPSS version 15.0 for Windows was used for all 
analyses (176).  
 
Categorical and continuously distributed data 
 
Comparison of categorical data was generally performed using the Х2 test. This 
either tested the assumption of independence between two variables or was 
used to compare the proportions across groups. Comparison of means from 
continuous, normally distributed data were t tested. The Chi-square test is one 
of association. It measures the difference in proportions between observed and 
expected results. In this study, examples of categorical data include Dukes’ 
stage and age group. Age was also treated as a continuous variable where 
applicable. Continuous variables were tested using Cox proportional hazards 
models for significance before deciding whether they should be entered into 
multivariable survival models. The null hypothesis, H0, of the chi square test is 
that the two categorical variables are independent of each other. A p value 
reflects the probability of an event having taken place by chance. This value can 
be set at any desired level but for the purposes of this thesis the significant level 
of p was taken to be 0.05 or less. At levels less than this, the null hypothesis is 
rejected, suggesting a real change or association has occurred. The author 
performed all statistical analysis with advice from Dr. David Morrison and 
medical statisticians Miss Nicola Greenlaw and Dr. Gwen Allardice (WoSCSU). 
 
A logical approach to data analysis was adhered to throughout. In general, 
categorical variables were analysed using the Kaplan-Meier method with a log 
rank test. This was used in all univariate Kaplan-Meier models. Its major 
drawback is that it is unable to incorporate more than one variable in a model, 
hence the need for multivariate analyses. Visual inspection of log-minus-log 
plots was also undertaken. If lines are parallel, this indicates that the difference 
between categories is constant over time.  If they become closer or further 
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apart with time, this infers the hazards are not proportional over time. Thus a 
single hazard ratio fails to describe the variable in question.  
 
Univariate models 
 
Univariate survival analysis was performed applying the Kaplan-Meier method. 
The Log-rank test was used to compare the survival times between groups of 
patients. The log rank test compares two or more groups of survival data by 
arranging both observed and censored survival times in rank order. It is a non-
parametric hypothesis test based on the chi-square distribution. The null 
hypothesis (H0) is that the risk of death is the same in both groups. The number 
of deaths expected at any time should be distributed equally between the two 
groups by the number at risk. Any difference between the observed and 
expected is evidence against the H0.  
 
Multivariate modelling 
 
Multivariate survival analysis explored multiple factors employing Cox’s 
proportional hazards model (170). This is a particular type of proportional 
hazards regression analysis introduced by Cox in 1972. It evaluates the 
contribution of individual prognostic factors to survival whilst adjusting for other 
potential indicators. It is the logarithm of the relative hazard that is being 
modelled. The main advantages of this method are that it accounts for variable 
lengths of follow-up and that it can adjust for confounding variables. 95% 
confidence intervals were chosen for all models unless otherwise stated. 
Both stepwise multivariate models using SPSS and manual models were 
employed. Using manual models has the added advantage of forcing the program 
to include specific variables that may be clinically important in the model even 
if they are not statistically important.  A stepwise multivariate model would 
automatically only include the statistically significant variables. 
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Co linearity and proportionality 
 
Care was taken to avoid the potential problem of co-linearity. This becomes an 
issue when two or more overlapping variables are included in the same model. If 
variables were highlighted as inducing co linearity they were tested individually 
in the model to ensure no change in outcome of results. For example, MDT 
groups were not tested in the same model as hospitals or Health Boards since 
they all potentially overlap in their effects thus displaying co-linearity. Care was 
also taken to check the proportionality assumption for each variable. The 
proportionality assumption, as stated by Katz, is assuming that “the hazards for 
persons with different patterns of covariates are constant over time” (170). An 
example in relation to colorectal cancer is that we are assuming the relative risk 
of death from colorectal cancer in the first year following surgery in patients of 
different stages of disease is the same as the relative risk in the ensuing years, 
i.e. there is a linear relationship. Log minus log plots were taken for each 
variable in each proportional hazards model to check that the proportionality 
assumption held. These have the disadvantage that they are only applicable to 
individual variables. 
 
Linear regression models 
 
Linear regression modelling fits a straight line through a set of points in such a 
way that makes the sum of squared residuals of the model (that is, vertical 
distances between the points of the data set and the fitted line) is as small as 
possible. The goodness of fit summarises the discrepancy between observed 
values and the values expected under the model in question. Our alternative 
hypothesis in this thesis is that the introduction of an MCN caused improvements 
in overall survival for colorectal cancer patients greater than would have 
otherwise occurred. We would expect to see a positive increase in the slope of 
the line following the introduction of the MCN. This slope should be out of 
proportion to the change that would have otherwise occurred. A good model is 
one where we can accept the alternative hypothesis whereas a bad model is one 
where the alternative hypothesis is rejected either due to decreasing slope of 
line following MCN introduction. 
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In all plots α is the intercept of the line and β is the slope. 
 
Tables and Graphs 
 
All tables and graphs are adapted from output generated in SPSS version 15.0 
using Microsoft word or Excel. 
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3 Influence of demographic, socioeconomic 
and clinical factors on survival from 
colorectal cancer in the West of Scotland 
3.1 Introduction 
Survival from colorectal cancer is influenced by several factors: general health; 
the stage and site of cancer; and the treatment received.  Before comparing 
survival among patients treated within a Managed Clinical Network with those 
who are not treated within one, the effects of casemix (patient and disease 
factors) need to be quantified. The alternative hypothesis in this thesis is that 
the introduction of an MCN caused improvements in overall survival for 
colorectal cancer patients greater than would have otherwise occurred.  In this 
chapter the population of the West of Scotland from which the sample is drawn 
is described in ways that are relevant to understanding their survival from 
colorectal cancer.  We then describe aspects of patients’ clinical status and its 
relationship to survival in the West of Scotland population.  This chapter 
therefore provides the basis by which the effects of changes in the organisation 
of care can be assessed in ensuing chapters. 
Linkage of MCN and SMR06 datasets by names and dates of birth creates a 
uniquely comprehensive dataset allowing an accurate and region-wide 
assessment of broad, longitudinal outcomes and more specific clinical audit 
derived prognostic indicators for colorectal cancer patients. The linked dataset 
has two principal advantages.  Firstly, it allows survival in MCN and non-MCN 
patients to be differentiated.  Secondly, it allows more detailed clinical and 
pathological information on patients’ treatment to be included in survival 
analyses. Furthermore the relationships between socioeconomic circumstances 
(SEC) and associated key variables in colorectal cancer patients in the West of 
Scotland can be interrogated before going on to describe their effects on 
operative complications and survival. We sought to firstly summarise the broad 
socioeconomic trends in colorectal cancer patients across the entire region. This 
covers both a larger, less selective population than previous work by Hole et al 
  88 
(65). It also covers a wider time frame, incorporating the introduction of the 
MCN for colorectal cancer into patient management decisions. 
 
3.2 Summary of literature 
A number of studies have reported that differing socioeconomic circumstances 
are associated with different survival outcomes from colorectal cancer 
(44,63,65,73-75,177,178).  The effects may be due to either disease factors 
(more advanced stage at presentation); patient factors (emergency rather than 
elective presentation and comorbidity) or differences in treatment – offering 
different types of operation to patients by surgeons with differing levels of 
expertise. The effects of delay in time to first treatment may also help to 
explain differences in survival. The impact of the Calman-Hine report has been 
assessed from a regional viewpoint in the North West of England (28). We aim to 
ascertain whether or not adopting the recommendations of the report in the 
West of Scotland has had any objectively measurable effect upon overall survival 
for this patient group.  
 
3.3 Aims & Objectives 
Aims 
i. To describe the study population in terms of demographic and clinical 
characteristics relevant to understanding their survival from colorectal 
cancer.  
 
ii. To quantify the effects of demographic and clinical factors on overall 
survival from colorectal cancer in the West of Scotland. 
 
iii. To describe socio-economic patterns in operative complications and 
survival in patients receiving surgical intervention for colorectal cancer 
both in a temporal manner (before and after MCN inception) and in a 
cross sectional way with MCN and non-MCN patients. 
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Objectives 
 
i. To summarise the demographics of the combined Cancer registry and MCN 
dataset and identify patients meeting the inclusion criteria from relevant 
data. 
ii. To produce descriptive statistics. 
iii. To produce survival models. 
 
3.4 Method 
Inclusion criteria for this chapter: 
 
The population under study included all patients diagnosed with a single 
colorectal cancer and treated in the West of Scotland from 01/01/1980 to 
31/12/2005 with date of death data up to 30/09/2007. This allows for more 
complete follow up and thus more precise estimates of survival.  
 
Linkage and derivation of dataset 
 
The SMR06 records for all 40487 patients diagnosed with colorectal cancer from 
1980 to 2005 were checked in order that only patients meeting the inclusion 
criteria for the study were selected. Figure 5 below demonstrates the exact 
numbers of patients excluded from the initial SMR06 records to arrive at the 
final working dataset. 
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Figure 5 - Flow diagram for case linkage and dropout 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Multiple Primary cancers 
 
Identification and exclusion of all separate records for new primary cancers in 
the same individuals was performed. A total of 1502 cases with more than one 
SMR06 entry were identified. This represents 2.7% of the total. These were due 
to patients having had synchronous tumours. They represent a group of patients 
that are thought to be different to most in terms of pathophysiology (179). The 
incidence of synchronous carcinoma is reported as being between 1.5% to 7.6% in 
other series of colorectal cancer patients (81).  
SMR06 records 
N= 40487 
Pts >99yrs & <15yrs 
N = 17 
Appendicular tumours 
N = 283 
Multiple primaries 
N = 1502 
missing/incorrect data in 
>= 1 field 
N = 721 
 
N = 34 
Working dataset 
N = 37964 
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3.5 Results 
In order that long term survival outcomes could be derived for the patients from 
the MCN clinical audit database, a linking process was undertaken to identify all 
patients with death records. 
This section explores the trends from 1980 to 2005 regarding variables available 
for analysis as well as detailing relationships between socioeconomic 
circumstances, health board of origin, sex, Dukes’ stage of disease and overall 
survival. This then highlights areas to be considered in more detail in further 
analyses. Furthermore, patients not enrolled in the MCN are compared with 
those enrolled in the MCN 
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Figure 6 shows the origins of the 7749 patients successfully linked to the cancer 
registry records from the MCN clinical audit database. 
Figure 6 - Flow diagram summarising linking process of SMR dataset with MCN dataset to 
produce a working combined dataset following exact matches, Soundexing, and manual 
matching. 
 
 
 
 
 
+ 
SMR06 
Patient records 
n= 37,964 
 
MCN dataset 
n = 8,563 
LINKAGE 
Working dataset 
n = 7,749 
Exact matches 
N=6,979 
Manual & soundex 
matching 
N= 770 
Multiple Primary 
tumours 
N= 1502 
 
 
A total of 37964 patients were identified from the SMR06 data. These were all 
newly diagnosed colorectal cancer patients in the West of Scotland from 1st 
January 1980 to 31st December 2005. The age range was from 11 to 104 with a 
mean age of 70.76 and standard deviation of 11.679. 283 patients were excluded 
from analysis as they were diagnosed with cancer of the appendix. Despite this 
cancer being included in the ICD 10 classification of colorectal tumours it is an 
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atypical cancer which behaves differently compared to other colorectal tumours 
(180,181). 
 
Completeness of data 
 
The definition of completeness used in this thesis was the proportion of 
information entered into a field on the database. To that end, an entry of ‘not 
applicable’ was included as a bona fide entry as it indicates both that the field 
has not been left empty and that a member of the clinical audit staff has had to 
make a decision as to whether or not the field is appropriate to that patient. For 
example in the case of a colonic cancer patient, an MR scan would not be 
applicable as a part of the assessment of their tumour. In the MR scan field, the 
member of audit staff would enter ‘not applicable’ instead of leaving it blank. 
This then would count towards the completeness of the field. 
With the passage of time, more variables have been added to both the cancer 
registry dataset and the MCN clinical audit database. This provides more 
information for analysis but has two main disadvantages. Firstly, comparison of 
older (pre-MCN) patient data with newer patient data is restricted to the fewer 
variables available at that time. Secondly, as the size and complexity of the 
newer dataset increases, it becomes more susceptible to inaccuracy. 
The following table summarises the various variables available for analysis at 
different times. 
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Table 3 - Summary of available variables for all patients in the combined Cancer 
Registry/MCN audit dataset from 1980 to 2005 according to year group.  
 
1980 onwards 1997 onwards 2000 onwards 
Unique patient identifier Earliest date of surgery All clinical audit fields* 
Sex Age at surgery  
Date of incidence Dukes’ stage at diagnosis  
Site of cancer Therapy objectives  
Health Board of residence   
Local council area   
Deprivation category   
Date of death   
*These fields are summarised in clinical audit proformas in the appendix. 
 
 A mean case ascertainment of 98% was achieved for the eight variables 
available from 1980 onwards. This is one of the main strengths of this study and 
is recognised in the field of cancer registry studies, (Dr. David Brewster, 
director, Scottish Cancer Registry, personal communication). 
 
MCN audit data 
 
The MCN clinical audit dataset contains clinical, pathological, oncological and 
nursing related variables. See appendix for a copy of the four proformas 
currently used for data collection. These include general demographics and 
details proforma, a pathology form, an oncology form, and a nursing form. 
Of the 8,563 sets of patient details obtained from the MCN, 7749 (90.5%) 
matched with SMR06 records, using a combination of exact matches, Soundexing 
and manual matching techniques.  
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Cases with multiple tumours 
 
1502 cases with multiple tumours were identified during the matching process 
(figure 5). Within this population there was a higher percentage of males, 58.5%, 
compared to the general population of colorectal cancer patients in the West of 
Scotland.  The remaining variables had a similar distribution to those in the 
study population of patients with single tumours. 
 
Table 4 summarises the overall demographics for colorectal cancer patients in 
the West of Scotland from 02/01/1980 to 29/12/2006. Ages are grouped to allow 
comparison with previously published series (65). Overall women were 3 years 
older than men (mean ages of women and men difference 3.0, 95% CI 2.8-3.2 
years) There was also an increase in mean age with time overall, and for both 
sexes separately (ANOVA, P <0.001 for all 3 tests). Men increased in mean age at 
incidence from 67.43 in 1980 to 69.05 in 2005 with women increasing in mean 
age at incidence from 71.00 to 71.57 over the same time period. 
 
No statistically significant difference was noted when comparing proportions of 
colon cancer patients from different deprivation groups with sex (p=0.836) 
whereas a statistically significant difference was found when comparing 
proportions of rectal cancer patients from different deprivation groups with sex. 
32.7% of male rectal cancer patients were deprived compared to 29.7% of 
female rectal cancer patients. The affluent group contained 12.6% of the male 
patients whereas 14.9% of females’ rectal cancer patients were in the affluent 
group. N = 10095, p<0.001. A higher proportion of male rectal cancer patients 
were from the deprived group compared to females, 32.7% and 29.7% 
respectively. 
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Table 4 - Descriptive demographics of the study population. All 37964 patients registered as 
having colorectal cancer in the West of Scotland from 1980 to 2005. 
 
 Male Female Total 
Sex (%) 19023(50.1) 18941(49.9) 37964(100) 
Age Range 94(11-105) 93(14-106) 95(11-106) 
Mean age (sd) 69.15 (11.1) 72.17 (12.0) 70.65 (11.7) 
Median age 70.14 73.57 71.79 
Age group     <55 
                      55-64 
                      65-74 
                      >=75 
2027 
4039 
6765 
6192 
1669 
3112 
5535 
8625 
3696 
7151 
12300 
14817 
Colon cancer 13329 (47.9) 14521 (52.1) 27850 (100) 
Rectal cancer 5694 (56.3) 4420 (43.7) 10114 (100) 
Affluent* 2749 (49.1) 2845 (50.9) 5594 (100) 
Intermediate* 10319 (49.9) 10364 (50.1) 20683 (100) 
Deprived* 5907 (50.9) 5706 (49.1) 11613 (100) 
    
*Data were missing for 76 patients regarding deprivation category  
 
Health Board of residence 
 
The aim of a Managed Clinical Network is to provide equitable standards of care 
across the area that it covers.  We therefore compared demographic and clinical 
characteristics of patients from each of the five West of Scotland Health Board 
areas to determine if there were significant differences in casemix before 
calculating clinical outcomes. Firstly, absolute numbers of patients in each 
Health Board are considered in order to appreciate the variability throughout 
the West of Scotland. 
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Figure 7 demonstrates a wide range in absolute numbers of patients being 
diagnosed and treated in each Health Board.  
 
Figure 7 - Health Board of residence for all colorectal cancer patients in the West of 
Scotland from 1980 to 2005. N=37964. 
 
 
 
Figure 8 then highlights how these patients are distributed in relation to site of 
lesion. Overall 27850 patients (73.4%) and 10114 patients (26.6%) have colonic 
and rectal cancers, respectively. Furthermore, there is a statistically significant 
difference in these proportions across the region, p< 0.001. This appears to be 
explained by a higher proportion of rectal cancer patients in the Lanarkshire 
Health Board.  
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Figure 8 - Proportions of patients with colonic or rectal lesions in each Health Board. All 
patients with colorectal cancer in the West of Scotland from 1980 to 2005. N = 37890, p 
<0.001 
 
 
   
Socioeconomic Circumstances 
Figure 9 shows a drop in the proportion of deprived patients with time from 35% 
in 1980 to 30% in 2005. This is mirrored by an increase in the proportion of 
intermediate patients from 52% in 1980 to 60% in 2005, while the proportion of 
patients in the affluent deprivation group remains relatively constant with time 
according to this figure. A Chi square test for trend of  deprivation group of 
patients divided into 5 yearly intervals for all colorectal cancer patients in the 
West of Scotland from 1980 to 2005 yielded a p value of <0.001. 
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Figure 9 - Deprivation group vs year of incidence for all colorectal cancer patients in the 
West of Scotland from 1980 to 2005. N = 37888. 
 
 
 
 
Relationship between age and deprivation from 1980 to 2005 
 
Affluent patients tend to be older than their more deprived counterparts. Although there is a 
trend noted with regard to deprivation and site of tumour, it is possible that this could be 
partly explained by age. The following analyses explore this.  
Table 5 summarises the ANOVA results comparing age at diagnosis with 
deprivation group for all 37,964 colorectal cancer, all rectal, and then all 
colonic cancer patients in the west of Scotland from 1980-2005. Overall this 
suggests that there is a statistically significant relationship between SEC and 
patients with colonic cancer. This explains the significant trend seen in the 
population overall. Rectal cancer patients fail to demonstrate a significant 
difference in mean age between different degrees of SEC. Thus, age may be a 
confounding factor for the observed associations between colorectal cancers and 
socio-economic circumstances – and vice versa.  Survival analyses should 
therefore be adjusted for both variables to reduce their confounding effects.  
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Table 5 - Summary statistic 1-way ANOVA of mean ages by deprivation group for all 
colorectal cancer, all rectal cancer, and all colon cancer patients in the West of Scotland 
from 1980 to 2005.   
 
   Sum of 
Squares 
df Mean 
Square 
p 
colorectal cancer Between Groups 2761.93 2 1380.97 <0.001 
 Within Groups 5176137.58 37887 136.62  
Rectal Between Groups 666.70 2 333.35 0.09 
 Within Groups 1412041.28 10092 139.92  
Colon Between Groups 1868.41 2 934.20 <0.001 
 Within Groups 3750870.85 27792 134.96  
 
 
The relationship between sex and deprivation 
 
There are significantly more men with rectal cancer across all deprivation 
categories. This is not the case with regard to colonic cancer patients. There 
was no statistically significant difference in the proportions of males and 
females in each deprivation group (df = 2, Chi square 5.129, p=0.08). Whilst 
there are no socio-economic differences in the proportions of men and women 
with colon cancer (df = 2, Chi square = 0.538, p=0.836), there were significantly 
greater proportions of affluent men with rectal cancers, as evidenced below. 
 
Figure 10 highlights that for rectal cancer patients, there is a persistently higher 
proportion of male patients compared to females across the deprivation 
categories. In the affluent group 52.2% are male and 47.8% female. This 
difference is more pronounced in the deprived group where 58.7% of patients 
are male and 43.7% female. Overall the difference in proportions of male to 
female patients across the different deprivation categories is statistically 
significant, P<0.001. 
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Figure 10 - Comparison of sex with deprivation group for all patients with rectal cancer in 
the West of Scotland. n=10095 df = 2, Chi square = 16.90, p<0.001. 
 
 
Exploring the relationship between Dukes’ stage and deprivation 
 
There are more affluent people with Dukes’ A disease and more deprived people 
with Dukes’ D disease. Figure 11 shows there is a larger proportion of affluent 
people with early stage disease and a larger proportion of deprived patients with 
advanced disease. 14.7% of affluent patients have stage A disease compared to 
13.0% of deprived patients. 22.0% of affluent patients have stage D disease 
compared to 24.7% of deprived patients. n = 11126, p = 0.058.  While there is no 
clear socio-economic trend overall, there does seem to be a consistent and 
clinically important relationship between increasing deprivation and later stage 
at presentation.   
Additional testing of these variables using the Spearman rank test confirmed no 
correlation between SEC and Dukes’ stage. 
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Figure 11 - Dukes' stage and deprivation group in all colorectal cancer patients from 1997-
2005, excluding those with an unspecified Dukes' stage. n = 11166, p =0.058 
 
 
 
No significant difference in stage at presentation compared to socioeconomic 
circumstances was found in any of the sub groups studied. These included 
colonic cancer patients only, rectal cancer patients only, male colon only, 
female colon only, male rectal cancer patients only, and female colon patients 
only. These findings are consistent with previous findings in Europe but not with 
trends reported in the USA. 
 
Patients not enrolled into the West of Scotland MCN 
 
An aim of the MCN is to review all patients diagnosed with colorectal cancer in 
the region. This should provide access to specialist care for all patients. We 
compared the characteristics of patients included and not included in the MCN. 
Figure 12 demonstrates the reduction in overall numbers of patients enrolled 
into MCN care between 2001 and 2005 as the colorectal cancer MCN was formed. 
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Figure 12 - Numbers of patients not enrolled into the West of Scotland MCN with time, from 
2001 to 2005. 
 
 
 
 
Figure 12 summarises temporal trend in patient enrolment into the MCN. 
Patients in the MCN were on average two years younger than those managed 
elsewhere, p<0.001 (95% CI -2.788 to -1.276). 
Stage of disease is a recognised prognostic indicator for all cancers (182). It is 
therefore relevant to understand whether patients treated within an MCN differ 
from those not treated within an MCN with respect to their cancer stage. Table 7 
shows the main differences in the populations of patients enrolled and not 
enrolled in the MCN. Of note is that there is a far lower proportion (16.9%) of 
patients with an unspecified Dukes’ stage in the MCN compared to those not in 
the MCN (42.9%). Also, almost 30% of patients not enrolled in the MCN are in the 
Dukes’ D category. In general, patients in the MCN have less advanced disease.  
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Table 6 - Descriptive demographics for all 7749 patients enrolled and not enrolled in the 
MCN from 2001 to 2005.  
 
Numbers in brackets are % of total unless otherwise indicated. 
  in MCN not in MCN p 
Age at incidence mean (range) 68.9 (21-97) 73.77 (24-105)  
 sd. (95% CI) 11.3 (68.60-69.22) 12.01 (73.31-74.22) <0.01* 
Deprivation status affluent 767 (65.3) 408 (34.7)  
 intermediate 2956 (66.8) 1470 (33.2)  
 deprived 1336 (64.3) 760 (35.7) 0.12 
Sex male 2745 (65.6) 1441 (34.4)  
 female 2355 (66.1) 1208 (33.9) 0.63 
 Total 2649 (34.2) 5100 (65.8)  
*tested using ANOVA 
 
The descriptive statistics from table 6 show that there was a significant 
difference between the ages of patients enrolled and not enrolled in the MCN 
with those enrolled having a mean age of 3.8 years younger than their 
counterparts not in the MCN. There was no statistically significant difference 
between the two groups in relation to both deprivation status and sex. 
 
Table 7 - Comparison of Dukes' stage with all colorectal cancer patients enrolled and not 
enrolled in the MCN from 2001 to 2005. N=7749, P< 0.001 
 
  in MCN Total 
  Yes (%) No (%)  
Dukes’ stage A 637 (12.5) 163 (6.2) 800 (10.32) 
  B 1528 (30.0) 302 (11.4) 1830 (23.6) 
  C 1483 (29.1) 273 (10.3) 1756 (22.7) 
  D 589 (11.5) 774 (29.2) 1363 (17.6) 
  Unspecified* 863 (16.9) 1137 (42.9) 2000 (25.8) 
Total 5100 (100) 2649 (100) 7749 (100) 
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*The overall statistical significance did not change when the 2000 patients with 
Dukes’ unspecified cancer were removed from analysis. 
 
 
Given that there are demographic differences between the population of 
patients enrolled in the MCN and the population not, it is important to explore if 
there is a difference in overall survival. 
 
Survival 
 
The alternative hypothesis in this thesis is that the introduction of an MCN 
caused improvements in overall survival for colorectal cancer patients greater 
than would have otherwise occurred. We are interested in whether the 
reorganisation of services has accelerated or augmented the putative 
improvement. The following graphs represent the long-term changes with time 
for colorectal cancer patients, colon cancer patients, and rectal cancer patients. 
Three year survival was tested but did not add any important insights over and 
above those seen with five year survival. Graphs displaying these findings are in 
the appendix.  In the following Kaplan Meier plot, Figure 13, a statistically 
significant difference in the overall survival of these two groups with patients in 
the MCN demonstrating a 5.15 year increase in median overall survival compared 
to those patients not in the MCN. These are contemporaneous groups, thus 
eliminating the effect of comparing groups of patients from before with after 
MCN inception. 
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Figure 13 - Kaplan Meier plot of overall survival comparison between those patients enrolled 
in the West of Scotland MCN and those not from 2001-2005. n =7749, Log Rank test, 
p<0.001. 
 
Given the higher survival among patients treated within the MCN, table 8 
explores factors that could explain this.  
Age at incidence, degree of socioeconomic deprivation, degree of disease 
burden, having a colonic tumour and whether or not the patient has entered the 
MDT process all help to account for the difference in overall survival seen in the 
Kaplan Meier plot. These differences could be further explored if there were 
further clinical and pathological data available for the population of patients not 
entering into the MCN process.   
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Table 8 - Factors influencing overall survival for all 7749 patients diagnosed with colorectal 
cancer in the West of Scotland from 2000-2005. 2649 patients were not in MCN and 5100 
were in the MCN 
 p Univariate  
HR (95% CI) 
Multivariate  
HR (95% CI) 
In MCN or not <0.01 2.01 (1.87-2.15) 1.71 (1.59-1.83) 
(in MCN baseline)    
Age at incidence <0.01 1.03 (1.03-1.04) 1.03 (1.03-1.04) 
affluent  <0.01 1  
Intermediate 0.05 1.09 (1.00-1.19) 1.16 (1.06-1.26) 
Deprived <0.01 1.23 (1.12-1.35) 1.28 (1.16-1.41) 
Dukes' A <0.01 1  
Dukes' unspecified <0.01 6.82 (5.81-8.01) 6.17 (5.25-7.25) 
Dukes' B <0.01 1.81 (1.53-2.15) 1.82 (1.54-2.16) 
Dukes' C <0.01 3.05 (2.59-3.60) 3.22 (2.73-3.81) 
Dukes' D <0.01 11.92 (10.12-
14.03) 
12.72 (10.80-14.99) 
Sex 1.00 1.00 (0.94-1.06)  
Site of lesion (rectum 
vs colon) 
<0.01 1.24 (1.15-1.32) 1.14 (1.07-1.23) 
 
Following the findings from table 8 we went on to explore the relationship 
between  site of tumour and stage of disease as they were independent 
prognostic indicators. Table 9 shows a statistically significant difference in the 
incident proportions of rectal and colonic cancers according to stage with more 
rectal cancers presenting at Dukes’ stage A compared to colonic cancers and 
more colonic tumours presenting at Dukes’ D compared to rectal cancer. 
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Table 9 - Relationship between Dukes' stage at presentation and site of tumour for all 11166 
patients from 1997-2005. Pearson Chi square <0.001 
 
  rectum colon Total 
Dukes’ stage stage A 609 940 1549 
    21.8% 11.2% 13.9% 
  stage B 776 2896 3672 
    27.8% 34.6% 32.9% 
  stage C 839 2465 3304 
    30.0% 29.5% 29.6% 
  stage D 572 2069 2641 
    20.5% 24.7% 23.7% 
Total 2796 8370 11166 
  100.0% 100.0% 100.0% 
 
Overall Five year survival 
 
Figure 14 charts the increase in overall 5 year survival for the population of  
colorectal cancer patients in the West of Scotland region from 1980. There is an 
increase with time from fewer than 25% in 1985 to over 40% in 2001. There 
appears to be a stepwise increase between 1996 and 1997 from 32.48% to 
39.37%. 
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Overall Five year survival 
Figure 14 - Overall 5 year survival for all colorectal patients in the West of Scotland from 1980 to 2001. 
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The following figures (figures 16 and 17) display the trends noted for colonic and 
rectal cancer patients surviving five years. An overall increase in survival occurs 
with time from 22.5% in 1985 to 45.0% in 2001 for colon cancer patients. There 
are larger variations in survival with time for females with rectal cancer 
compared to males. This may well reflect the smaller numbers of patients with 
rectal compared with colonic cancers, with females having a lower incidence 
than men in the West of Scotland. 
Figure 15 – Comparison of overall five year survival for all 27795 colorectal cancer with all 
10095 rectal cancer patients in the West of Scotland from 1980 to 1996. 
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Figure 15 highlights that there appears to be very little difference in the overall 
5 year survival trends for both sexes. Again, there is a general increase in 
survival with time from an average of 26% in 1985 to 42% in 1996. There is no 
obvious difference between sexes.  
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Figure 16 - Comparison of overall five year survival for all 17700 male and female colon 
cancer patients in the West of Scotland from 1980 to 2001. 
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Figure 17 - Comparison of overall five year survival for male and female in all 10095 rectal 
cancer patients in the West of Scotland from 1980 to 1996. 
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Figure 17 illustrates a greater increase in five year overall survival for rectal 
cancer patients compared to colonic patients between 1980 and 2001. The 
steeper rise in survival seems to occur in the mid 1990s when the TME technique 
was being learned, adopted and applied across the West of Scotland. 
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Linear Regression Models 
 
Linear regression was used to quantify the increase in percentage of overall 
survival (the coefficient of the line) and to estimate any additional effect of the 
MCN after adjustment for time (per year). 
In order to gauge whether or not an increase in the percentage of patients 
surviving three years had occurred with time we employed linear regression to 
the values generated for overall three-year survival. We fitted three models 
using linear regression: a model with one explanatory variable, the year of 
incidence; a model with two explanatory variables, the year of incidence and a 
binary variable indicating whether the survival was pre-MCN or post-MCN; a 
model with three explanatory variables, the two previously mentioned and an 
interaction term between the year of incidence and pre/post MCN.  The model 
including the interaction term tests for a significant difference in the slope 
parameters for the two groups (pre-MCN and post-MCN).  If there is a significant 
interaction this implies that a difference in survival has taken place following 
the introduction of the MCNs. The following graphs demonstrate situations where 
a significant difference in the slope was obtained. No significant differences 
were found for five year overall survival so all plots refer to overall three year 
survival. In all plots α is the intercept of the line and β is the slope. 
Figure 18 to 20 demonstrate only those linear regression models producing 
statistically significant results. In terms of three year overall survival, there 
were statistically significant results for all female colorectal cancer patients 
from 1997-2005, female rectal patients from 1980-2005, and all rectal patients 
from 1980-2005. In terms of five year overall survival, only female rectal cancer 
patients were found to have a significantly improved survival after the 
introduction of the MCN than would have been expected. In figure 18 there 
appears to have been a decrease in survival from 52% to 50% over time from 
1996 to 2000, followed by an increase from 50% to 52% after the MCN was 
introduced. The paucity of data points is the most likely explanation for this. 
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Figure 18 - Linear regression. Overall three year colorectal cancer survival in all 
females in the West of Scotland from 1997-2005. Dashed vertical line represents 
the introduction of the MCN1 Pre MCN α = 2454.51, β= -1.20, Post MCN α = -
1384.46, β = 0.72. Year of incidence x MCN interaction, p = 0.022 
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Figure 19 - Linear regression. Overall three year rectal cancer survival for 
females in the West of Scotland from 1980-2005. Dashed vertical line represents 
the introduction of the MCN. Pre MCN α = 2079.022 , β = 1.015 
Post MCN α = -8194.1058 , β = 4.12 
Year of incidence x MCN interaction, p = 0.031 
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Figure 20 - Linear regression. Overall three year rectal cancer survival for all 
patients in the West of Scotland from 1980-2005. Dashed vertical line represents 
the introduction of the MCN. Pre MCN α = -2145 , β = 1.098  
Post MCN α = -5326.7 , β = 2.69  
Year of incidence x MCN interaction, p = 0.025 
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Figure 21 - Linear regression. Overall 5 year rectal cancer survival for females in 
the West of Scotland from 1997 to 2005. Dashed vertical line represents the 
introduction of the MCN. Pre MCN α = -2068.3914 , β = 1.059 
Post MCN α = -6862.14 , β = 3.45  
Year of incidence x MCN interaction, p = 0.022 
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Is the introduction of an MCN associated with increased overall survival? 
 
A comparison amenable for inclusion in a Cox model is that of pre-MDT years 
with MDT years in order to provide a binary variable for pre and post inception 
of the MCN. The major drawback of this approach is that patient data before 
2001 is limited to fewer variables.  
 
All colorectal cancer patients undergoing curative intent surgery 1997-2005 
 
The following table (Table 10) summarises the findings for both univariate and 
multivariate analysis for all colorectal cancer patients from 1997-2005 including 
a binary variable for pre and post MCN inception. All variables with the 
exception of the MCN variable remain individual prognostic indicators following 
adjustment in the multivariate model.  Unadjusted survival was not significantly 
different when comparing patients from before inception of the MCN with those 
after the MCN 
 
Table 10 - Univariate and multivariate findings for all 6851 colorectal cancer patients 
undergoing curative intent surgery from 1997-2005. (Pre MCN = 1997-2000. MCN = 2001-
2005) 
 
  
p 
Univariate 
HR (95% CI) 
 
p 
Multivariate 
HR (95% CI) 
MCN vs not  0.89 0.95 (0.87-1.03) 0.19 0.94 (0.87-1.03) 
Age at incidence 0.00 1.04 (1.04-1.05) 0.00 1.04 (1.04-1.05) 
affluent  0.00  0.00  
intermediate 0.01 1.76 (1.05-1.32) 0.00 1.23 (1.10-1.38) 
deprived 0.00 1.28 (1.13-1.44) 0.00 1.27 (1.12-1.44) 
Dukes' A 0.00  0.00  
Dukes' unspecified 0.00 1.71 (1.43-2.04) 0.00 1.70 (1.42-2.03) 
Dukes' B 0.00 1.50 (1.34-1.68) 0.00 1.41 (1.26-1.58) 
Dukes' C 0.00 2.04 (1.81-2.29) 0.00 2.15 (1.91-2.43) 
Dukes' D 0.00 4.76 (3.81-5.96) 0.00 5.70 (4.56-7.13) 
Male (baseline: female) 0.00 1.17 (1.03-1.20) 0.00 1.24 (1.15-1.34) 
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Survival in all colorectal cancer patients undergoing curative intent surgery 
from 2001-2005 
 
Cancer registry data can provide only limited information into changing 
determinants of survival.  Further information – particularly on clinical 
management – was available from MCN audit data. A further aim of this chapter 
is to ascertain factors influencing overall survival in patients undergoing curative 
intent surgery. It is in this subset of patients that the MCN process could affect 
the largest change in outcomes. Sufficient data for this population were only 
available for patients in the MCN. The following table displays the Cox 
proportional hazards model univariate and multivariate findings for all 3763 
patients with colorectal cancer undergoing curative intent surgery from 2001 to 
2005. It shows that age, deprivation category, Dukes’ stage, extra mural vascular 
invasion, and sex were all significant prognostic indicators of long-term 
outcome. The MDT in which patients were treated was a significant independent 
variable on univariate analysis, but not when included in the multivariate model. 
 
 
Multivariate modelling was then used in order to assess the relative contribution 
of various variables of interest to overall patient survival in the population 
undergoing curative intent surgery from 2001-2005. 
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Table 11 – Multivariate Cox proportional hazards model for all colorectal cancer patients 
undergoing curative intent surgery in the West of Scotland from 2001 to 2005. n = 3763. HR 
= Hazard Ratio. *continuous variable. 
 p Univariate 
HR (95% CI) 
Multivariate 
HR (95% CI) 
    
age at incidence* .000 1.044 (1.04-1.05) 1.05 (1.04-1.05) 
Deprivation – affluent .041   
Deprivation – intermediate .165 1.15 (0.98-1.35) 1.141 (0.95-1.37) 
Deprivation – deprived .014 1.35 (1.13-1.60) 1.28 (1.051-1.572) 
Dukes’ A .000   
Dukes’ B .000 1.71 (1.40-2.10) 1.46 (1.056-2.015) 
Dukes’ C .051 2.64 (2.20-3.22) 1.58 (1.216-2.053) 
Dukes’ D .484 5.68 (4.27-7.54) 4.87 (3.215-7.375) 
Differentiation – well .084   
Differentiation – moderate .975 1.03 (0.77-1.37) 0.99 (0.68-1.44) 
Differentiation – poor .332 1.50 (1.10-2.06) 1.22 (0.82-1.83) 
Distal margin positive .002 2.16 (1.48-3.12) 2.05 (1.29-3.24) 
Extra mural vascular invasion .000 2.03 (1.80-2.23) 1.61 (1.40-1.85) 
Apical node positive .000 2.37 (1.95-2.88) 1.68 (1.34-2.10) 
 
The previous analysis was repeated substituting Dukes’ stage with pathological 
tumour stage (pT) and pathological nodal stage (pN) as these are more specific 
measures than Dukes’ stage. No difference was found although fewer patients 
had complete data on TNM stage. Dukes’ was therefore retained as it gives the 
model more power.   
 
All rectal patients undergoing surgery with curative intent 
A separate analysis was undertaken for all rectal cancer patients in the West of 
Scotland from 2001 to 2005. This was for three main reasons. Firstly, rectal 
cancer patients are known to display better outcomes compared to colon cancer 
patients. This includes better one and five year relative survival for both men 
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and women (183). Secondly, there are a different set of objective pathological 
variables for this population, owing to the different anatomy of rectal tumours. 
Finally, the surgical management and preoperative treatments for rectal 
carcinoma can differ in important ways from that of colon cancer, as previously 
outlined. 
 
Table 12 demonstrates that five of the seven variables tested retain their 
statistical significance as independent prognostic indicators in the 702 rectal 
cancer patients undergoing surgery with curative intent in the West of Scotland 
from 2001 to 2005. A positive circumferential margin had the largest influence 
on overall survival (HR 2.06, 95% CI 1.50-2.83) whereas age at incidence had the 
most modest significant effect on overall survival with a 4% increase in hazard 
per year. As before, this analysis was repeated substituting Dukes’ stage with 
pathological tumour stage (pT) and pathological nodal stage (pN). No statistical 
difference was found although fewer patients had complete data on TNM stage 
so Dukes’ was retained as it gives the model more power. Also, type of admission 
was omitted from this model as we were interested in planned care within the 
MCN setting rather than emergency surgery. Of note is that type of admission 
was a significant independent prognostic indicator, p<0.001. 
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Table 12 – Univariate and multivariate model for all rectal patients undergoing surgery with 
curative intent in the West of Scotland from 2001 to 2005. n = 702. 
 P Univariate 
HR (95% CI) 
Multivariate 
HR (95% CI) 
Circumferential margin +ve <0.001 2.76 (2.08-3.66) 2.06 (1.50-2.83) 
Distal margin positive 0.03 2.29 (1.28-4.08) 1.97 (1.05-3.68) 
Extra mural vascular invasion 0.002 2.33 (1.83-2.96) 1.61 (1.19-2.18) 
age at incidence <0.001 1.04 (1.03-1.05) 1.04 (1.03-1.06) 
Dukes’ A 0.001 1.00  
Dukes’ unspecified <0.001 2.69 (1.87-3.90) 2.82 (1.73-4.58) 
Dukes’ B 0.02 1.77 (1.23-2.55) 1.75 (1.10-2.76) 
Dukes’ C <0.001 2.86 (2.03-4.04) 2.43 (1.56-3.78) 
Dukes’ D 0.03 5.57 (3.04-10.20) 2.78 (1.10-7.03) 
deprivation – affluent 0.61 1.00  
deprivation – intermediate 0.60 1.21 (0.86-1.69)  
deprivation – deprived 0.35 1.30 (0.91-1.87)  
sex - female as baseline 0.38 1.05 (0.85-1.29)  
 
Colon patients undergoing surgery with curative intent 
 
Table 13 shows that eight of the ten variables entered into the multivariate 
model retained their individual prognostic significance. There was no 
independent effect observed according to which MDT a patient was treated in. A 
perforated tumour had the largest effect on survival in the multivariate model 
with an increased hazard of 74%. Emergency versus routine/urgent admission 
was also an independent negative prognostic indicator as were extra mural 
vascular invasion and worsening socioeconomic circumstances. Dukes’ stage 
retained its negative prognostic significance as did age at incidence. Hospital 
MDT group and age were not statistically significant predictors of outcome in the 
adjusted multivariate model.
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Table 13 - Multivariate results for all 2774 colon cancer patients undergoing surgery with 
curative intent in the West of Scotland from 2001 to 2005. n = 2774 
  UNIVARIATE  MULTIVARIATE 
 p HR (95% CI) p HR (95% CI) 
tumour perforation – no 0.00 1.00 0.00 1.00 
tumour perforation – yes  2.12 (1.81-2.49)  1.74 (1.42-2.12) 
Admission type - routine/urgent 0.00 1.00 0.00  
Admission type – emergency  1.97 (1.74-2.24)  1.50 (1.28-1.76) 
peritoneal surface not involved 0.00 1.00 0.01 1.00 
peritoneal surface involved  2.04 (1.77-2.35)  1.26 (1.05-1.50) 
extra mural vasc invasion – no 0.00 1.00 0.00 1.00 
extra mural vasc invasion – yes  1.94 (1.69-2.24)  1.52 (1.29-1.79) 
Affluent 0.00 1.00 0.03 1.00 
Intermediate 0.10 1.17 (0.97-1.41) 0.21 1.15 (0.93-1.42) 
Deprived 0.00 1.40 (1.14-1.71) 0.01 1.34 (1.07-1.69) 
bowel prep – no 0.00 1.00 0.00 1.00 
bowel prep – yes  1.85 (1.62-2.12)  0.72 0.61-0.85) 
Dukes' A 0.00 1.00 0.00 1.00 
Dukes' unspecififed 0.00 2.34 (1.75-3.12) 0.01 1.56 (1.11-2.18) 
Dukes' B 0.00 1.68 (1.30-2.17) 0.60 1.08 (0.81-1.44) 
Dukes' C 0.00 2.54 (1.98-3.28) 0.00 1.52 (1.14-2.04) 
Dukes' D 0.00 5.41 (3.85-7.59) 0.00 4.26 (2.89-6.29) 
age at incidence 0.00 1.04 (1.04-1.05) 0.00 1.05 (1.04-1.06) 
MDT  0.43    
Sex 0.21 1.09 (0.96-1.23)   
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Determinants of survival in all rectal cancer patients undergoing curative 
intent surgery 1997-2005 
 
Unadjusted survival from rectal cancer was 18% lower (HR 0.82, 95% CI 0.70 to 
0.96) following introduction of the MCN.  However, after adjustment for 
patients’ age, Dukes’ stage and sex, survival was found to have increased by 23% 
(HR 1.23, 95% CI 1.05 to 1.44) after introduction of the MCN 
 
Table 14 - Univariate and multivariate findings for all 1921 rectal cancer patients undergoing 
curative intent surgery from 1997-2005. (Pre MCN = 1997-2000. MCN = 2001-2005).  
  
p 
Univariate HR  
(95% CI) 
 
p 
Multivariate HR 
(95% CI) 
Pre and post MCN 0.01 0.82 (0.70-0.96) 0.11 1.23 (1.05-1.44) 
Age at incidence* 0.00 1.04 (1.03-1.05) 0.00 
 
1.04 (1.04-1.05) 
affluent  0.14    
intermediate 0.05 1.25 (1.00-1.56)   
deprived 0.07 1.25 (0.98-1.60)   
Dukes' A 0.00    
Dukes' unspecified 0.00 1.65 (1.24-2.20) 0.00 1.91 (1.43-2.57) 
Dukes' B 0.00 1.56 (1.28-1.89) 0.00 1.50 (1.23-1.82) 
Dukes' C 0.00 2.13 (1.74-2.60) 0.00 2.29 (1.87-2.81) 
Dukes' D 0.00 3.27 (1.93-5.56) 0.00 3.76 (2.21-6.38) 
Sex§ 0.02 1.19 (1.03-1.39) 0.00 1.25 (1.07-1.45) 
*continuous variable,   §female baseline 
 
All colon cancer patients undergoing curative intent surgery 1997-2005 
 
Table 15 demonstrates that for all 6851 colon cancer patients in the West of 
Scotland undergoing curative intent surgery between 1997 and 2005 we found 
that age at incidence, deprivation group, Dukes’ stage and sex were all 
statistically significant independent prognostic indicators in both univariate and 
multivariate analyses. The binary variable for pre and post MDT was not 
statistically significant on univariate analysis. 
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Table 15 - Univariate and multivariate findings for all 6851 colonic cancer patients 
undergoing curative intent surgery from 1997-2005. (Pre MCN = 1997-2000. MCN = 2001-
2005). *continuous variable 
 p Univariate 
HR (95% CI) 
p Multivariate 
HR (95% CI) 
Pre and post MCN 0.99 1.00 (0.91-1.10)   
Age at incidence* 0.00 1.04 (1.04-1.05) 0.00 1.05 (1.04-1.06) 
affluent  0.00  0.00  
intermediate 0.03 1.16 (1.02-1.32) 0.07 1.19 (0.99-1.44) 
deprived 0.00 1.29 (1.12-1.49) 0.00 1.46 (1.19-1.78) 
Dukes' A 0.00  0.00  
Dukes' unspecified 0.00 1.76 (1.40-2.19) 0.00 2.21 (1.65-2.95) 
Dukes' B 0.00 1.48 (1.29-1.70) 0.00 1.67 (1.29-2.15) 
Dukes' C 0.00 1.99 (1.72-2.31) 0.00 2.63 (2.04-3.39) 
Dukes' D 0.00 5.14 (3.99-6.61) 0.00 6.52 (4.63-9.15) 
Sex (♀ baseline) 0.04 1.10 (1.00-1.20) 0.01 1.19 (1.05-1.35) 
 
Figure 22 confirms the heterogeneity in distribution of deprivation across the 
region in relation to 27,795 patients with colonic cancer. Glasgow Health Board  
has the largest proportion of deprived colon cancer patients (51.8%) whereas 
Forth Valley has the highest percentage of affluent patients (26.3%) with colon 
cancer. These differences are examined with reference to rectal cancer patients 
below. 
 
The following figure summarises the relationships between Health Board and 
proportions of patients with rectal and colonic cancers therein. Lanarkshire has 
the largest proportion of rectal cancer patients (28.7%) as well as the second 
lowest proportion of deprived patients (see figure 3 above). This contrasts with 
Argyll and Clyde where the largest proportion of colonic cancers occur (74.40%) 
and the proportion of affluent patients is higher. There is no clear cut linear or 
reciprocal relationship between these two factors. 
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Figure 22 - Proportions of colon and rectal cancers across Health Boards in the West of 
Scotland from 1980-2005. n = 37890, chi squared = 21.54, df = 4,  p<0.001. 
 
 
 
Exploring site of lesion in relation to Socioeconomic Circumstances 
 
Affluent patients tend to have more colonic and fewer rectal cancers. From 1980 
to 2005 data regarding site of lesion are available. The relationships between 
socioeconomic circumstances and distribution of colonic and rectal lesions are 
illustrated below.Table 16 represents the statistically significant larger 
proportion of deprived patients presenting with rectal cancer (27.4%) compared 
to affluent patients (24.1%). In contrast, there is a larger proportion of affluent 
patients with colonic cancer (75.9%) compared to deprived patients (72.6%), Χ2 = 
7.73, df = 2 p<0.001. 
 
Table 16 – Comparing proportions of colonic and rectal cancer patients in the West of 
Scotland population from 1980-2005 according to deprivation group. n = 37890, χ2 = 15.86, 
df = 2, p<0.001 
SEC Rectum (%) Colon (%) Total 
Affluent 1372 (24.5) 4222 (75.5) 5594 (100) 
Intermediate 5552 (26.8) 15131 (73.2) 20683 (100) 
Deprived 3171 (27.3) 8442 (72.7) 11613 (100) 
 
This result was further explored by comparing the proportions of patients with 
rectal and colonic in different deprivation groups from two separate time 
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periods, namely, 1980-1985 and 2000-2005. These results are summarised in 
Table 17 below. 
 
In both periods, the same relationship between site of lesion and SEC was found, 
namely that more deprived patients have a higher proportion of rectal lesions 
compared to colonic lesions. Affluent patients demonstrate the reciprocal of this 
with a higher proportion of colonic lesions. 
 
Table 17- Comparison of proportions of patients with rectal and colonic cancer in different 
periods of time, 1980-1985 and 2000-2005. n =17126. 
Time 
period 
n rectal (%) colonic (%) Chi square df p 
1980-1985 7805 2156 (27.6) 5649 (72.4) 15.63 2 <0.001 
2000-2005 9321 2529 (27.1) 6792 (72.9) 7.73 2 0.021 
  
This finding could be confounded by age. 
 
 
 
 
Socio-economic circumstances, type of admission and type of surgery 
 
The following table, table 17 highlights the higher proportion of affluent 
patients admitted electively compared to deprived patients – 60.73% compared 
to 50.76% respectively. There is an inverse trend in emergency admissions with 
affluent patients having the lowest proportion (39.27%) compared to deprived 
patients, with the highest proportion (49.33%). These trends are statistically 
significant, p<0.001. 
 
Table 18 - Socioeconomic circumstances compared to type of admission for all patients 
diagnosed with colorectal cancer in the West of Scotland from 2000-2005. Chi 26.50, df 2, P 
<0.001. n = 6252. 
SEC Elective (%) Emergency (%) Total (%) 
Affluent 563 (60.73) 364 (39.27) 927 (100) 
Intermediate 2015 (55.91) 1589 (44.09) 3604 (100) 
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Deprived 872 (50.76) 849 (49.33) 1721 (100) 
Total 3450 (55.18) 2802 (44.82) 6252 (100) 
 
We also compared all 4315 patients presenting electively for colon cancer 
surgery with 1113 presenting as an emergency between 2000 and 2005 and found 
no statistically significant difference in the proportions of patients from each 
deprivation group. Chi 4.203, df 2, p = 0.122. 
 
Is there any difference in time taken to first treatment with regard to 
deprivation status? 
Following the results from table 17 above, we would expect that as there is a 
statistically significant difference in the proportions of elective and emergency 
admissions compared to socioeconomic status there could be a difference in 
time to first treatment according to socioeconomic circumstances. 
 
Of the 7749 patients with colorectal cancer in the West of Scotland from 2000-
2005, 5668 (73.1%) had data regarding time taken from date of diagnosis to date 
of first treatment. Of these, 5656 patients waited up to a year for treatment. 
There was no difference seen between groups from different social 
circumstances. This information is displayed in figure 23.  
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Figure 23 - Boxplot of time taken to first definitive treatment for all 5656 patients with 
colorectal cancer and valid data from 2000-2005 according to deprivation group. n =5668. 
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Table 19 displays the 1-way ANOVA analysis undertaken to test for a significant 
difference in mean time taken to first definitive treatment. The mean times to first 
definitive treatment for affluent, intermediate and deprived patients were 30.57, 32.29 
and 30.66 days respectively. There was no statistically significant difference found, p = 
0.34. 
 
Table 19 - 1-way ANOVA of socio-economic group by time to first definitive treatment from 
date of diagnosis for 2786 colorectal cancer patients from 2000-2005. 
 N Mean Std. 
Deviation 
Std. 
Error 
95% CI  
Lower 
Bound 
95% CI 
Upper 
Bound 
affluent 450 30.57 27.80 1.31 28.00 33.15 
intermediate 1627 32.29 30.30 0.75 30.82 33.76 
deprived 709 30.66 28.06 1.05 28.59 32.73 
Total 2786 31.60 29.35 0.56 30.51 32.69 
 
 
 Sum of Squares df Mean 
Square 
F Sig. 
Between Groups 1875.29 2 937.65 1.09 0.34 
Within Groups 2396843.43 2783 861.24   
Total 2398718.72 2785    
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Relationship between socioeconomic circumstances and decision to undergo 
surgery. 
 
Table 20 shows proportions of all patients within each DEPCAT group receiving 
surgery or not. This result indicates that there is no statistically significant 
evidence that surgical treatment is associated with patients’ socio-economic 
circumstances. There is a 1.7% difference between affluent and deprived, and a 
socio-economic trend from affluent to deprived. It indicates that the chances of 
receiving surgery are not affected by SEC. When subdivided into rectal and 
colonic cancer patients there was no statistically significant difference found 
with n=1993 (p=0.164) and n=5029 (p=0.905) respectively. 
Table 20 - Comparison of deprivation group with decision to undergo surgery in all 
colorectal patients in the West of Scotland from 2000 to 2005. n = 7022, p = 0.474 
Deprivation category 
 
receiving surgery 
n (%) 
 
not receiving surgery n 
(%) 
 Affluent 919 (85.3) 158 (14.7) 
Intermediate 3411 (84.3) 633 (15.7) 
Deprived 1590 (83.6) 311 (16.4) 
 
 
The above findings were further explored using univariate and multivariate Cox 
proportional hazards modelling in order to determine which factors exert an 
independent influence upon outcome.  Of all the factors tested on univariate 
analysis, all retained their significance in the multivariate model apart from site 
of tumour. By not having surgery, the HR was 2.04. If a patient presents as 
anything but an elective case, the HR was 2.78. There was an increasing HR 
noted with worsening SEC with affluent as a baseline. Worsening disease stage 
was also an independent prognostic indicator with a HR of 34.74 for Dukes’ D 
disease compared to Dukes’ A as baseline. Increasing age retained its 
significance as an independent prognostic indicator in the multivariate model. A 
5% increased risk of death (HR 1.05) was seen with every years increase in age. 
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Table 21 – Combined univariate and multivariate analysis of factors determining patient 
outcome in all colorectal cancer patients in the West of Scotland from 2000 to 2005. n = 
7022. *continuous variable. 
 
  Univariate  Multivariate 
Variable p HR(95% CI) p HR(95% CI) 
      
     
surgery yes or no 
(yes baseline) 
<0.001 10.19 (8.29-12.52) <0.001 2.04 (1.48-2.82) 
presentation for 
surgery 
<0.001 3.26(2.83-3.75) <0.001 2.78 (2.37-3.26) 
(elective baseline)     
affluent 0.00 1.00 <0.001 1.00 
intermediate 0.03 1.14(1.01-1.28) 0.01 1.25 (1.05-1.50) 
deprived 0.00 1.35(1.18-1.53) <0.001 1.57 (1.29-1.91) 
Dukes' stage A <0.001 1.00 <0.001 1.00 
Dukes' stage 
unspecified 
<0.001 3.55(3.00-4.21) <0.001 3.33 (2.60-4.25) 
Dukes' stage B <0.001 1.92(1.62-2.27) <0.001 1.74 (1.39-2.19) 
Dukes' stage C <0.001 9.17(7.71-10.92) <0.001 3.54 (2.82-4.43) 
Dukes' stage D <0.001 41.46(32.72-52.53) <0.001 34.74 (25.04-48.19) 
colon or rectum  
(colon baseline) 
<0.001 1.27(1.16-1.40) 0.21 0.91 (0.79-1.05) 
age  (by year)*  <0.001 1.04(1.04-1.05) <0.001 1.05 (1.04-1.05) 
sex (female 
baseline) 
0.21 1.05 0.97  
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Patients were divided into 2 groups. Firstly, those from 1997 to 1999. Then 2000 
to 2005, i.e. pre-MCN inception and MCN respectively. Our hypothesis is that any 
differences noted with regard to type of surgery performed could be due to the 
effect of open discussion of cases in the MDT forum. We found that patients 
from 1997-1999 from more affluent circumstances were significantly (p=0.018) 
more likely to receive a curative surgical procedure. As noted above, socio-
economic deprivation is not associated with more advanced stage at 
presentation.   This pertains to all colorectal cancer patients before the 
inception of the MCN, that is, before 2000. Given that there is no difference in 
stage at presentation, as presented above, there may be other reasons to 
explain this difference. There was no difference found when comparing 
proportions in the same group from 2000 onwards. MCN implementation, Intent 
of surgery vs Deprivation group in all colorectal cancer patients undergoing 
surgery in the West of Scotland from 2000-2005. n=6776, p=0.172 
 
Further subgroup analyses confirmed this trend for patients with colonic 
tumours. Those with rectal cancer did not display the same trend however. This 
may be due to the lower number of overall cases of rectal cancer. 
Table 22 provides evidence for the factors determining the decision as to 
whether the intent of operation was deemed curative or palliative.  
Only Dukes’ stage and presentation for surgery were statistically significant 
determinants in relation to operative intent. These retained their significance in 
the multivariate model.  
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Table 22 – Univariate and multivariate findings for all 4873 colorectal cancer patients 
undergoing surgery from 2000-2005 in the West of Scotland. Factors linked with operative 
intent. 
 
Variable   Univariate  Multivariate 
 p OR (95% CI) p OR (95% CI) 
Age 0.64 1.00 (1.00-1.01) 0.00 1.01 (1.00-1.02) 
Sex 0.38 0.94 (0.81-1.08) 0.51 1.06 (0.89-1.27) 
Deprivation group     
Affluent 0.08 1 0.09 1 
Intermediate 0.08 1.22 (0.98-1.51) 0.38 1.13 (0.86-1.47) 
Deprived 0.03 1.31 (1.03-1.66) 0.04 1.34 (1.01 – 1.79) 
Dukes’ A 0.00 1 0.00 1 
Dukes’ B 0.00 0.07 (0.04-0.14) 0.00 3.98 (2.07-7.68) 
Dukes’ C 0.00 0.34 (0.26-0.45) 0.00 12.09 (6.28-23.26) 
Unspecified 0.03 0.77 (0.61-0.97) 0.00 8.59 (4.51-16.37) 
Dukes’ D 0.00 15.37  (11.67-20.26) 0.00 189.86 (98.04-367.69) 
Presentation for 
surgery (elective 
baseline) 
    
Emergency 0.00 3.38 (2.89-3.96) 0.00 3.00 (2.48-3.64) 
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Surgical complications and socio-economic deprivation 
 
We sought to determine the extent to which postoperative complications are 
related to colorectal cancer patients in the West of Scotland. Thirteen 
commonly measured surgical and general medical complications were tested for 
their relationships with all 6321 colorectal cancer patients together, then 
separately with 4467 colonic cancer patients, and 1854 rectal cancer patients. 
No statistically significant association was found between greater socio-
economic deprivation and any of the complications.   
 
Survival analyses 
 
Kaplan-Meier survival curves provide a helpful visual indication of survival 
differences between risk groups with logrank p-values indicating whether there 
are overall differences between them.  However, Kaplan-Meier plots are 
univariate and therefore do not adjust for confounding effects such as the age 
differences between patients from different socio-economic groups.  Cox 
Proportional Hazards Models (CPHM) allow for multiple adjustment of risk factors 
between groups. Additional information on casemix was available in the Cancer 
Registry from 1997 onwards and from 2000 onwards, further information was 
available from the MCN audit which was linked to Registry data. These are 1980-
2005, 1997-2005 and 2000-2005. 
 
 
Figure 24 indicates that increasing socio-economic deprivation was associated 
with significantly poorer all-cause survival (logrank test, p = 0.037) among all 
11030 colorectal cancer patients treated by surgery in the West of Scotland 
between 1997 and 2000.  
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Figure 24 – All-cause Kaplan-Meier plot for all 3870 patients undergoing surgery for 
colorectal cancer in the West of Scotland from 1997 to 2000. n =11030. Log rank = 0.037 
 
 
Figure 25 demonstrates a statistically significant and consistent relationship 
between worsening socioeconomic circumstances and poorer overall survival for 
all 7160 colorectal cancer patients undergoing surgery from 2000 onwards.  
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Figure 25 - All-cause Kaplan-Meier plot for all patients undergoing surgery from 2000 to 
2005 according to socioeconomic circumstances. n = 7160, p = 0.003 
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All colorectal cancer patients 
From 1980 to 2005, univariate analysis of all 37,964 patients with colorectal 
cancer yielded statistically significant differences for age group, deprivation 
group, Health Board of residence, year of incidence, and site of tumour. 
Inclusion of these five significant variables in the multivariable model returned 
results indicated that only site lost its individual prognostic significance for 
overall survival. In particular, being deprived confers an excess hazard of 15% 
compared to affluent patients, following adjustment for age group, Health Board 
of residence, and year of incidence. 
 
Table 23 presents unadjusted (univariate) and adjusted (multivariate) hazard 
ratios for all-cause mortality among colorectal cancer patients in the West of 
Scotland between 1980 and 2005.  Increasing age, worsening socioeconomic 
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circumstances, Health Board of residence and year of incidence were all 
significant predictors of all cause survival in both univariate and adjusted 
analyses.  Compared with patients in the most affluent areas, patients in 
intermediate and deprived areas had increased mortality of 6% and 15% 
respectively.  Compared with patients <55 years of age, those aged over 74 were 
at over 2.5 times greater hazard of death.  Only Health Board five had a 
significantly different survival from the baseline area, Health Board one, with 
12% greater hazard (HR 1.12, 95% CI 1.07 to 1.17).  Hazards fell by 2% each 
successive year. 
 
Table 23 - Univariate and multivariate results for all 37890 colorectal cancer patients with 
colorectal cancer in the West of Scotland from 1980 to 2005. SEC, age group, Health Board 
of residence, and year of incidence all contribute to explaining differences in overall 
survival. 
  Univariate  Multivariate 
 p HR (95%CI) p HR (95%CI) 
Sex (female baseline) 0.30 1.01 (0.99-1.03)   
affluent 0.00 1 0.00 1 
intermediate 0.00 1.08 (1.04-1.12) 0.00 1.06 (1.03-1.110) 
deprived 0.00 1.17 (1.13-1.21) 0.00 1.15 (1.11-1.19) 
Age <55 0.00 1 0.00 1 
Age 55-64 0.00 1.24 (1.18-1.30) 0.00 1.26 (1.20-1.32) 
Age 65-74 0.00 1.55 (1.48-1.62) 0.00 1.58 (1.51-1.65) 
Age >=75 0.00 2.44 (2.34-2.55) 0.00 2.54 (2.43-2.66) 
Health Board 1 0.00 1 0.00 1 
Health Board 2 0.33 1.02 (0.98-1.07) 0.78 1.01 (0.96-1.05) 
Health Board 3 0.13 1.04 (0.99-1.08) 0.47 1.02 (0.97-1.06) 
Health Board 4 0.00 1.07 (1.03-1.11) 0.53 0.99 (0.95-1.03) 
Health Board 5 0.00 1.09 (1.04-1.14) 0.00 1.12 (1.07-1.17) 
Year of incidence 0.00 0.98 (0.97-0.98) 0.00 0.97 (0.97-0.98) 
Site (colon baseline) 0.00 1.06 (1.04-1.09) 0.17 1.02 (0.99-1.04) 
 
Table 24 focuses on patients from 1997 onwards. The addition of Dukes’ stage 
and operative intent add a further two statistically significant, independent 
prognostic indicators of overall survival. Initially, the variables from the previous 
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table were used.  Year of incidence lost its independent effect in this model. All 
other variables remain statistically significant. Deprivation remains an 
independent predictor of mortality even after adjustment for age, stage and site 
of lesion, exerting a 24% increase in hazard for deprived patients when 
compared to the affluent group. There were significant variations in hazard ratio 
between Health Board areas (p<0.01) such that residents of Boards three and 
four were at 13% and 14% lower hazard, respectively, compared with Board one.  
 
Table 24 - Cox proportional hazards modelling results for all colorectal cancer patients 
undergoing surgery from 1997-2005. 
  Univariate  Multivariate 
  p HR (95% CI) p HR (95% CI) 
affluent 0.00  0.00  
intermediate 0.00 1.10 (1.04-1.17) 0.01 1.09 (1.02-1.17) 
deprived 0.00 1.23 (1.15-1.31) 0.00 1.24 (1.15-1.34) 
Age <55 0.00  0.00  
Age 55-64 0.01 1.15 (1.04-1.26) 0.00 1.23 (1.11-1.36) 
Age 65-74 0.00 1.44 (1.32-1.57) 0.00 1.57 (1.43-1.73) 
Age >=75 0.00 2.44 (2.24-2.66) 0.00 2.38 (2.17-2.62) 
Health Board 1 0.01  0.00  
Health Board 2 0.26 0.95 (0.88-1.04) 0.27 0.95 (0.87-1.04) 
Health Board 3 0.32 0.96 (0.98-1.04) 0.00 0.87 (0.80-0.95) 
Health Board 4 0.38 1.03 (0.96-1.11) 0.00 0.86 (0.79-0.93) 
Health Board 5 0.17 1.06 (0.98-1.14) 0.96 1.00 (0.92-1.09) 
Year of incidence NS    
Intent of operation  
(curative baseline) 
0.00 6.75 (6.44-7.08) 0.00 4.10 (3.86-4.35) 
Site (rectum baseline) 0.00 1.15 (1.10-1.20) 0.00 1.15 (1.09-1.22) 
Dukes' Stage A 0.00  0.00  
Dukes'  unspecified 0.00 6.16 (5.57-6.80) 0.00 2.92 (2.62-3.27) 
Dukes' stage B 0.00 1.65 (1.49-1.82) 0.00 1.40 (1.26-1.55) 
Dukes' stage C 0.00 2.70 (2.44-2.98) 0.00 1.75 (1.58-1.95) 
Dukes' stage D 0.00 9.88 (8.94-10.92) 0.00 3.41 (3.04-3.83) 
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3.6 Summary – Demographics and Determinants of Survival 
Overall survival is poorer among patients from more deprived areas. Compared 
to their affluent counterparts, deprived patients with colorectal cancer have a 
24% increased hazard following adjustment for age, stage of disease, Health 
Board of residence and operative intent. 
A mean case ascertainment of 98% was achieved for the eight variables available 
from 1980 onwards. We found that median age at incidence was three years 
higher in women compared to men. There was an increase in mean age at 
incidence with time for both sexes separately and overall (ANOVA, P <0.001 for 
all 3 tests). Men increased in mean age at incidence from 67.43 in 1980 to 69.05 
in 2005 whereas women increased in mean age at incidence from 71.00 to 71.57 
over the same time period. 
No statistically significant difference was noted when comparing proportions of 
colon cancer patients from different deprivation groups with sex (p=0.836) 
whereas a statistically significant difference was found when comparing 
proportions of rectal cancer patients from different deprivation groups with sex. 
32.7% of male rectal cancer patients were from the deprived group compared to 
29.7% of female rectal cancer patients. The affluent group contained 12.6% of 
the male rectal cancer patients whereas 14.9% of female rectal cancer patients 
were in the affluent group. N = 10114, p<0.001. We noted a higher proportion of 
rectal cancer patients in the Lanarkshire Health Board compared with other 
health boards. 
 
A reduction in the proportion of deprived patients with time from 35% in 1980 to 
30% in 2005 was noted. This was mirrored by an increase in the proportion of 
intermediate patients from 52% in 1980 to 60% in 2005, while the proportion of 
patients in the affluent deprivation group remained constant with time. We 
found that affluent patients tended to be older at time of incidence compared 
to their more deprived counterparts. Furthermore, there were significantly more 
men with rectal cancer across all deprivation categories. This was not the case 
with colonic cancer patients. There was no statistically significant difference in 
the proportions of males and females with colorectal cancer in each deprivation 
group but we found that affluent patients tend to have more colonic cancers and 
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fewer rectal cancers. Also, there were more affluent people with Dukes’ A 
disease and more deprived people with Dukes’ D disease in this population. 
Regarding patients enrolled in the MCN, there was a 5.15 year increase in 
median overall survival compared to those patients not in the MCN. Of the 
measurable variables age at incidence, degree of socioeconomic deprivation, 
degree of disease burden, having a colonic tumour (as opposed to rectal) and 
whether or not the patient had entered the MDT process all help to account for 
the difference in overall survival seen between those enrolled in the MCN and 
those not. In terms of five year overall survival, only female rectal cancer 
patients were found to have a significantly improved survival following 
introduction of the regional MCN compared to the baseline improvement that 
would have been expected without an MCN. 
For all 3763 patients with colorectal cancer undergoing curative intent surgery 
from 2001 to 2005 age, socioeconomic circumstances, Dukes’ stage, extra mural 
vascular invasion, and sex were all significant prognostic indicators of overall 
long-term outcome. The MDT in which patients were treated was a significant 
independent variable on univariate analysis, but not when included in the 
multivariate model. In all rectal cancer patients undergoing curative intent 
surgery from 1997-2005 survival was found to have increased by 23% (HR 1.23, 
95% CI 1.05 to 1.44) after introduction of the regional MCN in 2001. 
We found that the chances of receiving surgical intervention for colorectal 
cancer are not determined or influenced by socioeconomic circumstances. This 
demonstrates an equitable and unbiased provision of service. This is a key tenet 
of the MCN model and aim of the cancer services reorganisation. 
No statistically significant association was found between greater socio-
economic deprivation and any of the immediate postoperative complications 
recorded. 
Increasing age, socio-economic deprivation, Health Board of residence and year 
of incidence were all significant predictors of all cause survival in both 
univariate and adjusted analyses for all 37890 colorectal cancer patients in the 
West of Scotland from 1980 to 2005.  Compared with patients in the most 
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affluent areas, patients in intermediate and deprived areas had increased 
mortality of 6% and 15%, respectively.  Compared with patients <55 years of age, 
those aged over 74 were at over 2.5 times greater hazard of death. 
3.7 Discussion 
Regarding demographics of our population, we found results consistent with 
previous series (67). There was a significant increase in mean age at incidence 
with time in the West of Scotland from 1980 to 2005. Of the entire colorectal 
cancer population in the region from 1980 to 2005, 19023 (50.1%) were male. 
The mean age of males was 69.15 compared to 72.17 for women. Three year 
overall survival has increased from around 30% in 1980 to approximately 45% in 
2004 with rectal cancer survival increasing more markedly from 30% in 1980 to 
approximately 55% in 2004. The increase was more pronounced for female 
patients with rectal cancer. We have demonstrated a statistically significant 
larger proportion of Dukes’ A tumours at the rectum along with a higher 
proportion of Dukes’ C & D stage tumours in the colon. Stage A disease at 
incidence is more common in the rectum than colon. Women tend to present 
with more proximal lesions compared to men, who tend to present with more 
distal lesions. A higher proportion of non-MCN patients had Dukes’ stage D 
disease (44.4% versus 23.7% respectively). Non-MCN patients were also 
significantly older. Site of lesion remains a significant independent prognostic 
indicator. There was significant variation in overall survival between Health 
Boards despite adjustment for age, sex, stage and SEC. 
Trends with age 
 
The mean age at diagnosis has recently been reported as 73 in a large review of 
the US literature on colorectal cancer (184). This compares well to the mean age 
of 71 in the West of Scotland. This difference may be a significant difference as 
it involves large populations. It could be explained by the fact that the 
population in the West of Scotland is more deprived, the methods of data 
collection are more accurate, and the case ascertainment percentage is higher. 
Methods of cancer detection may also be more widely employed in our 
population as we have a different healthcare system compared to the US. The 
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population of the West of Scotland may also be less prone to migration, a 
common cause of underreporting of incident cases of cancer. 
 
In the United States, men are more likely to develop colorectal cancer and to 
die from it than their female counterparts. Women tend to develop colorectal 
cancer later in their lives than men (184). Data presented in the results section 
confirm these two findings in our population with men outnumbering women by 
19023 to 18941 at a mean age of 69.15 compared to 72.17 (p<0.001). It is 
thought that this is due to a biological protective effect of oestrogens as women 
are found to develop colorectal cancer more frequently after the menopause. To 
date though, this has only been supported by a large study showing a protective 
role of exogenous hormones in the risk of colorectal cancer among women (185). 
Unfortunately there was no way to account for degree of comorbidity in our 
patients. Only 1618 patients of a total 11070 undergoing surgery (i.e. 14.62%) 
had ASA grade assigned. This was felt to be too small a number to provide 
meaningful results. One method of attempting to account for this would be to 
match patient details with SMR01 records. The number of hospital admissions 
during the six months prior to diagnosis could then be calculated and be used as 
a proxy marker for comorbidity. 
 
We have shown that there was a significant increase in mean age at incidence 
with time in the West of Scotland from 1980 to 2005. This was statistically 
significant for both sexes together and individually (P <0.001 ANOVA). 
We wanted to know whether there was an age bias when selecting intent of 
operation in the West of Scotland. Our results indicate that of the 5196 patients 
with these data, there was no significant difference in operative intent between 
age groups (p= 0.827). Unfortunately these data have only been recorded since 
the inception of the MCN so there is no way to tell whether or not the MCN has 
had an effect in the decision making process with regard to intent. We were also 
unable to assess the degree to which elderly patients are given chemotherapy 
for metastatic disease. This is an area where there has traditionally been a lot of 
bias towards younger patients due to the perception that older colorectal cancer 
sufferers will fare worse than their younger counterparts when given 
chemotherapy. This issue is summarised succinctly in a recent editorial (186). 
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Of the 11063 patients from 1997-2005 with data regarding age at surgery there 
was no statistically significant difference between the year of incidence and the 
age group at surgery (p=0.051). This was also confirmed by testing ANOVA using 
age as a continuous variable. 
 
Numerous questions abound with regard to age and colorectal cancer patients. 
These become more important as the population demographics change towards a 
more elderly population. One could also argue that as patients who will be 
undergoing resection become older, they require a wider range of specialities to 
provide input into their management as they are more likely to have more co 
morbidities. This provides a reason for MDT discussion and has repercussions for 
changes in service provision. 
 
In an MDT the prevailing attitude should be equality of treatment at any age, 
dependent upon suitability for treatment. Previous reports suggest that there is 
a bias towards younger patients when selecting for suitability for chemotherapy 
(187). Prior to this, a Dutch group had already reported in a series of 294 
patients who were stage and site matched, that there were no statistically 
significant differences in postoperative complications and cause specific survival 
when comparing a group of young patients (mean age 63) and a group of older 
patients (mean age 80) (188). 
 
A further issue regarding age is that of age at surgery. With an increasingly older 
population (proven above) one would expect to find a significantly larger 
proportion of patients in the >75 age group with time. It would appear from our 
data that this is not the case. This may point towards a bias in patient selection 
for surgery but it may also mean that the decision to palliate patients is being 
made appropriately. 
Trends with gender 
 
Of the entire colorectal cancer population in the region from 1980 to 2005, 
19023 (50.1%) were male. The mean age at incidence for males was 69.15 
compared to 72.17 in women, mean difference of 3.02 years with a 
corresponding 95% confidence interval (2.78,3.25) assuming equal variances. 
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This result indicates that women are in general older by three years at time of 
incidence compared to men, confirming findings from a large U.S. review paper 
by Payne (184).  These appeared to be spread equally between Health Boards 
but chi square testing revealed a statistically significant difference between 
Health Boards in relation to sex. This is likely to be due to the large number 
involved. It is accounted for in any conclusions drawn from the data.  
 
Women have a greater risk of proximal colorectal cancer, which tends to be 
more advanced when diagnosed. Despite this, women experience a better 
survival outcome compared to men for this type of tumour. The better overall 
survival prospects are thought to relate in part to biological and genetic factors 
and in particular to sex differences in the immune function, where female sex 
steroids offer women protection both from the disease and also in terms of 
survival (184). We measured overall survival for all 14097 patients with 
colorectal cancer from 1997-2005. There was no statistically significant 
difference between the groups at a mean follow-up of 4.6 years (Log Rank = 
0.55). This is due the fact that adjustments had not been made for age, stage 
and site. 
 
There are variations between women and men in the type and location of 
colorectal cancer experienced (outlined below), which relate in part to 
biological factors including hormones and gene expression.  For example, right-
sided colon cancer is highest among women, men more often have cancer of the 
left colon, and men are more frequently diagnosed with rectal cancer. These 
findings suggest sex or biological differences between men and women. Research 
on hormonal factors also suggests a biological basis for the gap (185).  Women 
tend to develop colorectal cancer at a later age, which may reflect the 
protective effect of female hormones prior to the menopause, and possibly also 
Hormone Replacement Therapy (HRT). Studies of the association between HRT 
and colorectal cancer suggest it reduces the risk of colon cancer but not rectal 
cancer (189).  Further evidence to support this theory comes from the US where 
a reduction in women’s colorectal cancer rates was witnessed in the 1950s when 
hormonal treatment came into use. It was not witnessed in men until the 1980s 
or 1990s.  There is also an association between cancers of the female 
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reproductive system and colorectal cancer (184). Despite this, women, on 
average are older at presentation for colorectal cancer in our region.  
 
The largest colorectal care survey ever undertaken in Australia found that men 
were more likely to suffer from colorectal cancer than women and that rectal 
cancer was more common in men than women (71). We have confirmed both of 
these findings herein with a total of 10114 rectal cancer patients from 1980 to 
2005, 5694 (56.3%) of whom were men. 
 
Overall survival 
 
To our knowledge, this is the first time that this type of linear regression 
modelling has been applied to explore the effects of introducing an MCN in 
relation to overall survival of colorectal cancer patients. 
 
Three year survival 
 
It has been demonstrated that from 1980 to 2004 there was a steady increase in 
three year overall survival for both sexes in colon cancer and rectal cancer. 
Three year overall survival has increased from around 30% to approximately 45% 
in 2004 with rectal cancer survival increasing more markedly from 30% in 1980 to 
approximately 55% in 2004. The increase was more pronounced for female 
patients with rectal cancer. In all cases of rectal cancer, the most pronounced 
increase in survival was seen to happen around the mid-1990s. This can best be 
explained by the introduction and adoption by rectal surgeons of the TME 
technique for resecting the rectum and mesorectum en bloc (92). Only now are 
surgeons beginning to treat colonic resection with the same embryological 
approach to enable more accurate resection of the tumour, the so-called CME – 
complete mesocolic resection. This technique aims at the separation of the 
mesocolic from the parietal plane and true central ligation of the supplying 
arteries and draining veins right at their roots. It is almost never performed in 
the UK (190). 
 
Our novel approach to assessing long-term survival differences using linear 
regression models generated some significant new findings for colorectal cancer 
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patients in the West of Scotland. We tested all permutations of three year 
overall survival from before and after inception of MDT care. Firstly we tested 
long-term differences from 1980 onwards. We then looked at 1997 onwards. The 
significant findings were than from 1980 onwards three year overall survival for 
rectal cancer has significantly improved. It has also significantly improved for 
females alone but not males alone. This suggests that the survival improvement 
for females is so great that it explains the increase noted for both sexes. A 
possible explanation is that women have a better stage at presentation or there 
are more female cases so their increase in number exerts a bigger effect on 
survival. In fact though, there are more male cases of rectal cancer and they 
have a lower Dukes’ stage at presentation. These findings could also have been 
confounded by casemix, or the paucity of data points resulting from too short a 
follow-up period. 
Data for overall three year survival from ISD shows a steady increase in survival 
with time from 1980 onwards (58). This was not demonstrated in our linear 
regression model for overall three year survival in colorectal cancer patients. It 
may simply be a reflection of the shorter time frame of our data recording 
coupled with a smaller number of patients than those in the ISD database.  
 
Five year survival 
 
It has been shown that similar patterns of survival exist at five years, as do three 
years for colorectal cancer patients in the West of Scotland. The larger 
differences in survival between male and female rectal cancer patients appear 
to be attenuated slightly in terms of five year survival. However, these figures 
reflect overall survival so perhaps cancer specific or relative survival models 
would attenuate the difference further. 
 
Nonetheless, a switch from colonic tumour patients surviving longer to rectal 
patients surviving longer is noted in the five year data. Again this seems to have 
happened around 1993 and could be partly attributed to the introduction of 
TME. 
 
Our novel approach of linear regression modelling was not applied to five year 
overall survival as it was felt that the data were not mature enough to provide 
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any meaningful results. The West of Scotland data would be worth analysing in 
this way once deaths from 2010 are complete. 
 
Trends with Site of Tumour 
 
Survival following resection of colorectal cancer relates in part to location of the 
cancer, with better prognosis for distal cancers (see Table 24). Distal cancers 
tend to present at an earlier stage too, particularly in men, whilst in women the 
majority of colorectal cancers are right sided. 
 
Site of lesion has been shown to bear strong correlation to stage of disease in a 
large U.S. study examining 40% of the American population. They concluded that 
stage of presentation was more advanced with more proximal disease (191). 
We have been able to confirm these findings in the West of Scotland. We have 
provided evidence of a statistically significant larger proportion of Dukes’ stage 
A tumours at the rectum along with a higher proportion of Dukes’ C & D stage 
tumours in the colon. 
 
Univariate analysis of our dataset confirmed a significant difference in survival 
between rectal lesions and other colonic sites. This agrees with published data 
from ISD, with stated observed 5 year survival rates of 43.75% for rectum and 
41.25% for colon and respectively (192). Although it is encouraging that we have 
been able to corroborate previous findings regarding trends with site, the 
problem remains with accurate anatomical description. There are currently no 
internationally agreed definitions for exactly where the proximal and distal 
boundaries of the rectosigmoid area are. As a result there is a tendency to either 
group it along with rectum or with colon, thus creating a potential source of 
error when attempting to interpret outcomes from different studies. This is 
further compounded by variation in reporting by pathologists. It is hoped that 
published guidelines will be adhered to thus helping to reduce the uncertainty in 
this area (193).  
 
 
 
 
148 
 
Trends with Stage 
 
Staging of disease is an extremely important part of patient work up as 
described in the introduction. Ideally, it is optimal to diagnose patients at as 
early a stage as possible. To that end, recording of stage data is equally 
important, in order to facilitate this. We have shown that with time the number 
of patients not having a Dukes’ stage recorded has risen from 12.3% in 1997 to 
23.1% in 2005 with a peak of 31.1% in 2003. Whilst this has important 
implications for adjuvant treatment selection there are a few reasons why this 
may have occurred. 
Some patients with a polyp cancer are diagnosed and treated at colonoscopy. A 
diagnosis of cancer is made histologically. No Dukes’ stage is ever attributed as 
they have already had complete resection of a tumour. Staging will not affect 
treatment. 
More pathologists are turning towards the TNM classification for staging 
colorectal cancer patients. 
 
Those patients in whom a polyp is resected and found to be cancerous should all 
go on to be discussed at an MDT and receive the appropriate treatment. The 
royal college of pathologists’ minimum dataset was introduced in 1996 so the 
reduction in Dukes’ stage recording should not be due to reduction in reporting 
by pathologists (84). It is possibly due to recording errors by the audit team 
when collating data to be sent to the MCN database (Margaret Balsitis, personal 
communication). 
 
We have also compared our data with those most recently published by the 
National Cancer Intelligence Network (NCIN) (194). It is encouraging that we 
have a higher rate of stage data in the West of Scotland however the trend 
towards an increased number of patients without Dukes’ Stage recorded requires 
addressing. 
 
Our comparison with the NCIN data demonstrates a further difference in stage 
proportions. In the West of Scotland stage D disease accounts for 18.73% of cases 
with stage data. This compares to only 9.2% from the eight cancer registries 
reporting in England. These data cover the period before, during and after 
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inception of MCNs so perhaps if they were broken down and compared over more 
recent years the discrepancy would be less. If these data are accurate, it bodes 
well for the potential success of screening in the West of Scotland, as patients in 
this region may benefit more from down staging of disease. By removing all 
patients with unknown stage it has been shown that a higher proportion of stage 
D patients persists in the West of Scotland. Down-staging of disease at diagnosis 
will confer a survival benefit. This is the hope with increasing public awareness 
and the current screening programme in Scotland (195). 
 
The incidence of stage I disease in the United States is now 30%. This compares 
to 13.9% and 13.1% of known stage A patients in the West of Scotland and NCIN 
series respectively (194). It is thought that this increase is due in the main to 
better screening. Increased public awareness of symptoms and lower threshold 
to attending a physician also remain important  (139). 
For people who have none of the risks described earlier, digital rectal 
examination and testing of the stool for hidden blood are recommended annually 
beginning at age 40. Flexible sigmoidoscopy is recommended every 5 years at 
age 50 or older. A double contrast barium enema every 5 to 10 years, and 
colonoscopy every 10 years are acceptable alternatives (196).  
 
Our findings with regard to age suggest a significant difference in stage at 
presentation with differing age group. Fewer stage D patients were found in the 
older age groups, with a higher proportion of patients in stages B and C occurring 
in the middle two age groupings. It was necessary to explore this further in 
terms of sex differences. Stage A and stage D disease was more common in 
males whereas there was a preponderance of females with stage B disease. 
Stage C disease was found to have almost equal incidence between sexes. With 
regard to the West of Scotland there is a significant change in stage distribution 
at presentation with time for males only. Pearson Chi squared test = <0.001. This 
was not significant for females (Pearson Chi squared test = 0.190). This is for all 
patients in the MCN so does not exclude palliative procedures nor those patients 
who did not go ahead with, or were unfit for, surgery. 
 
The next finding concerns site and its relationship to stage. We confirmed the 
known trend that as one travels distally along the gastrointestinal tract, the 
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likelihood of patients presenting with an earlier stage tumour increases 
(p<0.001). A more proximal tumour will present later as it takes more time to 
become symptomatic. This is thought to be due to the wider lumen of the 
proximal colon and the liquid nature of its content. There is more space for the 
tumour to grow into before either obstructing the bowel or causing pressure 
symptoms by pressing on to adjacent structures. This echoes previously cited 
findings by Cheng at al that “The disease stage was highly correlated with the 
anatomical site of location. Localised disease increased from 31.9% among 
cancers of the proximal colon to 37% in the descending colon and 41.5% in the 
distal colorectum. The percentage of regional disease stage decreased from 
proximal to distal” (197).  This is in comparison to rectal cancers - they will 
produce more easily recognisable symptoms (e.g. bright blood compared to 
altered blood, tenesmus, and change in bowel habit) and hence are diagnosed at 
an earlier stage. 
A further statistically significant result was found by comparing just stage A and 
B disease in the rectum versus colon. Stage A disease is more common in the 
rectum than colon. 
 
Again, we have confirmed previous findings from the USA for our population, 
namely that that there is a statistically significant difference between sex and 
site for lesion. Women tend to present with more proximal lesions compared to 
men, who tend to present with more distal lesions (184). 
 
It is thought that these differences are due to underlying genetic heterogeneity 
between the sexes. Difference sex hormone profiles are also putative causes for 
the observed difference. McGrath et al also found that patients with rectal 
cancer were both more likely to be male and also more likely to have a stage A 
tumour when compared to colonic tumour patients (71). This was a statistically 
significant finding and is confirmed in our series. 
 
The Influence of the MCN 
 
One of the aims of this thesis is to compare outcome of the group of patients in 
the MCN with those not in the MCN. As has been shown, the number of patients 
not entered into the MCN dramatically decreased from 2001 onwards, as the 
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evolving network captured more patients and their clinical data. The average 
figure for each year thereafter is around a set point 400 patients. One would 
expect this number to remain constant with time, as there will always be a 
number of patients not registered with the MCN because they are DCO 
diagnoses; private hospital patients, those diagnosed and remaining in care 
homes to be palliated, or those that are treated in another region then migrate 
into the West of Scotland before dying here. These rates can vary significantly 
between countries due to different laws surrounding autopsy without consent. In 
countries where no consent is required for a post mortem examination there will 
be a higher rate of cancer diagnosis after death (198). 
Since those patients not in the MCN have no clinical audit data associated with 
them we were only able to compare variables relating to age at incidence, site 
of lesion and Dukes’ stage, i.e. the cancer registry variables. In summary, the 
groups were very heterogeneous. Two-sample t testing revealed a statistically 
significant difference in age at incidence, with patients not in the MCN being 2 
years older on average. A higher proportion of the non-MCN patients had Dukes’ 
stage D disease (44.4% versus 23.7% respectively). This reflects the fact that 
many of the patients not entering MDT care may be too unwell and are therefore 
palliated at home or the diagnosis is made at post mortem.  
 
In relation to site of lesion, the numbers were similar. The only discrepancy was 
in terms of unspecified lesions. Of those in the MCN only 9% had a lesion of 
unspecified site whereas 15.3% of patients not in the MCN had an unspecified 
site. This may reflect the fact that site of lesion is more important for patients 
in the MCN as it influences their surgical and chemotherapeutic management. 
Many patients not in the MCN may not need to have their site recorded as it will 
have no influence on outcome. 
 
A significantly higher proportion of rectal cancer patients were found in the 
Lanarkshire Health Board. Also a higher proportion of male rectal cancer 
patients were from the deprived group compared to females, 32.7% and 29.7% 
respectively.  
We demonstrated that site of lesion remains a significant independent 
prognostic indicator and that there was significant variation in overall survival 
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between Health Boards despite adjustment for age, sex, stage and SEC. This may 
be due to other hitherto unidentified variables accounting for differences or it 
may indicate a true difference in outcome due to differences in service provision 
in some Health Boards. 
An aim of the MCN is to capture as many cases of colorectal cancer as possible. 
Following comparison of groups enrolled and not enrolled in the MDT process it 
seems that the MCN selected younger individuals with better prognoses and 
more accurate staging data. Various explanations could account for this as 
outlined previously. It is also likely that with the passage of time the process of 
patient identification and data capture becomes more efficient at identifying 
patients with colorectal cancer. This will reduce the selection bias of the MCN 
process.  
Analysis to determine whether there has been an increase in patient survival 
showed that being treated before the MDT era or within an MDT does not act as 
an individual indicator of prognosis. This is possibly due to the relatively short 
period of time over which differences have been studied. 
In relation to socioeconomic circumstances, the distribution of socioeconomic 
deprivation in the West of Scotland has altered such that there has been a shift 
from fewer deprived patients in our region to more in the intermediate group 
(p<0.001). The proportion of affluent patients with colorectal cancer seems to 
have remained constant with time. If this trend continues then it should 
translate into a measurable survival improvement. The effects of screening 
would need to be accounted for also. 
The findings regarding postoperative complications demonstrated no direct 
correlation with a patient’s preoperative SEC in any of the subgroups studied. 
This means that long-term differences in survival are not explained by events 
occurring in the peri-operative period in this population, and is an argument for 
excluding the first 30 days post-op from future survival analyses. 
Long-term survival demonstrated a significant difference between deprivation 
groups with poorer survival in more deprived populations. We showed this 
consistently among patients from 1997 onwards and then in the cohort from 2000 
onwards, i.e. under the influence of an MDT decision making process.  
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Novel linear regression modelling showed that for select subgroups of patients 
there has been an increase in three year overall survival as a result of having 
been treated by the MDT process. These subgroups include all female colorectal 
cancer patients from 1997-2005, female rectal cancer patients from 1980-2005 
and all rectal cancer patients from 1980-2005. Only female rectal cancer 
patients demonstrated a survival benefit from MDT treatment over five years. 
 
These findings suggest that the MDT process has somehow benefitted women 
with rectal cancer over men from MCN inception. This is perhaps due their 
differing anatomy and relative ease for rectal cancer resection. It could also 
reflect a difference in underlying demographics and co morbidities between the 
sexes. Unfortunately there are not enough data from before 2000 to further 
explore this. 
 
Socioeconomic Circumstances 
  
We sought to examine the potential bias inherent in the MCN system towards 
those from deprived socio-economic backgrounds. In order to do this we looked 
at different stages in the process from diagnoses to end of follow-up. This was 
done firstly in relation to stage at presentation. Then we looked at deprivation 
and its effect on time from referral to treatment. We ascertained if there were 
any differences in type of operation received in relation to deprivation before 
assessing immediate 30-day outcome after surgery. Finally we looked at long-
term outcomes in terms of the effect of deprivation on survival. Accepting that 
unbiased patient selection, management, and outcome in relation to deprivation 
is a marker of an equitable service this allows assessment of the service quality 
to be made. 
The proportions of patients in each deprivation group are consistent with 
previously published data on Carstairs scores for Scottish postcode sectors from 
the 2001 Census by Philip McLoone (199). 
 
A central component of the MDT ethos is to provide an equal standard of care to 
patients from all backgrounds. Using depgroup (modified DEPCAT) as our 
objective measure for socio-economic deprivation we have ascertained that in 
our population there is no difference in deprivation status compared to stage at 
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presentation. This result holds when examining rectal cancers alone, colon 
cancers alone, and further by examining each sex within these subgroups.  
In the present study we found no statistically significant difference in stage at 
presentation according to deprivation group. The overall p value for all 
colorectal cancer patients was 0.058. No other subgroups under study achieved 
statistical significance. The current literature regarding this topic comes mainly 
from the UK although 2 US studies are commonly cited. Opinion is divided as to 
whether or not deprivation influences stage at presentation. Some groups have 
found no relationship between deprivation and stage at presentation whereas 
others have found an association (65,200,201)(64,73,202). 
 
In relation to entering the MDT process, it has also been shown that deprived 
patients may experience delay to referral and may also be less able to access 
services such as specialist surgery or adjuvant therapy (203,204). 
Although this may act more as a political point we have demonstrated that 
waiting longer than 62 days from time of referral to first definitive treatment 
has no detrimental effect on outcome. This is presumably because consultants 
employ their own clinical judgement to expedite cases they deem to need 
treatment more quickly than others.  
 
Once a patient has entered into the MDT process, it has been reported that they 
are more likely to receive certain types of operations if they are more socio-
economically deprived. Patients lower on the socio-economic scale have been 
found to be more likely to undergo APE than AR for cancer where there is a 
choice of operation (43,44). It is thought that overall an APE negatively impacts 
quality of life in addition to having lower long-term cost-effectiveness for the 
NHS when compared to anterior resection. In our series of 1390 patients having 
either an APE or AR we found no statistically significant difference when 
comparing proportions of patients from each deprivation group with type of 
operation. 
 
In a series of 653 cases of colorectal cancer patients a group from the North East 
of Scotland reported few differences in proportions of patients receiving surgery 
with relation to deprivation however they did report that more deprived patients 
were statistically less likely to be offered radiotherapy as an adjunct to 
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treatment. This is grade C evidence (177). We are not currently in a position to 
explore this aspect further in our cohort. Instead we examined the intent of 
operation according to deprivation group. We found no statistically significant 
difference between operative intent and deprivation in 3524 colonic cancer 
patients or 1399 rectal cancer patients undergoing surgery. This, however does 
not ignore the fact that the decision as to whether a resection is curative or 
palliative is based solely on the surgeon’s impression at time of surgery. 
Therefore one surgeon may label a case as curative where there is a borderline 
resection adequacy whereas another surgeon would label it palliative. This 
problem has previously lead to the suggestion that the ‘true’ hazard ratio for 
cancer survival rates in curative resection cases in some hospitals is probably 
higher than that calculated (68). 
 
It has been previously demonstrated that socially deprived patients have poorer 
cancer-specific survival than their less deprived contemporaries. We already 
know that more deprived patients are not as healthy as their affluent 
counterparts. This holds true with regard to longevity also, with affluent 
individuals living longer (74). McArdle and Hole reported in 2002 that among 
other factors (namely sex, stage and age) deprivation significantly influenced 
survival following potentially curative resection for colorectal cancer. This was a 
larger study covering 11 different hospitals in the central belt of Scotland, a 
region with a large socio-economic spread and large population (65).  More 
recently Smith (2006) and colleagues have proffered results demonstrating that 
social deprivation was an independent risk factor for increased length of stay 
and associated with increased postoperative mortality (64). We were not able to 
confirm this finding in our population. We found that of the 163 colorectal 
cancer patients who died within 30 days of surgery there was no statistically 
significant difference in deprivation group at the 5% probability level (p = 0.088).  
 
Then when looking at overall survival (not cancer-specific survival as with Hole 
and McArdle) in a univariate model for deprivation, we found a significant 
difference in survival for all colorectal cancer patients at 6 years. This 
difference was however explained by age, sex, Dukes’ stage, bowel preparation, 
tumour differentiation and extra mural vascular invasion in a Cox multivariate 
model.  
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As a set of results these are encouraging. They provide evidence for the case 
supporting the equal provision and outcomes of the Regional Colorectal cancer 
service to all patients despite the large degree of heterogeneity in social 
deprivation within our region. The Dukes’ stage finding is in relation to only 
those patients who had stage of disease recorded so results have to be taken in 
light of this. It is always important to bear in mind that deprivation is also a 
variable that is inherently difficult to measure objectively. It is also possible 
that these measures are demonstrating the ecological fallacy, namely that 
individual patients’ socioeconomic circumstances are not measured, only an 
aggregate estimate of the circumstances of a group of patients from one 
postcode area.  
  
A further finding cited in 2003 is that the more deprived in society are less likely 
to take up the offer of screening for colorectal cancer thus potentially increasing 
the gulf between themselves and the less deprived in relation to survival 
outcome (94). However, Rachet et al have demonstrated, within the framework 
of a randomised controlled trial, that it is possible for the most socially deprived 
patients to attain the survival rates of the most affluent patients (205).  There is 
a lag of around five years in this happening. We have demonstrated that our 
current service is selecting patients equally, treating them equally, and 
producing equal outcomes in regard to deprivation, irrespective of uptake of 
screening. 
 
The current literature regarding this topic comes mainly from the UK although 
two US studies are commonly cited. Opinion is divided as to whether or not 
deprivation influences stage at presentation. Some groups have found no 
relationship between deprivation and stage at presentation (65,200,201) 
whereas others have found an association (64,73,202). 
In relation to entering the MDT process, it has also been shown that deprived 
patients may experience delay to referral and may also be less able to access 
services such as specialist surgery or adjuvant therapy (203,204).  
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3.8 Conclusions 
It appears that the introduction of the MCN has lead to improvements in survival 
for particular groups of patients only. 
 
The number of multiple primary cancer cases in this region is consistent with 
other similar series elsewhere. The percentage of male multiple primary cases 
was higher than the number of females in the West of Scotland colorectal cancer 
population. 
 
A higher proportion of male rectal cancer patients have deprived socioeconomic 
circumstances compared to their female counterparts, 32.7% and 29.7% 
respectively (p<0.001). Patients not enrolled in the MCN were found to be 2.03 
years older than those experiencing MCN care. There was a lower proportion 
(17.6%) of patients with an unspecified Dukes’  
 
stage in the MCN compared to those not in the MCN (41.1%). Also, more than 25% 
of patients not enrolled in the MCN are in the Dukes’ D category. In general, 
patients in the MCN have less advanced disease. There was no difference in the 
proportions of patients from different socioeconomic backgrounds when 
comparing those in the MCN with those not in the MCN. Patients in the MCN 
demonstrated a 1.45 year increase in mean survival compared to those patients 
not in the MCN. 
 
Age at incidence, degree of socioeconomic deprivation, degree of disease 
burden, having a colonic tumour and whether or not the patient has entered the 
MDT process were all independent variables found to account for the difference 
in overall survival seen in the Kaplan Meier plot of patients enrolled and not 
enrolled in the MCN. This difference could be further explored if there were 
further clinical and pathological data available for the population of patients not 
entering into the MCN process. 
 
An increase in overall five year survival with time for all colorectal cancer 
patients from fewer than 25% in 1985 to over 40% in 2001 was seen. There was a 
disproportionate rise in 5 year survival for rectal cancer patients compared to 
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colon cancer patients with time. This appeared to begin in the mid 1990s and is 
thought to be attributable to advances in rectal cancer resection surgery.  
There was no independent effect observed according to which particular MDT a 
patient was treated. This demonstrates that the type of treatments received 
throughout the region are similar enough to provide homogeneous outcomes. 
Further analysis using multivariate modelling showed that age at incidence, 
socioeconomic circumstances, Dukes’ stage and sex all help to explain overall 
survival to differing degrees in colorectal cancer, colonic cancer and rectal 
cancer patients. Overall survival is poorer among patients from more deprived 
areas. 
Compared to their affluent counterparts, deprived patients with colorectal 
cancer have a 24% increased hazard following adjustment for age, stage of 
disease, Health Board of residence and operative intent. 
We have herein identified important influences on survival that need to be 
included in any comparison of survival between treatment sites. Also, given that 
the MCN ethos is to provide equitable access to care and equity of management 
regardless of patients’ socioeconomic circumstances, many of these factors 
might be expected to have been reduced after the formation of the MCN, 
leading to survival improvements. 
We have analysed the records of 37,890 colorectal cancer patients in the West of 
Scotland over a 25-year period and confirmed expected proportions of colonic to 
rectal lesions as well as equal sex distribution. We also report a higher 
ascertainment for data regarding Dukes’ stage when compared to other 
published series. There was a large, statistically significant variation in socio-
economic conditions found between the five Health Boards. Overall, affluent 
patients tend to present more with colonic lesions than rectal cancer. Affluent 
patients also tend live longer than deprived patients, thus adding a further 
possible factor to explain differential survival outcomes between patients of 
different socioeconomic circumstances. 
The proportion of men with rectal cancer was significantly higher in the 
deprived group when compared to the proportions on the other two deprivation 
groups. In terms of Dukes’ stage, the overall relationship is that a consistent and 
clinically important relationship between deprivation and later stage at 
presentation exists with more affluent people presenting with Dukes’ A and 
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more deprived patients presenting with a greater, stage D, disease burden. We 
were able to attest that there was no statistically significant difference in time 
to wait to first treatment according to socioeconomic circumstances. This was 
despite the fact that we have also shown that more deprived patients attend 
more frequently as non-elective cases. 
A larger proportion of deprived patients underwent palliative procedures 
(p=0.018). This finding was not replicated in the years following MDT creation 
(p=0.360). SEC, age, stage and whether or not the patient had been discussed in 
an MDT all bore influence independently upon whether or not the patient 
underwent palliative or curative resection. 
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4 Degree of specialisation and Outcomes in 
management of MDT patients. 
4.1 Introduction 
There is a continuing body of evidence to support the treatment of colorectal 
cancer in high volume institutions where specialist colorectal surgeons are 
available (206). Both volume and specialisation can therefore be used as 
independent proxy measures for good quality care. The impact of MCNs has been 
described for various conditions and locations outside the West of Scotland 
(17,18). A full regional assessment of the effects of treatment for colorectal 
cancer by designated specialists has not been made in the West of Scotland. In 
this chapter we aim to assess whether the proportions of consultants performing 
procedures at differing thresholds have changed with time, i.e. following 
introduction of the MCN in the West of Scotland. 
 
Particular reference is made to rectal cancer surgery. It is recognised that the 
management of rectal cancer is more complex than colon cancer.  More complex 
preoperative staging, imaging, and more technically demanding surgical 
procedures are all required in the MDT approach to managing patients with 
rectal cancer. For these reasons it has been suggested that perhaps rectal 
cancer patients’ outcomes may be affected to a greater degree by the MDT 
process compared to colonic cancer patients (164). Although immediate 
postoperative complications demonstrate no difference between general and 
specialist surgeons, stoma rates do differ significantly (207). 
 
Debate continues as to the definition of what constitutes a specialist in the field 
of colorectal surgery. Currently, various definitions have been applied. 
Membership of the Association of Coloproctologists of Great Britain and Ireland 
has been used as a proxy measure for being a specialist. Regional peer opinion 
has also been employed to determine which consultants are specialists (175).  
More objective measures have also been sought. If a surgeon is undertaking more 
than 20 colorectal operations per year then he can be said to have enough 
expertise be called specialist. 
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In this chapter we use seven resections per year as the threshold for both colonic 
and rectal cancer resections. We have then used seven and a further division at 
ten resections per year for colon cancer surgery. This is firstly to be able to 
compare colon cancer outcome with rectal cancer at the same volume and 
secondly, to assess if the higher threshold of ten cases per year yields better 
outcome than seven, thus supporting the argument for specialisation in colonic 
surgery as well as rectal. Furthermore we decided that due to the small 
proportion of consultants performing greater than 20 resections per year, that 
this higher threshold would not include enough data to provide meaningful 
interpretations relating to our region. A lower threshold of 10 cases is therefore 
employed herein. 
 
4.2 Aims & Objectives 
Aims 
i. To assess if there has been an increase in the proportion of operations 
carried out by surgeons performing higher volumes of colorectal cancer 
operations in the West of Scotland since the MCN was formed. 
ii. To determine if overall survival is better for patients operated on by 
higher volume surgeons. 
 
Objectives 
 
i. To analyse variables from the MCN dataset pertaining to consultant in 
charge. 
ii. To derive levels of caseload per year per consultant. 
iii.  To further analyse site of tumour and type of presentation with regard to 
their effects in relation to volume.  
iv. To construct overall survival plots for differing surgeon volumes. 
v. To construct further univariate and multivariate models. 
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4.3 Method 
In addition to general methodology mentioned previously, a set of variables were 
created from the dataset in order that named consultant volume was able to be 
measured at differing thresholds. It was not possible to construct these variables 
prior to inception of the MCN as named consultant data were only recorded from 
2000 onwards. 
 
4.4 Results 
In total, 5937 patients underwent any type of surgery for colorectal cancer in 
the West of Scotland MCN from 2001 to 2005. Overall, 4773 (80.39%) patients 
had a named consultant. These patients form the population under study in this 
chapter, and are summarised in Table 25. In 2004 and 2005 the proportion of 
patients with no named consultant was higher than in other years.  
 
Of these 4773 patients, 3464 (72.57%) had a colonic cancer and 1309 (27.43%) a 
rectal cancer. 
 Table 25 - Proportions of the 5937 patients undergoing surgery with, or without, a named 
consultant per year. 
   Named consultant 
 n (%) 
Total 
  no yes  
year of  2001 260 (19.30) 1087 (80.70) 1347 (100) 
Incidence 2002 185 (15.29) 1025 (84.71) 1210 (100) 
 2003 215 (17.77) 995 (82.23) 1210 (100) 
 2004 286 (23.95) 908 (76.05) 1194 (100) 
 2005 218 (22.34) 758 (77.66) 976 (100) 
 Overall 1164 (19.61) 4773 (80.39) 5937 (100) 
 
 
ALL COLORECTAL CANCER PATIENTS 
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The following results are grouped into all colorectal cancer patients undergoing 
surgery, all colon cancer patients undergoing surgery, and all rectal cancer 
patients undergoing surgery. This is due to the fact that rectal cancer surgery is 
viewed as the realm of the specialist whereas emergency colonic resections are 
additionally undertaken by generalists. In extreme cases though, a general 
surgeon will still undertake the emergency, life-saving, temporising operation.   
Further divisions into elective and emergency surgery have also been performed 
for each group to fully explore patterns in care by consultants of differing 
volumes. 
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In figure 26 there is a wide spread in number of cases attributed to the 79 
named consultants for this year, 2001. 17 of these (21.5%) were the named 
consultant for > =20 cases, namely specialist consultants.  
 
Figure 26 - Number of cases performed per numbered consultant for all 863 colorectal 
cancer patients undergoing elective colorectal surgery in 2001. Line set at 20 cases per 
year. 
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In figure 27 there is a wide spread in number of cases attributed to the 60 
named consultants for this year, 2005. 12 of these (20%) were the named 
consultant for >=20 cases, namely specialist consultants. 
 
Figure 27 - Number of cases performed per named consultant for all 605 colorectal cancer 
patients undergoing elective surgery in 2005. Line set at 20 cases per year. 
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Figure 28  shows that there was a significant increase in the proportion of 
patients treated by higher-volume surgeons in the first 5 years of the MCN. In 
2001 52% of patients were operated on by a low volume surgeon. 21% of patients 
were operated on by a high volume surgeon. In 2005 these figures had reduced 
and increase to 42% and 26% respectively. 
Of note is that overall, 46% of patients were still treated by “non-specialist”  
low-volume surgeons. 
 
Figure 28 - All 4773 colorectal cancer patients undergoing surgery in the West of Scotland 
with a named consultant from 2001 to 2005. Linear-by-linear chi-square p <0.001. 
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Figure 29 shows a similar significant increase in the proportion of patients being 
treated by high-volume surgeons over time when looking at elective cases only. 
In 2001 only 24.8% of cases were undertaken by a high volume surgeon (>10 
cases / year) with almost half (46.9%) of elective cases being performed by the 
lowest volume surgeons. By 2005, high volume surgeons were performing 30.3% 
of all operations with the lowest volume surgeons performing 35.5%.  
 
 
Figure 29 - All 3789 colorectal cancer patients undergoing ELECTIVE surgery with a named 
consultant in the West of Scotland. Pearson Chi square P <0.001 
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Figure 30 shows there is no convincing evidence of an increase in high-volume 
surgeons for emergency patients over time. The other important feature of this 
graph is that a much larger majority of emergency patients are treated by non-
specialists/low-volume surgeons. 
 
Figure 30 - All 964 colorectal cancer patients undergoing EMERGENCY surgery with a 
named consultant in the West of Scotland. P = 0.048 
 
 
 
4.5 Colon Cancer Patients 
In relation to colon cancer resection by different volumes of operating surgeon, 
there is a statistically significant change in proportions with time. As shown in 
Figure 31, only 18.4% of cases were performed by a high volume surgeon. This 
had grown to 22.1% by 2005. Lowest volume consultants reduced their overall 
contribution from 56.3% to 47.8% over the same period. 
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Figure 31 - All 3464 colon cancer patients undergoing surgery in the West of Scotland with a 
named consultant. p = 0.03 
 
 
Figure 31 shows that for all 2353 colon cancer patients undergoing elective 
surgery in the West of Scotland there is a statistically significant increase in the 
proportion of patients being treated by high-volume/specialist surgeons (p = 
0.025). The proportion of high volume surgeons is initially higher for elective 
surgery compared to all types seen in Figure 31 (22.1% vs 18.4%). The magnitude 
of change seen for elective surgery is larger though, with a change of +5.1% with 
time for elective surgery compared to a 1.7% change for all types of colon 
surgery. 
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Figure 32 - All 2353 colon cancer patients undergoing elective surgery in the West of 
Scotland with a named consultant (p = 0.025). 
 
 
 
 
In contrast to all types of surgery and elective surgery there appears to be no 
change in the proportions of emergency cases being operated on by a specialist. 
This is evidenced in figure 33 below for all 918 colon cancer patients undergoing 
emergency surgery in the West of Scotland (p = 0.084). Also of note is the fact 
that throughout the period of study, low volume surgeons are the named 
consultant in greater than 60% of the total number of emergency operations. 
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Figure 33 - All 918 colon cancer patients undergoing EMERGENCY surgery in the West of 
Scotland with a named consultant (p = 0.084). 
 
 
Overall survival in all colon cancer patients undergoing surgery 
 
Having described temporal trends in relation to specialisation it is important to 
ascertain whether specialisation in itself carries an advantage to patients in 
terms of overall survival. 
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In figure 34 there is a statistically significant difference (Log rank <0.001) in 
overall survival between colon cancer patients being treated by low and medium 
or high volume consultants. There appears to be no significant difference 
between the medium and high volume cases. 
 
Figure 34 - Kaplan Meier plot for all colon cancer patients undergoing surgery in the West of 
Scotland from 2001 to 2005 according to volume of operating surgeon. n = 3464, Log Rank 
<0.001. 
 
 
We have also shown in figure 34 that low-volume/non-specialist care is 
associated with emergency presentation. In the following unadjusted survival 
plot, we show that there is a significant difference in overall survival for all 
colon cancer patients undergoing surgery with a named consultant according to 
presentation. This is therefore an important variable to include in a multivariate 
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model to further explore and account for differences in outcome perceived to be 
due to specialisation.  
In figure 35 there is a statistically significant difference (Log rank <0.001) in 
overall survival between colon cancer patients according to their presentation 
for surgery. Again, this is a further important variable to include in a 
multivariate model to further explore and account for differences in outcome 
perceived to be due to specialisation. 
Figure 35 - Kaplan Meier plot for all colon cancer patients undergoing surgery in the West of 
Scotland from 2001 to 2005 according to presentation for surgery. n = 3450, Log Rank 
<0.001. 
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Table 26 highlights the results from univariate and multivariate analysis of all 
3464 patients undergoing surgery with a named consultant. It shows that age, 
presentation for surgery, volume, socioeconomic status and site of cancer were 
all found to be independent prognostic indicators of overall survival. Following 
adjustment in the multivariate model, only age at incidence, presentation for 
surgery, volume of procedures per year, and socioeconomic circumstances 
remained independent prognostic indicators for overall survival in this large 
group. 
    
Table 26 - Univariate and multivariate Cox regression results for all 3464 patients 
undergoing surgery for colorectal cancer with a named consultant 
 
Variables in the model UNIVARIATE                             MULTIVARIATE 
  p HR (95% CIs) p HR (95% CIs) 
volume >10 0.00 1 0.02  
volume >=7 0.87 1.01 (0.87-1.18)  0.14 (0.91-0.81) 
volume <=7 0.00 1.34 (1.18-1.53)  0.35 (1.06-0.94) 
elective presentation 0.00 1 0.00  
emergency presentation  2.36 (2.14-2.61)  2.41 (2.18-2.65) 
Age at incidence 0.00 1.03 (1.02-1.03) 0.00 1.03 (1.02-1.03) 
sex - female 0.14 1   
sex - male  1.08 (0.98-1.19)   
affluent 0.00 1   
intermediate 0.01 1.17 (1.03-1.34) 0.00 1.21 (1.06-1.38) 
deprived 0.00 1.32 (1.15-1.52) 0.00 1.35 (1.17-1.55) 
rectum 0.00 1.00 0.53 1.00 
colon  1.37 (1.24-1.52)  1.03 (0.93-1.15) 
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4.6 Rectal Cancer Patients 
Overall 1309 patients with a named consultant had surgery for their rectal 
cancer. Of these, six had data missing regarding volume of cases performed by 
their named consultant. 
Table 27 summarises the proportions of surgeons performing surgery on patients 
presenting as an emergency or as an elective case. More than double the number 
of elective cases were operated on by surgeons carrying out more than seven 
resections per year. In contrast, only marginally more emergency operations 
were carried out by lower volume surgeons. 
 
Table 27 - Summary of comparison of all 1303 rectal cancer patients undergoing surgery, 
comparing presentation for surgery with surgeon volume, using a cut-off of seven cases per 
year. 
 
   surgeon volume Total 
  >7 cases / yr <= 7 cases / yr  
type of surgery  elective 871 (69.29) 386 (30.71) 1257 (100) 
 emergency 22 (47.83) 24 (52.17) 46  (100) 
 Total 893 (68.53) 410 (31.47) 1303  (100) 
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Figure 36 - All 1309 MCN rectal cancer patients with named consultants undergoing surgery 
at different volume thresholds. P = 0.004 
 
 
Figure 37 - All 1257 rectal MCN cancer patients undergoing ELECTIVE surgery with a named 
consultant at different volume thresholds. P = 0.090 
 
 
Figures 36 and 37 chart the changes in proportions of rectal cancer patients 
undergoing surgery overall and elective surgery, with time. There is a significant 
change with time for all patients undergoing surgery towards more specialist 
care but not for elective rectal resections.  
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Figure 38 shows that there was no trend with time for emergency surgery on 
rectal cancer patients according to surgeon volume. Given that the total number 
of patients is 46, a larger number of cases over a longer timeframe may result in 
a different pattern. 
 
Figure 38 - All 46 rectal MCN cancer patients undergoing EMERGENCY surgery with a 
named consultant. Pearson Chi-square,  p = 0.086. 
 
  
 
 
 
In contrast to Figure 34 for colon surgery, Figure 39 shows that there appears to 
be no statistically significant difference in overall survival for rectal cancer 
patients according to the volume of named consultant. We have used seven 
cases per year as a cut-off so it may be that there is a significant difference in 
survival at another volume threshold. There were no significant differences 
noted according to volume when elective patients and emergency patients were 
tested individually. 
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Figure 39 - Kaplan Meier plot for all 1309 rectal cancer patients with a named consultant 
undergoing surgery in the West of Scotland from 2001-2005. Log Rank 0.628 
 
In figure 40 there is a clear difference in overall survival for rectal cancer 
patients according to presentation for surgery. There is a relatively small 
number of emergency presentations (n=46) compared to elective (n=1257).  
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Figure 40 - Kaplan Meier plot assessing overall survival differences comparing presentation 
for surgery for all 1303 rectal cancer patients with a named consultant in the West of 
Scotland from 2001-2005. Log Rank <0.001 
 
Table 28 - Summary of all log rank results for Kaplan Meier plots regarding surgical volume 
in all colorectal cancer patient groups with named consultants in the West of Scotland from 
2001-2005. 
 n log rank 
Colon - all 3464 <0.001 
Colon - elective 2532 0.004 
Colon - emergency 918 0.532 
rectal - all 1309 0.628 
rectal - elective 1257 0.823 
rectal - emergency 46 0.395 
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In contrast to Table 26 for all colorectal cancer patients, table 29 shows the 
univariate and multivariate findings for rectal patients only. Only age at 
incidence and presentation for surgery remain independent as prognostic 
indicators following adjustment for sex, volume and socioeconomic 
circumstances. The increased hazard ratio of 2.70 for emergency presentation 
compared to elective presentation is noteworthy as it compares well with that 
seen for colorectal cancer patients in Table 26 (2.40).   
Table 29 - Univariate and multivariate Cox regression results for all 1309 patients 
undergoing surgery for rectal cancer with a named consultant 
Variables in the model p UNIVARIATE 
HR (95% CI) 
 p MULTIVARIATE 
HR (95% CI) 
volume >7 0.63 1.00    
volume <=7  1.05 (0.87-1.26)    
age at incidence 0.00 1.03 (1.02-1.04)  0.00 1.03 (1.02-1.03) 
sex - female 0.19 1.00    
sex - male  1.13 (0.94-1.35)    
elective presentation 0.00 1.00  0.00 1.00 
emergency presentation  3.10 (2.17-4.44)   2.70 (1.88-3.87) 
 
affluent 0.28 1.00    
intermediate 0.23 1.19 (0.89-1.58)    
deprived  0.11 1.28 (0.95-1.75)    
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4.7 Discussion 
Although there was a reduction in the total number of surgeons performing 
colorectal surgery from 79 to 60 over the period of study the proportion of 
named consultants for >=20 operations was -1.5% over the same time frame. The 
number of patients with a named consultant also reduced over the period of 
study with 2004 and 2005 having the poorest proportion of named consultants. 
This should be considered when interpreting these results as it raises the issue of 
accurate data collection. 
We have shown that there was an increase in surgery by high-volume surgeons 
between 2001 and 2005 from 21% to 26% of the total ( 
Figure 28). This indicates increasing specialisation with time. The specialisation 
was confined to elective colorectal cancer operations only.  
The majority (46%) of surgery for colon cancer is still performed by low-volume 
surgeons (Figure 31). Additionally, a much larger majority (66%) of emergency 
surgery is performed by low-volume surgeons (Figure 33). This makes sense, 
given that, unlike the SCAN area, WOSCAN does not have a specialist colorectal 
emergency service at present. A further important point is that the majority of 
emergency patients are treated by non-specialists/low-volume surgeons. 
Based on the findings of the multivariate analysis in Table 26, it appears that 
surgeon volume remains an independent prognostic indicator in this large group 
of patients. This follows adjustment for age, type of presentation for surgery, 
and socioeconomic circumstances. 
  
The majority (68.5%) of all rectal cancer surgery, in contrast, is carried out by 
high-volume surgeons (Table 27).  However, this effect appears to be confined 
to elective surgery only. A relatively small number (n=46) of emergency rectal 
surgery cases were carried out from 2001 to 2005 so perhaps this trend would 
change in a larger cohort over a longer period of study. Ideally a comparison of 
before inception of the MCN with after the MCN was created would provide clear 
evidence of an MCN effect. This is not possible due to lack of specific named 
consultant data prior to 2000. 
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The majority of emergency rectal surgery is carried out by low-volume surgeons 
(Figure 38). The proportion of emergency cases being performed by low volume 
consultants is far lower for rectal cancer than colon cancer. This reflects the 
fact that general surgeons will still perform definitive surgical procedures for 
colon cancer patients whereas rectal cancer patients may only be stented, or 
have a temporary defunctioning colostomy fashioned by a general surgeon thus 
providing time for staging, imaging and a definitive rectal cancer resection. 
There is a convincing increase in higher-volume surgeons carrying out elective 
rectal cancer surgery over time. 
 
Overall survival in colon cancer patients is related to both type of presentation 
for surgery and surgeon volume, as evidenced in both Figure 34 and Figure 35. 
Univariate and multivariate modelling (Table 26) further explores survival for 
the larger group of all colorectal cancer patients concluding that age at 
incidence, presentation for surgery, volume of procedures per year, and 
socioeconomic circumstances remain independent prognostic indicators for 
overall survival. Site of cancer was significant on univariate analysis. The effect 
was attenuated in the multivariate model though. We can therefore say that 
surgical volume is an important consideration in outcome for this population and 
may have implications for service provision in terms of providing specialist 
colorectal services for all patients previously operated on by lower volume 
surgeons. With reference to rectal cancer patients, we were not able to 
demonstrate a significant difference in overall survival using a volume threshold 
of seven cases per year. There was a statistically significant difference in 
survival for this group in relation to presentation for surgery (Figure 40).  
 
Following adjustment in the multivariate model, only age at incidence and 
presentation for surgery remained independent prognostic indicators of overall 
survival (Table 29). This suggests that despite an ongoing trend towards 
specialisation for rectal cancer surgery in our region, that the process may well 
have been taking place prior to inception of the MCN. The very low number of 
emergencies for rectal cancer also suggests that there is a greater tendency to 
temporise.  
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We are unable to tell whether the named consultant was simply the consultant 
in charge of the patient or whether the named consultant performed the 
procedure. We are also unable to tell if the patient had their definitive cancer 
resection at the time of operation or whether they went on to have further 
procedures following temporising surgery by a non-specialist. 
 
Overall, 4773 (80.4%) of patients had a named consultant with 1164 (19.6%) 
having no named consultant in the MCN. In the former group we are not able to 
say if the consultants were all surgeons since gastroenterologists and other 
palliative care physicians could be nominated as consultant in charge in some 
cases. In order to lessen this source of error we selected only those patients 
undergoing surgery. 
 
Only one method of objectively measuring volume has been used herein. 
It is entirely possible that some consultants were newly appointed, nearing 
retirement, or retired during the period of study. This may mean that a more 
exact and objective measure of number of cases should be sought to assess 
caseload. It may be that some senior consultants perform the majority of their 
resections in the private sector. These are not included in the current dataset. 
Some consultants in smaller hospitals may not achieve the threshold of seven 
resections per year for rectal cancer yet may consider themselves specialist. 
It appears that there is a statistically significant difference in overall survival for 
all colon cancer patients according to the yearly volume of operations performed 
by consultant. This is not the case for rectal cancer patients. This finding was 
confirmed for rectal cancer patients both in elective cases and emergency cases. 
Although these models are overall survival models they are not adjusted for 
common prognostic indicators such as age, stage and socioeconomic 
circumstances. 
A further variable worthy of exploring is seniority of operating surgeon. Although 
each patient has a named consultant it is possible that in some cases the named 
consultant was not the main operating surgeon. 
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4.8 Conclusions 
Trends in relation to volume of work undertaken by surgeons on colorectal 
cancer patients in the West of Scotland demonstrate that there was increasing 
specialisation over the period under study. This is evidenced by the increase in 
proportion of resections performed by higher volume surgeons and is 
encountered in both colon and, to a lesser extent rectal cancer surgery. 
 
It seems that increasing specialisation has had resultant effects on overall 
survival for colon cancer patients but not for rectal cancer patients thus far. To 
that end consideration should be given for service provision for colonic cancer by 
dedicated specialists only. This is important as the reason for having a colorectal 
subspecialty was that rectal cancers needed a specialist but colonic cancer 
procedures were deemed to be general operations. Further work should firstly 
address the issue of ensuring a named consultant surgeon for each patient 
undergoing resection and whether they consider themselves to be a specialist or 
not. It is clear that with the passage of time there may be more obvious survival 
benefits demonstrated from specialisation. The same methodology employed 
here should therefore be repeated in a population with more mature follow-up 
data. Unfortunately there were no data available regarding named consultants 
prior to inception of the colorectal MCN. This would have enabled a before and 
after study to be undertaken. 
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5 Effects of mechanical bowel preparation on 
post-operative complications and long-term 
survival after elective resection of colon 
cancer 
The decision as to whether to administer mechanical bowel preparation (MBP) or 
not to patients undergoing elective resection of colon cancer remains under 
debate. We suggest that the selective omission or administration of MBP in the 
correct populations of patients is an aspect of care that may have been 
improved through MCN working. We wished to explore the hypothesis that 
mechanical bowel preparation is associated with poorer long-term survival as a 
result of increased anastomotic leakage. The MCN and its audit data provide the 
context for investigating this as well as an idea of how well current 
recommendations regarding MBP are adhered to.  We carried out a retrospective 
study of a large cohort of surgically-treated colon cancer patients to determine 
the relationship between mechanical bowel preparation and overall survival 
after five years.   
We are not aware of any study regarding mechanical bowel preparation where 
long term follow-up has been reported. 
 
5.1 Introduction 
Recent meta-analyses have indicated that pre-operative mechanical bowel 
preparation confers no clear benefit and may be harmful for colorectal cancer 
patients in up to three months post-operative follow-up (113-115,208).  
However, the effects of bowel preparation on longer-term outcomes have not 
been reported. The use of mechanical bowel preparation remains a constant 
topic of discussion for colorectal surgeons regarding their management of cancer 
patients. Worldwide, there are ongoing debates regarding its benefit. This 
chapter uses the merged dataset to arrive at conclusions relating to how MBP 
affects the population in our region in order that surgeons can be better 
informed of the effects of MBP on their patients. 
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The overall short-term results of meta-analyses of randomised controlled trials 
of MBP have shown no clear benefit and, in some cases, worse postoperative 
complication rates (although no difference in postoperative mortality) (113-
115,208). The results of individual RCTs have also consistently shown no benefit, 
an exception being a lower risk of peritonitis among MBP patients reported by 
Contant and others (117,209,210) (211). Mechanical bowel preparation is 
generally unpleasant for patients and time consuming for nurses to oversee in 
the elderly or infirm. It was previously associated with a variety of complications 
such as dehydration, nausea, vomiting, mucosal lesions, hypokalaemia and other 
electrolyte disturbances (111,212). Although these side-effects still occur, they 
are less frequently observed through use of safer, more cost effective and better 
tolerated solutions and better maintenance of perioperative hydration (109). 
There are a number of ways in which MBP has been thought to act. It may 
decrease intraoperative contamination with faecal material thereby reducing 
the incidence of post-operative wound infection and residual intra-abdominal 
infection. It may prevent mechanical disruption of the anastomosis by the 
passage of hard faeces and improves the handling of the bowel intra-operatively. 
It may reduce the bacterial count within the colon. Conversely, it may also be 
associated with bacterial translocation through the bowel wall hence possibly 
contributing to post-operative infectious complications (213,214).There is little 
evidence to support these claims and yet bowel preparation remains standard 
practice in many hospitals in the USA (215).  
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5.2 Aim & Objectives 
Aim 
i. To assess the impact of MBP on short term (30 day), longer term outcomes 
and complications following resection of colon cancer in a defined 
population in the West of Scotland region, and to assess and quantify if 
there is any survival advantage from preoperative bowel preparation prior 
to surgery for colon cancer.  
Objectives 
 
i. To analyse the combined dataset with reference to postoperative 
complications. 
  
ii. To assess longer term overall survival as affected by mechanical bowel 
preparation. 
 
iii. To ascertain factors influencing overall survival in patients who had 
received and not received mechanical bowel preparation prior to surgery 
for colon cancer. 
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5.3 Method 
We carried out a retrospective cohort study on all patients undergoing 
potentially curative surgery for colon cancer (International Classification of 
Diseases, 10th edition, C18) after routine hospital admission in the West of 
Scotland between January 2000 and December 2005. Exclusion criteria were: 
emergency admissions; patients with rectal lesions; those with multiple tumours; 
and those not undergoing surgery (for example, palliative patients or those 
undergoing colonoscopic treatment).  Emergencies were excluded on the basis 
that acute obstructive symptoms may be a contra-indication to mechanical 
bowel preparation and overall prognosis is likely to be poorer than in the 
elective or urgent setting (216).  
We linked clinical audit data gathered by the West of Scotland Colorectal cancer 
Managed Clinical Network to Scottish Cancer Registry and General Register 
Office (Scotland) death records (SMR06/GRO(S)) to create a novel dataset.  
Linkage was carried out by exact matches of forenames, surnames and dates of 
birth and by phonetic algorithms (Daitch-Mokotov Soundex and New York State 
Identification and Intelligence System) where exact matches could not be 
obtained.  All patients’ clinical audit records were successfully matched to the 
Cancer Registry.   Death records up to 30th September 2007 were obtained. 
Postoperative complications had been prospectively recorded on a standard 
clinical audit proforma used for all cases of colorectal cancer throughout the 
region. Anastomotic leak, DVT (deep venous thrombosis), wound infection, 
fistula formation, intra-abdominal abscess, myocardial infarct, pulmonary 
embolism, and chest infection were all recorded as complications. 
 
The West of Scotland (population 2.4 million) is an area of Western Europe with 
a high incidence of colon cancer and wide variations in socio-economic 
deprivation (192).  To categorise socio-economic deprivation, we used the 
validated DEPCAT (deprivation category) classification (199). This uses four 
Census variables that have been shown to best correlate with health outcomes – 
overcrowding, car ownership, proportion of population in occupational Social 
Classes IV and V and male unemployment – to classify patients’ residential 
postcode sectors (population around 4000) on a categorical scale from 1 (most 
affluent) to 7 (most deprived) .  We further grouped DEPCATs into three 
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conventional categories:  affluent (DEPCATs 1 and 2), intermediate (3-5) or 
deprived (6-7).  
 
 
5.4 Results 
A total of 1730 patients underwent potentially curative routine or urgent 
resection for colonic cancer (886 male and 844 female, mean age 69.7 years, SD 
10.6) between January 2000 and December 2005. The median follow-up period 
was 3.52 years (mean 3.57, SD 1.73), range 0.1 to 6.7.  A summary of their 
demographics, Dukes’ stage and socio-economic characteristics is shown in Table 
1. Men were significantly more likely to receive MBP compared with women 
(p=0.022); patients with Dukes’ A tumours were more likely to receive MBP than 
those with Dukes’ D (92.7% vs. 83.6%, p<0.001) although there was no clear 
trend associating Dukes’ stage with likelihood of MBP; routine admissions were 
more likely than urgent admissions to receive MBP (86.7 vs 71.6%, p<0.001); and 
elective admissions were more likely to receive MBP than emergency admissions 
(87.0 vs 32.5%, p<0.001).  
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Table 30 - Baseline characteristics of 1730 patients undergoing surgery for resection of 
colon cancer, 2001-05. P-values for Pearson chi-squares except *, t-test of independent 
samples. 
All figures in 
brackets are 
% 
 Total (%) Bowel prep 
given 
(% of total) 
Bowel prep 
not given 
(% of total) 
p value 
n  1730 (100) 1460 (84.4) 270 (16.6)  
sex male 886 (51.2) 765 (86.3) 121 (13.7)  
 female 844 (48.8) 695 (82.3) 149 (17.7) 0.022 
      
Age  Mean  
(SD) 
69.71 
(10.64) 
   
 Range 70 (24-94)   0.037* 
      
Dukes' stage A 288 (16.6) 267 (92.7) 21 (7.3)  
 B 649 (37.5) 545 (84.0) 104 (16.0)  
 C 504 (29.1) 431 (85.5) 73 (14.5)  
 D 55 (3.2) 46 (83.6) 9 (16.4)  
 Unspecified* 234 (13.5) 171 (73.1) 63 (26.9) 0.005 
      
Deprivation 
category 
Affluent 294 (17.0) 251 (85.4) 43 (14.6)  
 Intermediate 988 (57.1) 840 (85.0) 148 (15.0)  
 Deprived 442 (25.5) 364 (82.4) 78 (17.6) 0.385 
      
Type of 
Admission 
Urgent 264 (15.3) 189 (71.6) 75 (28.4)  
 Routine 1466 (84.7) 1271 (86.7) 195 (13.3) <0.001 
      
Presentation 
for surgery 
Elective  1649 (95.3) 1434 (87.0) 215 (13.0)  
 Emergency 80 (4.6) 26 (32.5) 54 (67.5) <0.001 
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* Unpecified Dukes’ stage not included in Chi square analysis  
 
All cause survival was significantly higher (Log Rank p = 0.005) among patients 
treated with MBP in up to 7 years’ follow-up after surgery – see Figure 40.  
Figure 41 - Kaplan-Meier survival estimation of all-cause survival for patients receiving and 
not receiving mechanical bowel preparation before elective or urgent colonic cancer 
resection.   
 
This was further explored with univariate and multivariate Cox regression 
analysis to allow adjustment for confounding by age, stage, socio-economic 
circumstances, type of admission, presentation for surgery and surgical 
complications. Results are shown in Table 31. Patients who received mechanical 
bowel preparation had 28% lower mortality on univariate analysis, HR 0.72 (95% 
CIs, 0.57 to 0.91). Following adjustment for age, sex, disease stage and type of 
admission the survival advantage remained but after the addition of urgency of 
surgery to the model, the adjusted all-cause mortality for MBP was 0.85 and no 
longer statistically significant (p=0.22).   
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Increasing age, male sex, advancing Dukes’ stage and emergency presentation 
for surgery were independently associated with greater mortality. Urgent 
admission to hospital was not associated with significantly increased hazards in 
the adjusted model. 
 
Table 31 - Univariate and multivariate hazards of all cause mortality after elective colon 
surgery adjusted for age, sex, Dukes’ stage, mechanical bowel preparation, socio-economic 
circumstances (DEPCAT), type of admission, any surgical complication, and presentation 
for surgery.   
  
p 
UNIVARIATE 
HR (95% CI) 
 
p 
MULTIVARIATE 
HR (95% CI) 
bowel prep – no  1  1 
bowel prep - yes 0.00 0.72 (0.57-0.91) 0.22 0.85 (0.67-1.10) 
age (continuous) 0.00 1.05 (1.04-1.06) 0.00 1.05 (1.04-1.06) 
sex female  1  1 
sex male 0.04 1.20 (1.01-1.44) 0.00 1.31 (1.10-1.57) 
affluent 0.11 1   
intermediate 0.27 1.16 (0.89-1.50)   
deprived 0.04 1.34 (1.01-1.78)   
Dukes' stage A 0.00 1 0.00 1 
Dukes' stage 
unspecified 
0.00 2.09 (1.46-3.00) 0.00 1.82 (1.27-2.63) 
Dukes' stage B 0.01 1.48 (1.08-2.04) 0.04 1.40 (1.01-1.92) 
Dukes' stage C 0.00 2.20 (1.61-3.02) 0.00 2.14 (1.56-2.94) 
Dukes' stage D 0.00 6.56(4.31-9.99) 0.00 7.37 (4.83-11.25) 
admission type – 
routine 
 1  1 
admission type – 
urgent 
0.04 1.31 (1.01-1.69) 0.15 1.21 (0.93-1.58) 
any surgical 
complication 
0.48 0.86 (0.58-1.29)   
elective  surgery  1  1 
emergency surgery  0.00 1.94 (1.38-2.74) 0.00 1.92 (1.32-2.79) 
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We found no difference in the proportions of surgical complications for 
anastomotic leak, intra-abdominal abscess, and fistula formation between both 
sets of patients – see Table 32. In addition, we measured rates of three further 
complications that have been previously noted as occurring more often in 
patients receiving bowel preparation, namely myocardial infarction, deep 
venous thrombosis, and pulmonary embolism (210). We found no statistically 
significant difference in frequency of these complications between patients who 
did and those who did not receive MBP.  
 
Table 32 - Main postoperative (within 30 days of surgery) surgical complications in patients 
who received Mechanical Bowel Preparation (MBP).   Pearson chi-square p-values of 
differences between MBP and non-MBP groups. 
 
Complication n Received MBP p value 
    
Anastomotic leak 38 34 (89.5%) 0.38 
Intra abdominal 
abscess 7 6 (85.7%) 0.82 
Fistula 3 3 (100%) 0.46 
Wound infection 71 59 (83.1%) 0.76 
Myocardial infarct 31 25 (80.6%) 0.56 
Deep venous 
thrombosis 6 5 (83.3%) 0.94 
Pulmonary Embolism 5 5 (100%) 0.34 
Chest Infection 64 58 (90.6%) 0.162 
Not recorded 34 30 (88.2%) 0.533 
Any complication 215 187 (84.4%) 0.265 
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5.5 Discussion 
Patients who received mechanical bowel preparation before colon surgery had 
no better survival than those who did not in up to seven years’ follow-up.  A 
survival advantage of 28% remained after adjustment for age, sex, socio-
economic circumstances, Dukes’ stage and type of admission but was no longer 
significant after the addition of urgency of surgery to the multivariate model (HR 
0.85, 95% CI 0.67 to 1.10).  This suggests that the observed survival benefit was 
because of other factors related to emergency surgery. There are several 
possible explanations for our findings.  The first is that selection biases 
accounted for the improved survival among patients who received mechanical 
bowel preparation which confound any real association. We included a validated 
measure of socio-economic circumstances, the DEPCAT, so that the confounding 
effects of underlying morbidities, such as smoking-related illnesses, would be 
attenuated.  The second explanation might be that differential misclassification 
of patients occurred, such that those with better prognostic factors were 
systematically recorded as having poorer characteristics among patients 
receiving mechanical bowel preparation.  Thus, after adjustment in a 
multivariable model, outcomes would be better than expected among the MBP 
group.  This seems unlikely because the unadjusted Kaplan-Meier survival plot 
indicates improved survival among the cohort who received mechanical bowel 
preparation. The overall results of meta-analyses of randomised controlled trials 
of MBP have shown no clear benefit and, in some cases, worse postoperative 
complication rates (although no difference in postoperative mortality).(113-
115,208) The results of individual RCTs have also consistently shown no benefit, 
an exception being a lower risk of peritonitis among MBP patients reported by 
Contant and others.(117,209,210) (211) It is possible that while no measurable 
reduction in postoperative complications occurs with MBP, there are other, 
subtler biological effects that confer improved long-term survival.  Further work 
is needed both to replicate our findings and to explore biological mediators of 
survival such as C-reactive protein and albumin that might explain the long-term 
risks associated with emergency surgery (77,217)  Potentially modifiable aspects 
of patient care and management are also putative explanations.  
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5.6 Conclusions 
Long-term survival among colon cancer patients is not improved through 
mechanical bowel preparation prior to surgery nor does it reduce postoperative 
complications.  Given that randomised controlled trials have consistently shown 
no short-term benefit of MBP, we suggest that there remains little argument in 
favour of its continued use. 
 
There is no convincing evidence that mechanical bowel preparation affects short 
term outcomes for elective surgery for resection of colonic cancer. Meta-
analyses suggest that postoperative complications may be greater among 
patients who receive bowel preparation.  Despite this, it continues to be used 
routinely in many countries. 
The long-term survival of patients treated with mechanical bowel preparation 
has not been previously reported.  We followed-up 1730 patients for up to 7 
years and found that a 28% greater survival among non-emergency hospital 
admissions for colon cancer surgery could be explained by lower emergency 
surgery rates.  There was no significant survival advantage for patients given 
mechanical bowel preparation after adjustment for other risk factors.  There is 
little evidence to support the continued use of mechanical bowel preparation 
prior to colon cancer surgery.
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6 Type of rectal surgery as a proxy marker for 
quality of care  
6.1 Introduction 
This chapter addresses a further aim of this thesis, namely assessing extent of 
variation in treatment for rectal cancer within the West of Scotland and to what 
extent this has an impact on patient survival. In order to do this it has focussed 
on a current, nationally agreed objective measure of quality of surgery for rectal 
cancer patients - the APE (abdomino perineal excision) to AR (anterior resection) 
ratio. Rectal cancer patients have been chosen specifically as decisions relating 
to the timing and choice of surgical procedure are highly dependent upon the 
modern MDT process. Attaining the nationally agreed measure could therefore 
be regarded as a reflection or result of the MCN effect. As will be outlined, the 
APE: AR ratio can be viewed as a proxy measure for subspecialisation in rectal 
surgery. Subspecialisation in itself is thought to provide better surgical outcomes 
for patients as previously discussed (162). 
There are growing numbers of putative indicators of quality of care in rectal 
surgery. These cover the entire perioperative period and have been explored 
and incorporated into various guidelines for treating this complex cohort of 
patients (82,218). Among them are clear circumferential resection margins 
(CRMs), number of patients receiving pre operative chemoradiotherapy and 
reduced numbers of patients with postoperative local recurrence of tumour. 
Underlying these measurements is the assumption that patients are accurately 
staged and therefore selected appropriately for surgery. As has been previously 
discussed, patients in our region have staging data that compares well with 
other, larger published series (82). 
 
Rectal cancer is a common disease in the UK with 13 000 cases and 5000 deaths 
per year. In 2007, 379 men and 285 women died due to the disease in Scotland 
(22). Traditionally, there were two main perceived barriers to improved 
outcomes for patients with rectal cancer compared to colon cancer. These were 
a higher colostomy rate and higher local recurrence rate respectively. 
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In order to circumvent these problems, two major advances occurred. Firstly, 
technological advances in stapling devices: Smaller, more reliable and more 
ergonomically designed staplers allowed secure anastomoses to be made lower 
in the pelvis than before. This helped to reduce the APE to AR ratio as more 
patients became suitable for AR surgery. Secondly, the advent of total 
mesorectal excision (TME) lead to a reduction in local recurrence at the 
circumferential resection margin thus further improving outcomes and ultimately 
survival for rectal cancer patients compared to those with colonic lesions (52).  
It is now widely accepted that if the surgical principles of TME are adhered to 
the overall local recurrence rate should be <10% across all stages of rectal 
disease (219). 
 
The NHS was founded on a set of principles dictating delivery of speciality and 
sub speciality services to all patients in the UK independent of socioeconomic 
background, race or sex. It is widely accepted that this vector of service delivery 
results in improved outcomes and more specifically, improved resection margins 
in rectal cancer patients. Providing a service to patients with rectal cancer in 
this manner is therefore extremely important. 
 
Technological advances in CT resolution coupled with the greater availability of 
MRI scanning have resulted in improved preoperative staging. More precise and 
informed decisions can now be made regarding preoperative treatment plans. 
Postoperative reduction in CRM positivity has also been noted (220). Decisions 
regarding palliative and curative intent of surgery are now more accurate as a 
result.  
   
Key differences between rectal and colonic cancer 
 
There are various aspects of rectal cancer surgery that distinguish it from colon 
cancer surgery. The first and most obvious is anatomical location. The currently 
agreed definition of a rectal tumour has previously been stated by the Expert 
Advisory Committee of the ACPGBI. They maintain any tumour whose distal 
margin is seen at 15cm or less from the anal verge using a rigid sigmoidoscope 
should be classified as a rectal cancer (82). This is a grade C recommendation. 
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Secondly, and as a result of the anatomical location, rectal tumours are 
technically more difficult to resect. Locally advanced lesions present significant 
challenges for resection. Local invasion of the mesorectum and adjacent pelvic 
structures such as ureters, bladder and sacral nerves may occur. This, coupled 
with the narrow confines of the pelvis (especially in men), makes any attempt at 
resection particularly demanding for the surgeon (52). As mentioned in the 
introduction and background to this thesis, the management of rectal cancer is 
evolving. Preoperative ultrasound and / or MRI staging, preoperative 
radiotherapy, and depending on quality of resection, preoperative chemo 
radiotherapy are all modern adjuncts to surgical management of rectal 
carcinoma. 
 
Given that rectal cancer is inherently more difficult to resect and involves a 
more complex approach to management it has come under much more quality 
control scrutiny. 
 
Current surgical management of rectal cancer 
 
Surgery is the mainstay of curative treatment for localised rectal cancer and is a 
major element of the multimodal management approach to more advanced 
curative and palliative staged disease. Abdominoperineal excision (APE), anterior 
resection (AR) and Hartmann’s resection are three common options for the 
surgeon when excising a cancerous rectal lesion although many others exist (see 
appendix). Traditionally the curative procedure for lower rectal tumours was the 
APE which requires the removal of the anal sphincter complex. This necessitates 
a permanent colostomy. Whilst APE remains the only option in selected patients 
with very low rectal tumours where optimal oncological clearance is needed, for 
the majority the more modern technique of AR can be performed (221). This 
allows the retention of the sphincter complex and was generally considered 
preferable for the patient as it was assumed that a better quality of life resulted 
(222). More recently the Cochrane collaboration has published a review article 
stating that this assumption is not met. Patients with a permanent stoma do not 
seem to have a poorer quality of life than those without. They also concede that 
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firm conclusions cannot be drawn as it is a difficult area to produce objective 
outcomes (125). 
 
In the NHS then, recommendations for reduced stoma rates in rectal cancer 
patients are more likely to be based on the long-term cost benefits in AR 
patients. This is because the ongoing care and expense associated with stoma 
care in APE patients is removed. It must be borne in mind that a degree of 
morbidity is seen in those patients undergoing AR too. Common symptoms 
include diarrhoea, incontinence, and chronic pelvic pain (125). APE therefore 
currently remains a valid operation for tumours of the low rectum in proximity 
to the sphincter complex and in patients where it is felt that the functional 
results obtained with a low restorative resection would significantly affect 
quality of life or compromise continence. 
 
The introduction of the relatively modern total mesorectal excision (TME) 
technique and the use of low or ultra-low AR have led to significantly improved 
local disease control and overall survival for more patients with tumours in the 
lower rectum (52) (50). This is at the expense of poorer function in terms of 
bowel control and is coupled with the higher risk of nerve damage and 
subsequent bladder and erectile dysfunction. Positive circumferential resection 
margins are known to be a strong prognostic indicator of local recurrence in 
rectal cancer resection patients but there are currently no guidelines that state 
what proportion of positive resections margins in rectal patients is acceptable as 
an indicator of good quality surgery (84,223).    
 
 
Current literature does not span the entire rectal cancer population of a defined 
region where there is a different organisation of health care resources. It would 
be of benefit to compare these to test whether we have a system that is more or 
less discriminatory in terms of patient sex and socioeconomic circumstances. To 
that end we wanted to explore both variation in type of operation offered to 
rectal cancer patients then provide a closer analysis of factors that could 
contribute to or explain the variation. 
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6.2 Aims & Objective 
Aims 
i. To assess if there was any variability in the ratio of types of major 
resection for rectal cancer throughout the region. 
ii. To further explore this in order to ascertain factors that could explain the 
variability. 
Objective 
 
i. To logically and thoroughly analyse the combined dataset with regard to 
surgical procedures performed on patients with rectal cancer.  
 
 
6.3 Method 
Methodology was in keeping with that mentioned on page 73. In addition, there 
was an additional coding methodology adhered to in order that operations were 
correctly categorised (44). This can be seen in more detail in appendix 3. 
 
Inclusion and exclusion criteria 
Patients diagnosed with rectal cancer requiring surgical intervention in the West 
of Scotland from 2001 to 2005 were included in the study. Patients deemed to 
have advanced disease not amenable to surgical intervention, or those 
undergoing endoscopic treatment were excluded to minimise confounding 
effects on results.  
A number of patients with tumours at other sites within the bowel (n=15) were 
also coded as receiving APEs in our larger dataset of colonic and rectal cancer 
patients. They were excluded. 
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6.4 Results 
The characteristics of the population of rectal cancer patients in the West of 
Scotland from 2001 to 2005 can be seen in table 1. In total, 1574 patients met 
the inclusion criteria. The majority of patients were male (61%). The median age 
of all patients was 68. This represents a population skewed towards the right of 
a normal age distribution. This is in keeping with the incidence of rectal cancer. 
Of note is that 14.61% of patients had data missing regarding type of operation. 
This is highlighted in order to comment upon the degree of completeness of the 
dataset. 
Table 33 - Demographics and characteristics of the 1574 patients in the West of Scotland 
undergoing a surgical procedure for rectal cancer from 2001 to 2005. 
Variable  Frequency % 
Sex Male 960 60.99 
 female 614 39.01 
Age mean (SD) 67.03 (11.54) 
 
range  
median 
75 (22-97) 
68 
 
Operation type APE 325 20.65 
 AR 710 45.11 
 Hartmann's 37 2.35 
 Other 272 17.28 
 Total 1344 85.39 
 Missing 230 14.61 
Intent curative 1163 73.89 
 palliative 179 11.37 
 not recorded 232 14.74 
Admission type emergency 185 11.75 
 routine or urgent 1212 77.00 
 unknown 177 11.25 
Dukes' stage unspecified 316 20.08 
 stage A 322 20.46 
 stage B 381 24.21 
 stage C 434 27.57 
202 
 stage D 121 7.69 
deprivation group affluent 216 13.72 
 intermediate 935 59.40 
 deprived 418 26.56 
 Unknown 5 0.32 
age group <=60 422 26.81 
 61-70 488 31.01 
 71-80 480 30.50 
 >80 184 11.69 
Surgeon volume >7 cases / yr 896 56.93 
 <=7 cases / yr 413 26.24 
 missing 265 16.84 
year of incidence 2001 350 22.24 
 2002 316 20.08 
 2003 313 19.89 
 2004 331 21.03 
 2005 264 16.77 
Health Board Ayrshire & Arran  75.3* 17.60 
 Argyll & Clyde 69.0* 18.23 
 Glasgow 57.0* 31.45 
 Lanarkshire 62.0* 21.92 
 Forth Valley 60.3* 10.80 
Tumour 
perforation Yes  
101 6.4 
 No 1098 69.8 
 
Other†  
 
375 23.8 
    
 Total 1574 100.00 
 
*Values are expressed as a rate per 100,000 of Health Board population. Health 
Board population numbers are derived from GRO Scotland. † not recorded, 
Inapplicable, or missing. 
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Variation between MDT groups 
In figure 42 below the greatest proportion of ARs were performed in hospitals 4 
&7 (59.12%) whereas the lowest was in hospital 11 (47.06%). The largest 
proportion of APE resections were performed in hospitals 5 &12 (33.79%) with 
only 17.95% in hospital 18. The proportion of “other operations” varied from 
14.48% in hospitals 5 &12 to 28.13% in hospital 17. Similarly, a large variation in 
numbers of recorded Hartmann’s operations occurred. None were recorded in 
hospitals 8 & 13 whereas hospitals 2 & 9 recorded 9.62% of operations for rectal 
cancer as being Hartmann’s procedure.  Overall, a statistically significant 
difference was observed in the proportions of operations performed between 
MDTs (p = 0.004). 
 
Figure 42 also highlights the variation in rectal operations performed for cancer 
patients within the MCN (Managed Clinical Network). Nine of the 11 MDTs were 
attaining the now recommended rate of <30% APE for all rectal tumour 
resections (82). There was a constant proportion AR operations being performed 
across the region, ranging from 47% of total to 59% of total operations 
performed). A larger variation existed with regard to Hartmann’s procedures. It 
appeared that in hospitals 8, 13, 6, 14, 5 and 12 there were very few Hartmann’s 
procedures taking place whereas almost 10% of all rectal cancer resections were 
Hartmann’s in the MDT at hospitals 2 & 9. 
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Figure 42 - Summary of variation in use of main rectal cancer surgical operations by MDT in 
the West of Scotland. APE, abdominoperineal excision; AR, anterior resection. n = 1318, 
P=0.004 
 
 
By concentrating on only the two major operations for rectal cancer a non-
significant variation across all MDTs is demonstrated (p=0.122). This is shown in 
figure 43 below. 
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Figure 43 - Variation in use of only APE and AR rectal cancer surgical operations by MDT in 
the West of Scotland. n = 1018, p = 0.122. 
 
 
 
Variation between different Health Boards 
A statistically significant difference is observed in the proportions of operations 
performed between Health Boards (p = 0.001) This is possibly due to the large 
variation in number of operations recorded as other. In order to test this, a 
further comparison has been made, excluding all Hartmann’s operations other 
than AR and APE. 
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Figure 44 - Variation in use of main rectal cancer surgical operations by Health Board in the 
West of Scotland. APE, abdominoperineal excision; AR, anterior resection. n = 1344, p 
=0.001 
 
 
Again, by selecting only APE and AR operations the statistically significant 
variation seen across the region disappears. Despite there being a wide variation 
in total numbers of procedures carried out with over 300 in Glasgow and less 
than 150 in Forth Valley, the difference in proportions of APE to AR is not 
statistically siginificant (p=0.098). 
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Figure 45 - Variation in use of only APE and AR rectal cancer surgical operations by Health 
Board in the West of Scotland. n = 1035, p = 0.098 
 
 
Variation with time 
 
In figure 46 the ratio of APE to other operations was highest in 2001. This 
reduced with time. The proportion of  APE rectal operations was largest in 2001. 
The proportion of ARs was highest in 2003. Overall, a statistically significant 
difference was seen (p = 0.034) in proportions of operations performed for rectal 
cancer however this seems to be due to variation in type of operation and not 
due to a consistent trend towards less APEs and more ARs. In order to assess this 
a closer look at APE to AR ratio is required. 
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Figure 46 - Change in proportions of rectal cancer operations performed with time in the 
West of Scotland from 2001-2005. n =1344, p = 0.034 
 
 
 
 
As seen above with both MDT and Health Board, the variation noted when 
looking at all rectal cancer operations disappears when selecting only APE and 
AR. In figure 47 although a reduction in the overall number of APEs perfomed 
can be seen with time it was not statistically significant (p=0.121). If the length 
of time over which data were analysed was to be increased, a significant trend 
might emerge. 
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Figure 47 - Change in proportions with time of the 2 main rectal cancer operations, APE and 
AR. n = 1017, p =0.121 
 
.  
Comparing the population of rectal cancer patients receiving APE with those 
receiving AR 
 
Table 34 shows that the groups of patients undergoing APE  are well matched in 
terms of sex, stage and deprivation category with those undergoing AR. A far 
higher proportion of patients undergoing APE were emergency admissions (14.2% 
compared to 8.9%). This contrasts to the 18%  reduction in odds of undergoing 
APE as an emegency admission stated by Morris et al (44). Chi square testing of 
deprivation groups produced a p value of 0.576. This is particularly noteworthy 
and will be discussed below. Surgeon volume is an ongoing area of debate in 
relation to surgical outcomes (164). This table demonstrates a statistically 
significant difference in proportions of patients undergoing resection by surgeons 
operating on differrent volumes of patients. Again, this confirms previously 
published findings (44). Intent of operation was also found to be statistically 
significant (p=0.034) indicating that a higher proportion of patients undergoing 
curative resection have a sphincter saving operation. Of particular note is that 
we found no statistically significant difference between proportions of APE and 
AR in relation to sex nor deprivation group. In total, 26.2% of the APE patients 
had a positive circumferential margin whereas only 10.1% of AR patients had a 
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positive circumferential margin. These figures agree with those previously 
published in both Holland and Leeds (47) (49). 
Table 34 - Chi square test results used to assess differences in proportions of APE and AR 
in relation to ten variables of interest when comparing proportions of APE and AR only. 
  APE AR p 
  n = 325 
(31.4) 
n = 710 
(68.6) 
 
Age mean 
(SD) 
66.31(11.01)    
Gender Male 193 (59.4) 428 (60.3) 0.785 
 Female 132 (40.6) 282 (39.7)  
     
Type of 
admission 
Emergency  46 (14.2) 63 (8.9) 0.028 
 Other 275 (84.6) 633 (89.2)  
 Unknown 4 (1.2) 14 (2.0)  
     
Depgroup Affluent 49 (15.1 90 (12.7) 0.576 
 Intermediate 188 (57.8) 425 (60.1)  
 Deprived 88 (27.1) 192 (27.2)  
     
Dukes' stage A 58 (17.8) 88 (12.4) 0.121 
 B 95 (29.2) 207 (29.2)  
 C 97 (29.8) 239 (33.7)  
 D 15 (4.6) 34 (4.8)  
 unspecified 60 (18.5) 88 (12.4)  
     
Year of 
incidence 
2001 82 (38.14) 133 (61.86) 0.117 
 2002 65 (29.95) 152 (70.04)  
 2003 67 (21.91) 157 (70.1)  
 2004 54 (26.5) 150 (73.5)  
 2005 57 (32.57) 118 (67.43)  
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Surgeon 
volume 
> 7 cases / yr 202 (29.66) 479 (70.33) 0.030 
 <= 7 cases/yr 108 (36.73) 186 (63.27)  
Intent of 
operation 
Curative  280 (86.2) 648 (91.3) 0.034 
 Palliative 31 (9.50) 39 (5.50)  
 not recorded 14 (4.30) 23 (3.20)  
Health Board Ayrshire & Arran 57 (30.64) 129 (69.35)  
 Argyll & Clyde 60 (33.33) 120 (66.66)  
 Glasgow 88 (26.59) 243(73.41)  
 Lanarkshire 71 (33.33) 142(66.67)  
 Forth Valley 49 (39.20) 76 (60.80) 0.089 
MDT Group hospitals 1 & 3 54 (31.58) 117 (68.42)  
 hospital 16 15 (24.59) 46 (75.41)  
 hospitals 8 & 13 40 (37.04) 68 (62.96)  
 hospitals 2 & 19 21 (28.38) 53 (71.62)  
 hospital 11 32 (40.00) 48 (60.00)  
 hospital 17 12 (25.00) 32 (72.73)  
 hospitals 5 & 12 49 (24.14) 74 (60.16)  
 hospitals 4 & 7 27 (25.00) 81 (75.00)  
 hospital 18 21 (24.10) 66 (75.86)  
 hospital 10 15 (26.32) 42 (73.68)  
 hospitals 6 & 14 34 (32.38) 71 (67.62) 0.122 
CRM 
positivity 
Yes 70 (26.20) 58 (10.10)  
 No 197 (73.80) 517 (89.90) <0.005 
Tumour 
perforation 
Yes 27 (9.31) 43 (6.41)  
 No 263 (90.69) 628 (93.59) 0.112 
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Univariate and multivariate findings 
 
Of the 13 variables assessed on univariate analysis, only age (as a continuous 
variable), Dukes’ stage and circumferential margin positivity were found to be 
statistically significant. 
 
Table 35 - Results from univariate binary logistic regression analysis with APE as the 
dependant variable. 
Explanatory variable p OR 95% CI 
Age continuous 0.01 0.99 0.976-0.996 
Age categorical 0.23   
<=60  1.00 1.00 
61-70  1.04 0.76-1.43 
71-80  0.91 0.659-1.25 
>80  0.65 0.40-1.04 
Sex 0.51   
Male  1.00 1.00 
Female  1.09 0.85-1.40 
Deprivation group 0.69   
Affluent  1.00 1.00 
Intermediate  0.86 0.60-1.23 
Deprived  0.91 0.61-1.35 
Dukes’ stage 0.02   
A  1.00 1.00 
B  1.51 1.05-2.18 
C  1.31 0.91-1.88 
D  0.64 0.35-1.19 
Unspecified  1.07 0.72-1.59 
Type of admission 0.51   
Urgent/routine  1.00 1.00 
Emergency  1.13 0.79-1.62 
Year of incidence 0.23   
2001  1.00 1.00 
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2002  0.85 0.59-1.22 
2003  0.89 0.62-1.28 
2004  0.06 0.44-0.93 
2005  0.90 0.61-1.32 
Intent of operation 0.05   
Curative  1.00 1.00 
Palliative  0.66 0.44-1.00 
Circumferential margin <0.001   
Negative  1.00 1.00 
Positive  2.60 1.83-3.69 
Volume of surgeon 0.15   
< 7 cases per year  1.00 1.00 
>= 7 cases per year  0.82 0.63-1.08 
Health Board 0.05   
Health Board  1.00 1.00 
Health Board (1)  0.64 0.41-0.99 
Health Board (2)  0.65 0.42-1.01 
Health Board (3)  0.53 0.36-0.80 
Health Board (4)  0.64 0.42-0.98 
MDT groups 0.16   
MDT group  1.00 1.00 
MDT group(1)  0.98 0.60-1.60 
MDT group(2)  0.64 0.33-1.26 
MDT group(3)  1.20 0.71-2.03 
MDT group(4)  0.78 0.42-1.45 
MDT group(5)  1.37 0.78-2.42 
MDT group(6)  0.63 0.30-1.31 
MDT group(7)  1.56 0.93-2.60 
MDT group(8)  0.74 0.42-1.31 
MDT group(9)  0.65 0.36-1.20 
MDT group(10)  0.69 0.35-1.35 
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Table 36 - Results from multivariate binary logistic regression analysis with APE as the 
dependant variable. 
 p OR 95.0% C.I.for EXP(B) 
   Lower Upper 
Age* 0.03 0.98 0.97 1.00 
Depgroup 0.13    
Affluent  1.00 1.00  
Intermediate 0.07 0.65 0.41 1.03 
Deprived 0.06 0.61 0.36 1.01 
Stage of disease 0.31    
Dukes' A  1.00 1.00  
Dukes' unspecified 0.74 1.10 0.64 1.90 
Dukes' B 0.99 1.00 0.64 1.57 
Dukes' C 0.14 0.71 0.45 1.12 
Dukes' D 0.36 0.67 0.28 1.58 
Sex 0.58    
Male  1.00 1.00  
Female  1.09 0.80 1.50 
Volume 0.61    
< 7 cases per year  1.00 1.00  
>= 7 cases per year  0.91 0.65 1.29 
Type of admission 0.67    
Urgent/routine  1.00 1.00  
Emergency  1.12 0.68 1.84 
Year 0.35    
2001  1.00 1.00  
2002 0.06 0.64 0.40 1.02 
2003 0.11 0.68 0.43 1.09 
2004 0.18 0.72 0.44 1.16 
2005 0.26 0.75 0.46 1.23 
Operative intent 0.53    
Curative  1.00 1.00  
Palliative  0.82 0.44 1.52 
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Circumferential margin <0.001    
Negative  1.00 1.00  
Positive  3.49 2.32 5.27 
 
* age measured in continuous whole years. It became non-significant (p = 0.73) 
when grouped as an ordinal categorical variable.  
 
The following table demonstrates that of the three variables found to be 
statistically significant on univariate analysis (age as a continuous variable, 
Dukes’ stage and circumferential margin positivity) only the last retains its 
significance when entered into a multivariate model with the other two. 
Following adjustment for the other covariates, a positive circumferential margin 
confers a mortality risk of 3.68 times more than would be seen in a patient with 
a negative margin. 
 
Table 37 - Combined univariate and multivariate results. 
Factor Univariate OR  
(95% CI) 
Multivariate OR 
(95% CI) 
   
age (continuous)* 0.98 (0.97-0.99)  
Depgroup   
     Affluent 1.00  
     Intermediate 0.86 (0.60-1.23)  
     Deprived 0.91 (0.61-1.35)  
Stage of disease   
     Dukes' A 1.00  
     Dukes' unspecified 1.07 (0.72-1.59)  
     Dukes' B 1.51 (1.05-2.18)  
     Dukes' C 1.31 (0.91-1.88)  
     Dukes' D 0.64 (0.35-1.19)  
Sex   
     Male 1.00  
     Female 1.09 (0.85-1.40)  
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Volume   
     < 7 cases per year 1.00  
     >= 7 cases per year 0.82 (0.63-1.08)  
Type of admission   
     Urgent/routine 1.00  
     Emergency 1.13 (0.79-1.62)  
Year   
     2001 1.00  
     2002 0.85 (0.59-1.22)  
     2003 0.89 (0.62-1.28)  
     2004 0.06 (0.44-0.93)  
     2005 0.9 (0.61-1.32)  
Operative intent   
     Curative 1.00  
     Palliative 0.66 (0.44-1.00)  
Circumferential margin   
     Negative 1.00 1.00 
     Positive 2.60 (1.83-3.69) 3.58 (2.38-5.36) 
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6.5 Discussion 
Comparison with previous studies 
In terms of population demographics our sex distribution of 60.99% male to 
39.01% female compares well to that reported in previous series. The most 
recent UK paper quoted proportions of 63.2% males to 36.8% females. Tilney et 
al cite a sex distribution of 62.15% and 37.85% for males and females 
respectively (43,44). In contrast to these large scale studies, we found no 
evidence that males were more likely to undergo APE rather than AR.  
The mean age of our population (67.03) is also within 1 year of that reported by 
Tilney et al in their January 2008 study (43).  
 
In our population the percentage of emergency admissions (11.75%) is almost 
double that quoted in other similar series (5.8%) (44).  It is possible that inter-
regional differences exist in interpreting the term emergency. Otherwise this 
may point to the fact that patients with rectal cancer present later in their 
disease process in our region. This observation is supported by the proportion of 
patients in our cohort with Dukes’ stage D disease (7.69%) compared to 3.7% in 
the large Morris et al cohort. Dukes’ D disease is more likely to present as an 
emergency as patients are more likely to obstruct or decompensate 
physiologically if they have a large, obstructing tumour or metastases 
respectively. 
 
It appears that on average, patients diagnosed with rectal cancer in the West of 
Scotland present younger than those in other published series. A smaller 
proportion of patients are not only in the oldest age group (>80 years) but in the 
next oldest age group also (71-80 years). This amounts to 11.69 and 30.5 percent 
of the total compared to 12.2 and 33.1 percent in the large English series (44). 
There also remains a proportion of patients with Dukes’ stage of disease 
unspecified. In our series this was 20.08% of the population. That in the larger 
Morris population is 25.5%. Our data are therefore more complete in relation to 
staging of disease.   
 
Previous groups have noted a socioeconomic bias in the form of increased use of 
APE in more deprived patients. We were not able to demonstrate this in our 
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population suggesting that there is possibly less deprivation bias in patient 
selection processes for type of operation in the West of Scotland. This is 
particularly relevant given that ISD Scotland report a statistically significant 
trend with P<0.005 for both incidence and mortality in patients with rectal 
cancer in more deprived populations (192). If the incidence is rising in more 
deprived populations then we can expect to be treating more of these patients 
and should be offering them the same treatment as more affluent patients. 
 
Oncological outcomes 
It has been previously noted that inferior oncological outcomes occur following 
APE. In particular, the circumferential resection margin (CRM) positivity has 
been cited as being positive more often in APE operations when compared to AR 
(224) (48) (49). This was one of only two variables in this study retaining their 
significance in predicting likelihood of APE following regression analysis (table 
3). We therefore confirm that APE results in poorer resection quality in terms of 
margin involvement in our population despite adjustment for case mix. 
 
Regional Variation 
During the study period there were 17 hospitals grouped into 11 different 
functioning MDTs. These 11 MDTs together constitute the MCN for colorectal 
cancer in the West of Scotland. When considering all rectal cancer procedures, 
statistically significant variation was seen across MDTs in the region (figure 1). 
When concentrating on only APE and AR this disappeared (figure 2). 
 
This could partly be explained by a difference in case mix between MDTs with 
some hospitals encountering a higher proportion of patients with lower rectal 
tumours. It could also be explained by an internal difference in coding between 
hospitals. A further possibility is surgeon preference for performing certain 
operations for particular rectal lesions. This difficulty with variation in coding of 
operations has been noted previously (44,54). Fortunately though, a recent 
comparison of administrative data with the Association of Coloproctology of 
Great Britain and Ireland database concluded that there was a good correlation 
of accuracy between the two. This was particularly the case for rectal cancer 
operation data (55). 
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Furthermore, we looked at the variation between Health Boards. A similar 
picture to that at MDT level is seen when looking at numbers of rectal cancer 
resections across different Health Boards. The encouraging finding is that all 
have an APE rate below the 30% rate recommended by the ACPGBI, except Forth 
Valley (82). These guidelines were produced in 2007 however, which is later 
than the period under study. A statistically significant difference is observed in 
the proportions of operations performed between Health Boards (p < 0.05). This 
is more likely to be due to the larger variation in numbers of “other” and 
Hartmann’s operations being performed than a large difference in the APE to AR 
ratio. Indeed this was borne out in table 2 where Health Board was found to be 
not significant (p=0.089) when comparing proportions of APE to AR operations 
without Hartmann’s and other included.  
Again, when only APE and AR are analysed in relation to distribution of these 
operations across different Health Boards there was no statistically significant 
difference found (p = 0.098).  
 
Variation according to sex 
 
Unlike previous studies we found no significant difference in proportions of 
patients receiving an APE according to sex (p = 0.58). See table 36. 
We also found no significant difference in the proportion of patients receiving 
APE compared to AR in relation to deprivation group, unlike Morris et al. Both of 
these findings would suggest that the service offered to patients in this 
population could be viewed as less discriminatory on the basis of sex and 
deprivation. 
 
Variation with time 
 
The agreed aim of mid and high rectal cancer surgery is to preserve the 
sphincter complex as far as possible thus ensuring relatively normal bowel 
function. It has also been said that reducing permanent stoma rates reduces the 
future financial burden on the NHS. With time then, we would hope to reduce 
the rate of APEs performed. Figure 47 demonstrates that although there is a 
significant difference in the proportions of all procedures performed with time, 
it is not a constant reduction. Moreover, by concentrating only on the 
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relationship between APE and AR with time we are able to show no significant 
difference in proportions of operation performed with time. (p= 0.121) Whilst 
other centres have been able to show a definite reduction in APE rate with time 
it may be that we are not considering a trend over a long enough time frame in 
this series. It may also be that the region has potentially attained its lowest 
possible APE rate at an earlier stage. We may therefore be unlikely to see a 
significant drop with time. 
 
Most importantly, the overall APE rate over the study period never exceeds the 
recommended rate of 30% (82). This is an arbitrary number that has been arrived 
at through consensus recognising that it is difficult to determine what the ideal 
ratio of anterior resection to APE should be. A further recommendation is that if 
any doubt exists as to type of operation then experienced second opinion should 
be sought. It would be useful to know how often a second opinion is sought by 
surgeons, and in what circumstances. 
 
Rates of use of APE over time have been shown to be consistently dropping 
across other published series (43,45,225).  
 
The next stage in analysis was to explore the various significant results from 
binary logistic regression. Table 36 shows that when using APE as the dependent 
variable, only age and positive circumferential margin remain statistically 
significant indicators of whether or not a patient is likely to have had an APE 
resection instead of an anterior resection.  
 
Strengths and weaknesses of this study 
 
Incorrect or absent recording of operation type is a potential source of error in 
this study. Rate of APE may be falsely low as 12.09% of operations were not 
categorised. The fact that this study depends upon accurate OPCS codes has not 
been overlooked. We are aware that both accuracy and quality of coding rely on 
accurate input from audit staff. Not until their performance is regularly audited 
or until consultant surgeons are coding their operations themselves and having 
their practice audited by peers will we see a reduction in coding error and 
missing codes. Reassurance is taken from the conclusions of a recent study 
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stating that administrative data regarding rectal cancer patients has a good 
correlation of accuracy with prospectively collected data from the ACPGBI (55). 
 
Should intent of operation be used as a reliable discriminator? The decision as to 
whether an operation is deemed curative or palliative is now generally made by 
a team at a colorectal MDT whereas historically it was made by the consultant in 
charge. To that end it is now less subjective. More accurate staging data also 
adds to the objectivity of this decision. It is recommended that the term 
curative resection should be based on surgical and histological confirmation of 
complete excision. Surgeons should expect to achieve an overall curative 
resection rate of 60%, but it is appreciated that this will depend at least in part 
on the stage at which patients present (82). We feel this was perhaps an 
unreliable variable but is becoming more objective with time. As such, stronger 
conclusions will be able to be drawn as objective pathological evidence is added. 
 
There will always be a subset of patients for whom there is no option but to 
perform an APE. The main factor in determining this is distance (or height) of 
the tumour from the anal verge. It has been suggested that in these patients a 
more radical version of the traditional APE may need to be performed in order to 
ensure adequate oncological resection margins (226). A major drawback of this 
study is not being able to adjust for height of tumour. This would allow for more 
insight into how operations are applied according to height of tumour and how 
influential height is in making a decision regarding type of operation. 
 
Data regarding the proportion of procedures carried out laparoscopically is 
lacking. It is imperative that these data are also analysed as laparoscopic surgery 
has a steeper learning curve thus having a greater potential to produce more 
variation in practice across a region as trainees learn from the outset of training 
and consultants adopt the newer laparoscopic techniques. 
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Implications for clinical practice  
 
Quantifying and addressing the variations in surgical practice is a key component 
in trying to achieve a high quality of cancer care for all. 
 
Herein we have demonstrated that we are able to combine sources of routinely 
collated colorectal cancer data to view rectal cancer surgical practice at a 
regional level, covering a population of 2.2million. This is the first time this has 
been done for an entire, defined population of rectal cancer patients. 
 
Our population in the West of Scotland is age and sex matched with other 
populations. We have a higher proportion of patients presenting as emergencies 
and with more advanced disease at a younger age. This has implications for more 
investment in educating the population with regard to early signs and symptoms 
of rectal cancer as well as encouraging further uptake of the successful bowel 
screening project. 
  
In contrast to a large published series, and following multivariate binary logistic 
regression modelling, we show only statistically significant differences in the 
number of patients receiving an APE in relation to circumferential margin 
positivity. Univariate modelling revealed that patients undergoing APE were 
more likely to be older and have positive circumferential margins than those 
undergoing AR. These differences were then attenuated following adjustment in 
the multivariate model, with the exception of circumferential margin positivity. 
 
These findings differ from previously published series in that a patient is no 
more or less likely to receive an APE in our region according to their sex or 
deprivation. The service in our region appears to be less discriminatory with 
regard to these parameters. 
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Implications for further research 
 
Further work should assess the adherence to both NICE and ACPGBI guidelines 
relating to laparoscopic resections for rectal tumours. A further aspect for 
investigation would be that of node harvest, adherence to the NICE guidance of 
removing and examining a minimum of 12 lymph nodes from their resected 
surgical specimens. 
 
We are not able to accurately assess the height of each rectal tumour from the 
anal verge or proportion of perforated tumours. This would facilitate a far more 
accurate analysis of this population of patients as well as offering further insight 
into the reasons for the observed differences in practice. In addition, 
comparison could be made with other published series. 
 
6.6 Conclusions 
Variation exists in surgical treatment for rectal cancer in the West of Scotland. 
Unlike previously reported findings from elsewhere in the UK, we have been able 
to demonstrate that patients are no more or less likely to undergo an APE 
resection according to their sex, intent of operation or underlying socioeconomic 
circumstances. We therefore conclude that the service being offered to patients 
in our region is currently an equitable one.  
 
We have also confirmed (thus further validating) previous findings that CRM 
positivity retains statistical significance in a multivariate model and is associated 
with an APE resection rather than AR for rectal cancer.  
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7 Final Discussion  
Summary  
 
This thesis completes a more detailed analysis of survival outcomes for 
colorectal cancer patients in the West of Scotland than has been previously 
possible. This has enabled assessment of the degree to which services for 
colorectal cancer patients have affected the likelihood of desired health 
outcomes. I have created a merged dataset combining accurate cancer registry 
data with detailed clinical audit data to provide a unique insight into factors 
contributing to changes in overall survival for colorectal cancer patients since 
the inception of regional multidisciplinary team management strategies in 2001. 
I have also been able to nest current overall survival outcomes in the context of 
long-term survival by comparing contemporary outcomes with historical data 
from the cancer registry. 
 
To understand the impact of a reorganization of services, in this case the MCN, it 
was necessary to understand how survival with colorectal cancer has changed 
over time. This was measured both before and after inception of the novel 
service structure. The unadjusted overall survival figures from chapter three 
initially suggested an increase in overall five year survival with time with a 
disproportionate rise in survival for rectal cancer patients. Further analysis 
demonstrated this increase to be linked to female patients with rectal cancer 
only. 
 
In the MCN era, differences in overall survival across the region’s Health Boards 
and MDTs were seen. We were then able to adjust for known common 
confounders such as age, stage and deprivation to ascertain whether these 
persisted. 
 
After taking these factors into account we found that the observed effects of the 
common confounding variables observed on univariate testing were generally 
attenuated and explained in proportional hazards models. For all curative intent 
surgery on colorectal cancer patients in the West of Scotland we have now 
confirmed that age at incidence, stage of disease, distal margin positivity, 
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extramural vascular invasion, apical node positively and sex (in favour of 
women) were all found to exert significant individual prognostic influence upon 
survival. 
 
Having shown that survival has improved since 2001, to what extent can it be 
explained by known determinants of survival?  Following on from the 
aforementioned results there were new findings. We have now shown that bowel 
preparation exerts no significant survival advantage to patients either 
immediately postoperatively or in longer-term follow-up. We then investigated 
what other aspects of the reorganization might be responsible. Firstly, greater 
specialist care and particular aspects of this care, namely type of resection for 
rectal cancer in the form of APE or AR. With regard to type of resection for 
rectal cancer, the main finding was that there was no statistically significant 
difference in type of operation received in relation to patient’s socioeconomic 
circumstances. This suggests that the disparity noted in other parts of the UK is 
not occurring in the West of Scotland (43,44). 
 
We were able to demonstrate that the influence of socioeconomic circumstances 
did not remain a significant prognostic indicator for long-term overall survival in 
all colorectal cancer patients undergoing elective surgery for their cancer. This 
can be seen as a marker for service quality in that its selection of patients is not 
biased in terms of their deprivation.  
   
Unfortunately our data and analyses are not yet mature enough to be able to 
accurately assess the net impact of the MCN on 5-year overall survival. We are 
able to say that in relation to 3 year overall survival there is a significant 
improvement for rectal cancer patients when comparing figures from 1980 to 
2000 with those after inception of the MCN structure. There also appears to be 
an improvement in 3 year overall survival when comparing all female colorectal 
cancer patients from 1997 to 2000 with those post 2000 (i.e. in the MCN). This 
evidence is encouraging for exponents of MCN care. 
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Quality of data 
 
It has previously been noted that “Scottish health networks have developed 
impressive guidelines for collecting reliable data on the impact of cancer 
services on outcomes” (227). The practicalities of audit data collection vary 
across the West of Scotland.  In some units the main clinical/surgical forms are 
filled in by the surgeon, the pathology form by the pathologist and the 
chemotherapy form filled in by the oncologist. Clinical audit  staff support this 
process. They ensure that the various component audit forms are completed. 
They then attempt to complete missing entries from case note information or by 
referring back to the relevant clinician to attempt a higher rate of 
completeness. This may be a process that could potentially be improved by 
application of lean thinking to allow greater case ascertainment/ accuracy. 
 
Scotland’s cancer registration system compares well with those in other 
countries. Case ascertainment is believed to be approximately 95%. 
Computerised probability linking is quoted as being 99% accurate and procedure 
coding is thought to be correct in the vast majority of cases too (96%) (154). The 
initial, larger, SMR06 dataset is therefore accurate enough to be considered as 
reliable. The second dataset used is derived from the West of Scotland MCN 
database. As highlighted in the results section, there are areas of this dataset 
that vary in terms of their completeness. In some cases there is a disappointing 
trend towards reduction in completeness with time. This has been taken into 
consideration when interpreting results. 
 
The use of linked routine data sources can paint a unique picture unavailable to 
alternative methods of data collection. It transcends the barriers of sample bias 
that can be introduced when dealing with datasets from individual hospitals or 
sets collected by small teams. An advantage of using routinely collected data is 
the insight they provide into the recent past in the West of Scotland. It should 
be borne in mind that the patients have not been recruited into this study thus 
eliminating a further potential source of bias. Whereas results from specialised 
centres may be misleading due to referral bias and the possible effect of 
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specialisation in its own right, cancer registries allow the analysis of true 
epidemiological trends.  
 
A series of 1911 patients in Australia had a 96% ascertainment for Dukes’ staging  
(71). Using Dukes’ stage as an exemplar, our data are 78.8% complete for this 
variable from 1997 onwards but only 74.2% complete from 2001 onwards. This 
may reflect a change in practice from recording Dukes’ stage to TNM in some 
centres. It may also reflect an increase in number of patients deemed to be 
palliative from the outset. This therefore forgoes the need to record their 
Dukes’ stage. 
 
Artefact 
 
Artefact can arise through random error, confounding, and bias. Both random 
error and confounding factors are taken into account in statistical testing. Bias is 
discussed forthwith.  
 
Bias  
 
Bias can be either selection bias or measurement/observer bias. Is what we are 
recording truly an observation of what we are trying to measure or is it odd in 
some way? In order to test this I endeavoured to compare the novel findings with 
those previously published elsewhere. 
 
The linkage of data can introduce bias to the results. Firstly, there are a number 
of cases that inevitably fail to match. This means we are not accounting for the 
entire population of colorectal cancer patient in our analyses.  
 
Selection biases are a further well-known source of bias. There are varying 
numbers of DCO patients with colorectal cancer patients in different countries. 
A proportion of DCO patients will have died of colorectal cancer but may not 
have this fact recorded on their death certificates. This is bound to influence 
incidence and survival estimates. To what extent is not known. 
A certain proportion of patients will escape capture by the MDT and cancer 
registry process. 
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There are a variety of potential reasons why patients may never enter into the 
MDT care pathway for treatment of their colorectal cancer. 
 They are deemed too unwell at time of diagnosis to warrant any further 
intervention and are channelled straight into a palliative care pathway. 
 Other co morbidities and their treatment preclude the patient from being 
assessed by the colorectal MDT, e.g. end-stage organ failure. With time, 
almost all patients are now included in MDT discussion in order to ensure 
their capture i.e. for completeness of audit. 
 Post mortem diagnosis of colorectal neoplasm. 
 Migration to another area of the country. 
 Diagnosis in a private hospital. 
 
We know this is not such a large problem in Scotland as reported elsewhere in 
the UK (198). 
 
Exclusion and restriction of patients from analysis also introduces bias. This is a 
common criticism of the methodology for trials testing effects of 
chemotherapeutic agents. They tend to exclude patients at the extremes of age.  
In terms of exclusion, we omitted patients younger than 15 years and older than 
99 years from analysis. Although this does introduce bias we are primarily 
interested in the effects on survival of patients in this age group as they 
represent the vast majority of those undergoing treatment for colorectal cancer. 
 
Bias and confounders are artifices of the scientific process. They should 
therefore be minimised through rigorous methodology wherever possible. We 
have endeavoured to do this. 
 
Missing information 
 
Following matching of cases in the MCN dataset with those in the registry we 
were then able to assess how much information was missing. The proportion of 
matched cases with unknown values in various variable fields has previously 
been cited as an indicator of data quality. In his Review article Bray states that 
this can be due to problems with “the data collection system, or access to 
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necessary source documents; item and code values that are defined; or 
misapplication of coding rules.” (198) 
 
I have demonstrated in our dataset that there was certainly a degree of missing 
information. Having highlighted above how this information is collected we can 
assume that there are multiple points in the process where missing information 
could arise. Various measures can be instituted to overcome these problems. 
These range from reabstracting and recoding of a proportion of cases by a third 
party. This ensures reproducibility of results amongst data collectors. A 
computer-based, national system where data are entered directly at the time of 
MDT discussion would reduce the number of steps that data take to get from 
MDT to the MCN database. A nationally agreed minimum dataset such as that 
used by the Royal College of Pathologists would provide a baseline with which to 
compare patients across the nation (153). 
Perhaps, in the current climate of data transparency and individual consultant 
performance, the most important of the fields with a large proportion of data 
missing was the “consultant in charge” variable. Had this field been more 
accurate, a far more detailed analysis could have been undertaken relating to 
consultant specific outcomes and specialisation. 
 
In future perhaps a more appropriate methodology would be to apply a multiple 
imputation strategy. This is a validated and standardised way of accounting for 
missing data in epidemiological and clinical research situations and applies to 
most studies as they inevitably have some missing data. A recent review by 
Sterne et al highlights the various types of missing data and their consequences. 
They then go on to describe the application of multiple imputations and 
highlight some pitfalls (228). Results of a survey in the USA comment on 
predictors of completeness for their population (229). They note a marked 
variation for completeness of data when comparing information on patients in 
different hospital types and different age groups. These trends differ with 
respect to type of therapy received.  
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Factors affecting quality 
 
Descriptions of the quality of care can be targeted towards factors regarding 
either access to care, processes of care in hospital and then outcomes of care. In 
this thesis I was concerned with the processes of care and their outcomes.  
I recognise that there are a multitude of factors known to contribute to the 
worldwide variation in the outcomes of cancer care. I was necessarily restricted 
to analysing those regarding colorectal cancer patients in the West of Scotland 
region. Furthermore I was concerned with ascertaining the particular aspects of 
quality care that are potentially modifiable to improve outcomes for colorectal 
cancer patients. I initially summarised long-term outcomes for all colorectal 
cancer patients. I was then trying to dissect the various measurable aspects of 
their care to assess the aspects of care that impact on survival.   
 
Age 
 
Traditionally surgeons tend to evaluate patients on the basis of chronological 
age and not biological age. Novel work in Glasgow regarding biological age of 
tumours could help to provide a more accurate assessment thus improving 
patient selection(230).  
 
The percentage of elderly patients taking part in trials is reported to vary from 
2.5% to 35%. This does not represent the same proportion of these patients in 
the colorectal cancer population though (231). In future, it would be more 
appropriate to both recruit more patients and to recruit those representative of 
the colorectal cancer population. Current guidelines dictate that all colorectal 
cancer MCNs should have an active recruitment drive to clinical trials, especially 
in chemotherapy (135). Recently published data from the NCIN show worse 
relative survival in older populations. Unfortunately we were unable to estimate 
relative survival for our population but we are able to quantify numbers entering 
clinical trials – one of the putative reasons for poorer outcome in this group. In 
the West of Scotland MCN in 2007 only 1.3% of patients were offered a trial and 
accepted. For 4.7% of colorectal cancer patients there was no trial available. 
Overall, 9.2% of the patients were ineligible for trials; 0.6% were offered a trial 
and refused; and 2.9% were not offered a trial for clinical /other reasons. 
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(Vidhya Gunaseelan, data manager for the West of Scotland MCN), personal 
communication). 
These data are unpublished and have not been validated by each of the Health 
Boards but they do point to an area where improvement could be made to 
improve the lot of colorectal cancer patients, particularly the elderly.  
 
Pathology 
 
Employing Kaplan-Meier then multivariate analyses to determine prognostic 
indicators is not a new method in colorectal cancer pathology. Newland et al 
concluded that 6 different variables retained their prognostic significance in a 
multivariate model in 1994. “In order of diminishing potency, these were: apical 
lymph node involvement; spread involving a free serosal surface; invasion 
beyond the muscularis propria; location in the rectum; venous invasion and high 
tumour grade.” (232). The prognostic power of apical node positivity was again 
corroborated by Audisio in 2001 (88). A further paper reports a strong correlation 
between number of lymph node metastases and colorectal cancer patient 
survival (87). Most recently clarification of the prognostic significance of 
peritoneal tumour cells has been sought. Katoh and colleagues concluded that 
for patients with stage III colorectal cancer, peritoneal tumour cells is the most 
significant predictor in relation to risk of recurrence (79). 
Of the aforementioned variables, we have been able to measure most in our 
dataset. We found that apical node positivity correlated very strongly with a 
diagnosis of either Dukes’ C disease. This was therefore acting as a quality 
control measure for the staging data of our patients. Both extramural vascular 
invasion and degree of histological differentiation were also significant on 
univariate analysis. With regard to total number of lymph nodes examined, there 
was no statistically significant difference on univariate analysis when all groups 
were analysed together (n=3285, Log Rank = 0.076). This then became significant 
when the two extreme groups were analysed (log rank = 0.016). Current 
standards dictate that the minimum number of nodes harvested should be 12. 
What is understood is that increasing degree of node harvest increases the 
possibility of finding tumour in a node. This then increases the patient’s chances 
of converting their stage of disease from Dukes’ B to Dukes’ C with implications 
for need for adjuvant chemotherapy.  Our findings would suggest that even 
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increasing the number as high as 19 would confer additional survival advantage, 
but this advantage would perhaps be lost in a multivariate model.  
 
This was not the case for rectal cancer patients though, as there was a slight 
convergence in survival between the two extreme groups at around 6 years post 
incidence. Further confounding factors are the differences in practice among 
pathologists. There are many factors influencing the number of nodes identified. 
Adipose tissue and whether it is mesorectal, mesocolic or subserosal, length of 
specimen, time of fixation, and diligence of pathologist all have bearing on the 
final result. Nodes tend to shrink after chemoradiotherapy and are more difficult 
to find. Inflammation may cause reactive enlargement of nodes so in the setting 
of an adherent, fistulating or perforated tumour it may be easy to find multiple 
nodes. Once the apical node is identified and assessed for positivity, this aids in 
more accurate staging.  
 
Positive lymph node ratio has recently been described as a calculation which 
optimises patient staging and alters patient treatment stratification in relation 
to current practice. This was in a series of 495 colorectal patients spread across 
two hospitals (89). This could be tested in our larger population.  
 
Extramural Vascular Invasion 
 
As demonstrated previously, EVI is a significant prognostic indicator. This 
confirms recent work by Courtney et al whilst refuting the previous hypothesis of 
Jass (76,85). 
 
Circumferential Resection Margin 
 
Circumferential resection margin applies to rectal cancer patients only. We have 
examined the potential role of circumferential resection margin (CRM) positivity 
in relation to predicting survival. CRM status is thought to be a strong positive 
predictor of outcome. It is generally held that a positive CRM has a strong 
correlation with local recurrence, systemic failure and thus poorer survival 
(130,220). The univariate findings from the results section support this in our 
population of 1126 rectal and rectosigmoid patients with a Log Rank of <0.001. 
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This variable was also found to be one of seven variables remaining statistically 
significant in a Cox regression model of 17 separate elements previously found to 
have had a statistically significant impact on survival in Kaplan-Meier models.   
 
Ethnicity 
 
Data on ethnicity are not routinely collected in the West of Scotland despite the 
fact that our region is constantly becoming more ethnically and culturally 
diverse. What is known is that people of Scottish and Irish origin living in England 
have mortality above average compared to English nationals (184). This trend 
was noted to hold true for women from North and West Africa also.  Work by 
Mandelblatt and colleagues has demonstrated a significant difference in the 
mean age at diagnosis of colorectal cancer between differing ethnic groups (73). 
They suggest that this is linked to poverty too. It would be both relevant and 
interesting for this type of data to be collected prospectively in our region to 
ensure there is equality across races and that it translates into equal survival 
outcomes. One such study performed in Middlesex has shown that colorectal 
cancer presents at a significantly younger age in all ethnic minority groups when 
compared to the native Caucasian population with the Asian population 
presenting at the youngest age of all (233). This group also showed a significant 
increase in the number of right-sided lesions in the Afro-Caribbean population 
compared to others. Analysis was limited to 256 patients. This small number is 
the main drawback of the study.  
The most recent paper to report on trends in colorectal cancer in relation to 
race paints a dim picture. DeLancey et al conclude that despite a generalised 
decrease in colorectal cancer mortality since 1975, the disparity between 
blacks’ and whites’ is increasing (234).  
 
Disability 
 
Currently there are no published papers dealing with the issue of disability and 
colorectal cancer surgery or MDT care. One 2006 paper discusses this in relation 
to breast cancer, concluding that inequality in treatment exists. Various reasons 
for this are suggested including social stigmatism, misperceptions about patient 
abilities to cope, quality of life and preferences for care.  
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Type of Admission and Mode of Referral 
 
The most obvious trend in types of admission is the shift in numbers from routine 
to urgent. This occurred between 2003 and 2004. We think this is linked to the 
introduction of Government guidelines for patients with suspected malignancy  
(69). One published audit from a district general hospital of 180 urgent referrals 
challenged the effectiveness of these guidelines. Eccersley and colleagues 
mention that although the chances of having cancer as an urgent referral are 
higher than in other groups, the majority of patients that have cancer are not 
found in this group. They are found outside the new system (70). 
 
It is unsurprising to find that type of admission has a statistical significant 
impact on outcome with emergency admissions having worse outcome compared 
to elective. This holds true after matching for age, stage and deprivation group 
in colon cancer patients only. The type of admission does not retain significance 
in a Cox proportional hazards model for rectal cancer patients. 
Various questions abound regarding type of admission and emergency 
procedures. Firstly, should general surgeons be undertaking emergency 
operations on colorectal cancer patients or should there be a 24 hour on-call 
service for these patients?  
 
A comparison between our data and other published series can also be made in 
terms of admission type. Burton et al demonstrated in 2006 that of their 
emergency cases, the highest proportion were left sided cancers (20%) (235). 
They included sigmoid lesions in this group. Our data also show left sided lesions 
as being the largest proportion of emergency admissions in the West of Scotland. 
Our numbers are much larger and cover an entire region compared to the district 
general hospital population reported by Burton.  
 
Type of admission has previously been correlated with postoperative 
complications. In the first nationwide population based survey of colorectal 
cancer treatment McGrath et al simply noted numbers of patients suffering from 
postoperative complications in emergency cases and elective cases (71). There 
was no attempt to assess whether the differences were statistically significant or 
not. I took this a stage further in this study by examining whether or not there 
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was a significant difference between the main complications and types of 
admission. Only anastomotic leak and wound infection show significant 
differences between types of admission. PE, MI, intra abdominal abscess, fistula 
and DVT appear to occur at similar rates across admission type. 
 
It has been previously noted in the West of Scotland that Deprivation was 
associated with type of admission (65). We have demonstrated within our 
dataset that this trend remains. We examined all 7727 patients, finding a p 
value of 0.001 for the relationship between type of admission and deprivation 
category. 
 
Mode of referral  
 
There has also been a shift in mode of referral with time in our dataset. More 
patients are now being referred to A&E as opposed to colorectal outpatient 
clinics. Whether this represents a breakdown in relationship between primary 
care and secondary care. We have demonstrated that this trend has an adverse 
effect on patient outcomes {{8886 Nicholson,G.A. 2008}}. Whether this trend and 
its effect on survival is replicated in other regions is unknown.  
 
Intent of operation 
 
The decision as to whether or not an operation is deemed palliative or curative 
rests either with the consultant in charge at the time of operation or is decided 
upon postoperatively based on pathological measures. Whilst their opinion 
should be valued as an expert opinion, consultants designating operative intent 
introduces a potential source of bias in the results as they could be inadvertently 
or subconsciously designating a potentially curative operation as palliative. This 
would then exclude that patient from many of the analyses in this thesis.  
 
We compared our findings with other published figures. The overall percentage 
of curative intent procedures in our MCN dataset was 76.4%. This compares well 
with the 78.6% quoted by another Glasgow group from their retrospective study 
of 481 patients with potentially curative colorectal cancer in 2000 (236). 
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These figures are close but the fact that the more recent figure is lower may 
reflect the fact that the selection criteria are in evolution. Patients previously 
deemed suitable for potentially curative resection may now be more likely to 
have a trial of neoadjuvant chemotherapy first or are deemed palliative from 
the outset. The increased precision of MRI for staging rectal cancers also means 
that this subset of patients can be more accurately staged and categorised as 
either curative or palliative. 
 
Type of Operation 
 
Is there significant bias with relation to what type of patient receives what type 
of operation?  A more recent, national perspective on resection for rectal 
cancers showed that socially deprived patients are more likely to undergo APE 
resection than anterior resection. It is though that this negatively impacts 
quality of life in addition to having lower long-term cost-effectiveness for the 
NHS when compared to anterior resection (237). Patients lower on the socio-
economic scale have been found to be more likely to undergo APE than AR for 
cancer (43,44). This goes against the  “high quality of cancer care for all”  ethos 
of  MDTs and the government (The NHS cancer Plan 200). Similarly, another 
finding reported by Morris et al is that throughout England males were 
significantly more likely to receive an APE than females. This finding was 
mirrored by the significant result that women were more likely to receive an 
anterior resection than men (44). The results herein do not confirm the 
aforementioned findings. In our population there was no evidence of a statistical 
difference in either deprivation category or sex when comparing with type of 
operation performed, this was despite employing the same methodology to 
categorise operations. 
 
Morris and co-workers found no significant differences between type of 
operation received and age or stage at presentation. Stage at presentation was a 
statistically significant factor for patients admitted as emergencies only. These 
patients were also more likely to receive a Hartman’s procedure or an anterior 
resection than average. Again, our results disagree with these reported trends. 
We show no significant difference in type of admission. We show a significant 
difference (p = 0.018) in age group and type of operation, and a significant 
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difference upon comparing Stage at presentation with type of operation (p = 
0.007). 
 
Postoperative mortality 
 
Postoperative mortality is seen as a potential area that can be influenced by the 
MDT process. There is reliance upon the skill and experience of pathologist, 
radiologist and surgeon to accurately stage disease. If the correct management 
decisions are made at the time of MDT meeting then patients deemed unfit for 
surgery will not be put at risk of unnecessary operation. This then has a positive 
effect on postoperative mortality rates. Similarly, enhanced recovery 
programmes and improved intra-operative monitoring can maximise 
improvement in postoperative mortality. A recently published series of outcomes 
from 7290 colorectal cancer patients in England quoted an overall operative 
mortality of 6.7% (64). This compares extremely well to our region, where we 
have a rate of 6.8%. I have shown that there is no statistically significant 
difference in thirty-day mortality for all colorectal cancer patients undergoing 
surgery from 1997-2005. These are crude, unadjusted figures. 
 
One area of current interest is whether deprivation has an independent effect on 
peri operative outcome. We have previously demonstrated that no difference in 
stage at diagnosis occurs in relation to deprivation in the West of Scotland so we 
sought to discern whether there was a significant difference in postoperative 
mortality according to deprivation group. Results published by Smith et al found 
deprivation to be an independent risk factor for postoperative death. Another 
recently published paper by Harris et al demonstrated no significant difference 
in postoperative mortality in a series of rectal patients from one hospital MDT 
when comparing deprivation (63). We have been able to confirm these latter 
findings in our population of rectal cancer patients. The advantage we have over 
Harris is that our series covers an entire region. Whilst giving us the benefit of 
larger numbers, we are also introducing the added confounding factors 
associated with measuring aggregate outcomes from many different MDTs in the 
MCN. They will inherently consist of different team members and have a 
different case mix of patients with different surgeons operating on them. 
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We found a similar result when examining the link between deprivation and 
postoperative outcome in 2768 colon cancer patients undergoing surgery with 
curative intent (p = 0.530). There are no currently published series examining 
this in colon patients only however Smith et al found a statistically significant 
result when looking at all colon and rectal cancer patients together. They 
concluded that there must be a cause and effect relationship between 
deprivation and mortality. 
 
We conclude that deprivation does not in itself result in a poor postoperative 
result in our population. In terms of long-term outcome though, deprivation is a 
known individual prognostic indicator in our population. We could reason that 
the process of patient selection for operation, the subsequent management 
delivered, and the peri operative care received are not biased in relation to 
deprivation but that once the patient returns home, there are some 
environmental, social, psychological or underlying biochemical factors that 
somehow contribute to a poorer outcome than their affluent counterparts. 
 
We then went on to explore the intra-regional variations in postoperative 
mortality. We report that there is no statistically significant difference in 
postoperative mortality between the Health Boards or looking at a level below, 
in MDTs. This finding holds true when selecting curative resection patients only. 
It also holds true for emergency admission patients.  
 
Patients not receiving surgery 
 
The main population of interest in this work is those patients having surgery, as 
we are primarily interested in their outcomes. However, a proportion of the 
population did not receive surgery. It was interesting to note how the 
demographics, stage at presentation, type of presentation and DEPCAT of this 
group varied with time. 
 
Sex - Overall 505 (56.6%) male and 387 (43.4%) female. There is very little 
difference here between the patients receiving surgery, 54% male and 46% 
female. We found no significant change in proportion of men to women not 
having surgery despite the fact that women live longer.  
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Age - The majority of patients not receiving surgery were in the >=75 years 
group (54.4% of the total) compared to those receiving surgery (36% of the 
total).   
 
Stage - As one would hypothesise, the vast majority of patients not undergoing 
surgery are those with Dukes’ stage D disease (41.7% of total). This compares to 
only 17.6% in the group of patients that had a surgical procedure. One would 
also expect that a large proportion of the 54.1% of patients without a specified 
stage would also be Dukes’ D.  
 
DEPCAT - The distribution of socioeconomic circumstances in those not receiving 
surgery is very similar to those receiving surgery. 
 
This finding confirms the lack of bias in selection of patients for surgery. This 
holds with time. With a Chi Square value of 0.649 when comparing SEC with year 
of incidence. 
Type of admission – The percentage of patients not receiving surgery and 
presenting as an emergency is higher than that for patients having surgery – 
39.3% compared to 26.1% respectively.  
 
Site of cancer – In the group of patients not receiving surgery there was a far 
higher percentage of patients with rectal lesions compared to those receiving 
surgery (41.0% vs 27.4%) In all other sites, the percentage of patients undergoing 
surgery was higher than those not having surgery.  
 
Patients not undergoing surgery 
 
Patients not undergoing surgery are older and present at a later stage than those 
who have surgery. There appears to be no difference between the groups in 
relation to sex and degree of socioeconomic circumstances. 
Patients who do not undergo surgery are more likely to have a rectal lesion than 
any other site in the large bowel. 
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Time taken to definitive treatment 
 
The Clinical Standards regarding management of bowel cancer services from 
March 2008 state that the time from urgent referral to time of first treatment 
should be no more than 62 days (34). These guidelines are based on two other 
sets of guidelines thus making it unclear as to whether or not there is any 
evidence base to this cut- off point (238,239). Of note is that the mean time to 
wait for all patients was 34.22 days.  
Further univariate analysis of the urgent referrals only revealed that there was a 
significant survival advantage for the patients waiting more than 62 days to first 
definitive treatment. (Log Rank 0.042) This perhaps reflects the clinical 
discretion of the operating surgeon, knowing that some urgent referrals could 
easily wait longer than 62 days without detriment to their outcome. It would 
appear then, that establishing a 62 day rule for time from urgent referral to first 
definitive treatment has no significant survival benefit to patients as it still 
relies upon the surgeon’s experience and judgement. 
  
Stoma type 
 
It is an essential criterion of the Clinical Standards for the management of bowel 
cancer services that permanent stoma rate is not more than 40% in patients with 
rectal tumours. In this way, a permanent stoma (or lack of) is used as a measure 
of surgical performance and a proxy guide for the quality of cancer surgery.  (34) 
 
Following selection of all rectal cancer patients undergoing curative intent 
surgery for their tumour, I have shown that the overall rate of permanent stomas 
is 40.7% in the West of Scotland from 2001 to 2005. This includes patients 
admitted as an emergency. If emergency admissions are removed, the overall 
figure rises by 0.2% but this is influenced by a very high rate in 2001. The 
general trend is for a reduced overall rate with time in rectal cancer patients 
undergoing elective and urgent curative intent surgery.  
 
I have been able to demonstrate in a univariate model that all patients receiving 
a permanent stoma have statistically significantly worse survival when compared 
with those patients with a temporary stoma. Permanent stomas are most likely 
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to be fashioned for patients with low rectal cancer having an APE. When this 
particular group of patients was selected the survival advantage conferred from 
having a temporary stoma was not statistically significant. I have shown that 
with regard to both year of incidence and type of admission there is no 
statistically significant difference in the type of stoma fashioned. Overall 54.2% 
of patients received temporary stomas with 45.8% receiving permanent stomas. 
Further subtype analysis of these groups would determine whether the rate of 
permanent stomas could be reduced. 
 
Limitations exist when analysing stoma types with these data. Firstly, we do not 
know what proportion of temporary stomas were reversed. This is a potential 
source of bias due to misclassification in the results. We are also not able to 
assess accurately how much more ill patients receiving permanent stomas were. 
This would allow adjustments to be made. 
 
Clinical Nurse Specialist 
 
One of the key members, designated part of essential criterion 2b.2 of current 
clinical standards is a cancer clinical nurse specialist (CNS). There is no doubt 
that the role of the CNS is important. Their knowledge and experience help in 
many aspects of the management of patients from clinic, through administration 
to follow-up. There is no doubt that they aid in improving the patient’s overall 
experience and resultant quality of life but can the effect of their intervention 
into a patient’s experience of surviving cancer be objectively measured in some 
way? The simple answer is no, not directly. Despite the role of the CNS in the 
MDT being deemed essential, their input alone provides no currently measurable 
benefit to patient outcome.  
 
Multivariate findings 
 
The purpose of multivariate analysis is to control for known confounding 
variables. This then results in a more accurate assessment of the contribution 
that each of the known univariate variables has on overall survival. In the 
process of analysis further variables may be discovered to have a previously 
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unrecognised influence on survival. The main example from this thesis is that of 
mechanical bowel preparation.  
 
All Colorectal cancer Patients 
 
Of the 2740 colorectal cancer patients undergoing surgical resection with 
curative intent, age at incidence, Dukes’ stage, degree of tumour 
differentiation, distal margin positivity, extra mural vascular invasion, apical 
node positivity, and male gender were all found to contribute independently 
towards a poorer outcome.  These variables have previously been identified as 
prognostic indicators, as mentioned above. 
 
Preoperative and perioperative considerations 
 
Good quality care should begin with a good quality team making good quality 
decisions about carefully selected and staged patients. Before this happens 
though, there is a wait from time of referral to treatment. The Scottish 
Government have now met their 62 day target for colorectal cancer patients 
from date of urgent referral to treatment. I have confirmed in my analysis that 
the length of time from date of incidence to date of first definitive treatment 
was not found play a significant role in the long term survival of curative intent 
colorectal cancer patients.  
 
Even before the decision has been made to operate it is important to appreciate 
that MDT care for patients is associated with a large reduction in variation of 
decision making. Pfeiffer and Naglieri previously demonstrated that decisions 
made by an MDT are superior to those made by team members acting 
independently (39). Their work was regarding patients with learning difficulties. 
More recently, this has been replicated in the upper GI then colorectal cancer 
settings (240,241). 
 
The decision-making process can now be further honed. Various risk 
stratification tools for selected Dukes’ stage B and stage C patients have now 
been validated (77). It is possible that these will be widely adopted into clinical 
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practice as standard ways for ensuring decisions regarding treatment are made 
in a uniform manner.  
 
Preoperative management includes physiological optimisation of patients with 
other comorbidities. The anaesthetist usually oversees this facet of patient 
management. TED stocking and thromboprophylaxis with a low molecular weight 
heparin for all patients is mandatory. These are recommendations laid down by 
SIGN and are regularly audited in MCN reports (105). Antibiotic prophylaxis per-
operatively is also recommended. I have provided evidence herein that there is a 
very high concordance with SIGN guidelines with regard to administration of 
antibiotics. This applies to both elective and emergency surgery. This increased 
number of patients having this variable “not recorded” in 2004 and 2005 is 
disappointing though. 
 
 The use of mechanical bowel preparation remains controversial for rectal 
cancer operations. Its use for colonic resections is now considered unnecessary 
in most elective colonic resections (111). This is mainly due to the similar 
postoperative complication profiles seen in both groups. I have provided 
evidence that the trend in the West of Scotland is towards reduced use of bowel 
preparation for all colorectal cancer patients. I have also shown that in our 
population of elective resections, there is no statistically significant difference 
in postoperative complications between the two groups. This remains of limited 
power though due to the small number of patients suffering complications. 
 One of the main findings from the multivariate analyses was that the use of 
mechanical bowel preparation remained a positive prognostic indicator, even 
following adjustment for other well recognised predictors. The reason for this 
currently remains unknown but a recent experimental pilot study has indicated 
that different types of mechanical bowel preparation can have an objective 
effect on the mucosal cell turnover rate (214). Whether or not these hitherto 
undiscovered mechanisms can influence long-term survival of curative resection 
patients remains to be seen.  
 
Specialist colorectal surgeons resect a larger portion of colon and perform wider 
en bloc dissection when required. This was demonstrated as far back as 1994 
(242). In 2000 a group from the Western Infirmary in Glasgow reported that 
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lower local and overall recurrence rates were achieved by colorectal surgeons 
when compared to vascular or general surgeons. Follow-up in these patients was 
limited with a median period of 45 months. Another limitation was that only two 
specialist colorectal surgeons’ patient outcomes were studied along with six 
vascular / transplant surgeons and four general surgeons (236). Numbers of 
surgeons were therefore small and could not be said to be representative of a 
region. 
 
An additional consideration is that none of the patients studied underwent any 
form of adjuvant chemotherapy or radiotherapy. This means they cannot be 
directly compared to our population in terms of outcomes. 
 
TME revolutionising rectal cancer resections and becoming the gold standard 
operation APR is still necessary in 25% of patients with a lesion within 12cm of 
the anal verge (92) (243). 
 
Postoperative considerations 
 
Postoperative management is again a combination of inputs from different 
members of the MDT. The anaesthetist is usually involved immediately 
postoperatively. Then the roles of the pain team, physiotherapists and surgeon 
come in to play. The stoma team may also have input at this stage. Various 
aspects of postoperative care can again be audited objectively. These are laid 
out in the SIGN 77 publication regarding postoperative management in adults  
(244).  
Care of the patient begins as soon as they attend their primary care physician 
with symptoms or are diagnosed via screening. The quality of their care can 
therefore start being measured from there. The following factors can all 
influence the overall quality of care that a patient  receives: 
 
 Timely diagnosis 
 Correct diagnosis 
 Correct histopathogical and radiological staging 
 Delivery of diagnosis & explanation of treatment 
 Informed consent to treatment 
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 Appropriate neoadjuvant or adjuvant chemo or radiotherapy 
 Education regarding a stoma if appropriate 
 The most suitable operation performed by a suitably trained surgeon 
 Appropriate follow-up 
 
 
Specialist colorectal surgeons resect a larger portion of colon and perform wider 
en bloc dissection when required (242). 
 
Grilli et al concluded in 1998 that “While most studies suggest that cancer 
patients treated at specialized institutions have better outcomes, analysis of the 
process of care does not help to determine why this occurs, as the indicators 
used often have a questionable linkage to outcome” and “Overall, the literature 
in this area suffers from major methodological flaws and is of limited value in 
disentangling the components of specialisation more likely to lead to a better 
process and outcome of care” 
(245) 
 
The most recent Cochrane review for patients treated for non-metastatic 
colorectal cancer has concluded that there is an increased survival benefit from 
intensive follow-up. Although this conclusion may seem common sense it remains 
unclear which elements are the crucial determinants in follow-up and, more 
importantly for the NHS, how cost-effective they are (26). 
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Conclusions 
 
MCN care represents the main management model for colorectal cancer patients 
in the UK. This study acts as the best available analysis of current trends in 
survival for colorectal cancer patients in the West of Scotland as a result of 
having been treated in the first generation MCN. We have demonstrated that 
whilst the overall survival of patients is improving, it is only improving more than 
pre-MDTs for female rectal cancer patients. 
 
We have demonstrated that there is equal entry to the system of care, equality 
in type of operation offered, and equal postoperative outcome for patients 
across the socio-economic spectrum. 
 
There continues to be a disparity in use of bowel preparation in patients 
undergoing elective resections for cancer but this reflects the continued 
worldwide uncertainty as to its use in colorectal cancer surgery. 
 
 We have shown that no significant difference in operative intent between age 
groups (p= 0.827) existed. This again points to a system that is treating patients 
equally. This also bodes well for the aging colorectal cancer population. 
 
It is anticipated that through further evolution, MDT care will force the 
transformation of colorectal cancer from a cause of eventual demise into a 
chronic disease, treatable in the vast majority of cases.  
 
It is clear from the results I have proffered that there remains a great degree of 
heterogeneity in data recording and quality. This is generally accepted as being 
better quality than anywhere else in the UK but still requires to be as accurate 
as possible in order to obtain the most correct and objective results. A recent 
poster presentation pointed to the fact that data quality is improved by clinician 
rather than administrator data recording (246). 
The current situation is for the majority of surgeons to delegate data recording 
to audit staff. The question is whether it would be a better use of their time to 
record data themselves (thus improving quality) or spend more time adequately 
training administrative staff to the degree where there recording of data is on a 
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par with consultants. It is hoped that a real-time online system will replace that 
currently used to reduce the amount of error inherent in the system.  
 
Differences in survival 
 
It is unlikely that each individual MDT will comprise exactly the same elements. 
This is multi-factorial and includes the constraints of local service provision, size 
of each MDT, and experience of its members therein.   
 
Further patients specific factors contributing to the region’s heterogeneity in 
outcomes include: 
 Differing tumour stage at presentation  
 Difference in ratio of palliative to potentially curative procedures 
performed in each MDT  
 Difference in proportions in type of admission 
 Different frequencies of operative complications (related both to type of 
admission and patient co morbidity) 
 Preoperative patient comorbidity 
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8 Future Work 
The analysis of surgical outcomes should play as big a part in clinical governance 
as caring for patients themselves. It is through this continued scrutiny of process 
and results that excellence in patient care will flourish. 
 
This works on micro, meta and macro levels thus involving the MDT, MCN and 
national levels of policy. It is therefore the responsibility of colorectal nurse 
specialists, clinicians, trusts and politicians to detect, investigate and implement 
change on the basis of outcomes. 
 
Laparoscopic resection of colorectal tumours is now a well-validated and 
frequently used technique worldwide. Shorter postoperative hospital stay, 
reduced need for analgesia, improved cosmetic result and quicker return to 
normal bowel function are all benefits of a laparoscopic operation. 
Unfortunately, this modality of treatment is under-utilised and under recorded 
in the West of Scotland compared to most other UK regions.  
 
In future, if data are collected prospectively it would be useful to include BMI, 
amount of exercise taken, whether they’d had a splenectomy, neoadjuvant 
chemotherapy, neoadjuvant chemoradiotherapy, ASA status, and grade of 
anaesthetist as potential predictors in univariate models for inclusion in 
multivariate models. ASA is of particular importance as it would allow simple 
comparison and further validation of an accepted model of mortality risk 
prediction for patients with colorectal cancer (247). 
 
If amount and duration of chemoradiotherapy prescribed are recorded along 
with the proportion of patients that manage to complete the course this offers 
insights into both service quality and service structure. This would be invaluable 
if linked to survival outcome. 
 
Hopefully, the future of colorectal cancer services will see integration of the 
MCN datasets and uniform analysis of outcomes nation-wide. A major issue is 
that there are currently no regionally or nationally integrated data collection 
systems. A bespoke IT system for cancer services, or colorectal cancer in 
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particular, is wanting. This would have a number of obligatory fields for data 
entry thus ensuring an accurate minimum core dataset for all patients for the 
purposes of audit and research. Currently there is no regionally or nationally 
agreed strategy for the process of data analysis. This has the potential to cause 
overlap of analyses or duplication of work within regions. There is also the 
further possibility that data are analysed differently making inter-regional 
comparisons difficult if not impossible, if outcomes are measured in different 
ways. 
 
Ideally, further analyses should encompass all other aspects of MDT care with 
the potential to influence outcome. This includes chemotherapy, radiotherapy, 
imaging, and correlation with biochemical measurements including CRP and CEA. 
 
We have made no attempt to assess the role of enhanced recovery in outcomes 
for colorectal cancer patients. As this is a facet of the care pathway it would be 
worthwhile investigating in the future. 
 
Cause specific and relative survival measures for this population are necessary. 
This allows international comparisons to be made with our regional, and national 
colorectal cancer populations. 
 
Specific points from the MCN dataset: 
 
Operative intent is poorly completed. It has become worse with time. 13.4% in 
2001 to 23.9% in 2005 had no operative intent completed. It acts as an inclusion 
variable for patients. Many were therefore needlessly excluded due to poor data 
collection. It is a further potential source of bias. 
 
Recording of Dukes’ stage has also become worse with time. This is across all 
stages and not simply a reflection of many Dukes’ D palliative patients not being 
recorded. It is not clear whether this is due to the increased use of TNM as a 
preferred method of staging in some hospitals.  
 
Perhaps the worst recorded variable with the potential for greatest impact is the 
consultant in charge variable. Overall, there was a named consultant for 64.8% 
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of patients from 2001 to 2005, however this ranged from 67.8% in 2001 to 59.8% 
in 2004. Without this information it is impossible to calculate accurate volume 
figures for each consultant. 30 day mortality and survival cannot be attributed 
to each consultant nor adjusted for individual case mix. 
 
Relative survival 
 
Relative survival is currently the most accurate way of determining survival in 
cohorts of this type. It tries to overcome the inherent drawback of observed 
survival, namely, that observed survival is always likely to reduce with time in 
older patients as their risk from dying from other causes increases with time. 
Future work should aim to repeat analyses contained herein employing relative 
survival analysis. 
 
Lymph node ratio 
 
Lymph node status remains one of the most important pathological parameters 
measured as presence of tumour in lymph nodes determines the need for 
adjuvant chemotherapy. Although some node negative patients do receive 
chemotherapy this is usually only in the setting of a clinical trial (139). Apical 
node positivity is an independent adverse prognostic indicator. As such it adds an 
extra grade of severity to a patient’s TNM staging. It has been used successfully 
as an adverse prognostic indicator but does this variable have any significance in 
the role of MDT care? 
 
Other considerations using the combined dataset 
 
One useful variable missing from this dataset is an objective measure of 
comorbidity. Would POSSUM therefore be a valid tool for assessment of 
comorbidity in this population? If so, it would then be possible to ascertain what 
extent comorbidity and deprivation act independently or synergistically to lower 
survival? 
 
It would be interesting to assess whether consultants should or do fill-in their 
own audit forms and to what extent does it introduce bias if they do?  
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To help clarify the ongoing issues surrounding follow-up it would be useful to use 
this dataset to determine at what stage in their follow-up do “follow-up 
detected” recurrences occur. This could direct future policy. 
Again, in relation to follow-up, do high volume surgeons follow-up more 
frequently than their lower volume colleagues or vice versa? 
A further level of detail in some of these patients would be assessing whether it 
is possible to link these data with regional laboratory results to examine 
prognostic significance of CEA and LFTs in this large population. Using the data 
in this thesis it would be possible to analyse how survival differs in the subset of 
patients with synchronous/ metachronous tumours. This is a patient group for 
whom there exists a paucity of long-term follow-up and survival data in the 
literature. 
The last consideration would be to include patient data regarding treatment 
with chemotherapy and radiotherapy. It is possible to include these variables in 
order to further ascertain the precise nature of the determinants of improved 
survival and how these manifest through the MDT environment. 
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9 Appendix 
MCN Data Collection Proformas 
 
9.1 General demographics and details proforma 
9.2 Pathology form 
9.3 Oncology form 
9.4 Nursing form 
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Patient Demographic Details  - use patient label if available 
Forename ............................................................................  
Surname  ............................................................................  
Address   .............................................................................  
..............................................................................................  
 Postcode  ............................................................................ 
CHI No........................................................................... 
Date of birth .................................................................. 
Sex Male  Female  
Hospital of Diagnosis .................................................... 
Unit Number ................................................................. 
Referral and 1st Presentation for Colorectal Symptoms 
Date of cancer referral ...... /........../ ..........  
Date referral received ...... /........../ ..........  
Type of presentation Emergency  
Elective  Not recorded 
Urgency of referral Urgent  
Soon   Routine  Not recorded  
Source of cancer referral  
Primary Care Clinician  ColoR screening  
 Incidental  Review clinic  
 Cancer Genetic Clinic  Self referral to A&E  
GP ref directly to A&E  Not recorded  
 Referral from private healthcare  
Clinical Contacts (Clinician/Consultant in Charge along patient pathway for colorectal cancer) 
 
Clinician 1 ........................................... 
 
Clinician 2 ........................................... 
 
Clinician 3 ........................................... 
 
Clinician 4 ........................................... 
 
Specialty ..........................................  
 
Specialty ..........................................  
 
Specialty ..........................................  
 
Specialty ..........................................  
 
Date first seen ........ / ........ /..........  
 
Date first seen   ........./ ........ /..........  
 
Date first seen   ........./ ........ /..........  
 
Date first seen   ........./ ........ /..........  
Diagnostic Investigations (pre and peri-operative) 
Primary tumour Performed Completed  Cancer No cancer Equivocal Not recorded 
Rigid siggy Y   N   Y   N       
Flexible siggy Y   N   Y   N       
Colonoscopy Y   N   Y   N       
Ba Enema Y   N   Y   N       
CT colonography Y   N   Y   N       
Water soluble 
contrast enema Y   N   Y   N       
Metastatic Disease Performed  Cancer No cancer Equivocal Not recorded 
Chest x-ray or CT Y   N       
Liver: CT   
 MRI   
   US   
Y   
Y   
Y   
N   
N   
N   
 
 
 












Site of Primary Tumour 
Caecum    Appendix    Ascending colon    
Hepatic flexure   Transverse colon    Splenic Flexure    
Descending colon    Sigmoid colon    Colon unspecified    
Rectum   Not recorded     
For synchronous tumours rather than ticking the box please mark poorest stage as 1, and then next as 2 and so on. 
Date of Diagnosis ............ /............./ ...........  
(pre-operative)  
Mode of diagnosis Histology   Cytology   
 Imaging   Clinical   
Management 
Mode of first treatment Surgery   Endoscopic treatment   RT   Chemo   ChemoRT   
Other therapy   No active treatment   Pt refused all therapies    Pt died before trt   Not recorded   
254 
 
 
 
 
 
 
 
 
Managed Clinical Network for Colorectal Cancer 
Pathology Data 
 
Patient Demographic Details  - use patient label if available 
Patient name ....................................................................... 
Date of birth ....................................................................... 
Hospital  .............................................................................. 
Date of operation ........./ ........ / .........  
Surgeon  .............................................................................. 
Date of receipt ........./ ........ / .........  
Sex Male  Female  
CHI No...............................................................  
Unit No................................................................   
Path Report No .................................................  
Pathologist .........................................................  
Date of reporting.........../ ............ / .............  
Gross Description Metastatic Spread 
Site of tumour ...................................................................... 
Maximum tumour diameter: ......................mm 
Distance of tumour to nearer longitudinal margin .........mm 
Presence of tumour perforation (pT4) Yes  No  
Number of lymph nodes examined ............... 
Number of positive lymph nodes.................. 
(pN1 1-3 nodes, pN2 4+ nodes involved) 
Apical node positive (Dukes C2) Yes  No  
 Not identifiable ? 
Extramural vascular invasion Yes  No  
Rectal tumours Background abnormalities 
Tumour is: Above  At  Below  the peritoneal 
reflection 
Distance from the dentate line (AP only): ........... mm 
Histology 
Type:   Adenocarcinoma Yes  No  
(to include mucinous and signet ring adenocarcinoma) 
If no, other .................................................................  
 
Differentiation by predominant area: 
Well  Moderate  Poor  Undifferentiated  
Adenoma(s) Yes  No  
Synchronous carcinoma(s) Yes  No  
(Please complete a separate form for each tumour) 
Ulcerative colitis Yes  No  
Crohn’s disease Yes  No  
Familial adenomatous polyposis Yes  No  
 
Other comments.............................................................  
Local invasion Pathological staging 
Submucosa (pT1)  
Muscularis propria (pT2)  
Beyond muscularis propria (pT3)  
Tumour cells have breached the peritoneal surface  
or invaded adjacent organs (pT4) 
Tumour involvement 
Tumour involvement N/A Yes No 
Doughnut    
Margin (cut end)    
Peritoneal surface    
Non peritonealised margin    
Residual tumour biopsy    
Rectal tumours only  
Circumferential margin    
Histological measurement from tumour to circumferential 
margin: ............mm 
Complete resection at all margins Yes  No  
 
TNM pT pN pM 
 
Dukes 
Dukes A (growth limited to wall, nodes negative)  
Dukes B (growth beyond muscularis propria,  
nodes negative) 
Dukes C1 (nodes positive and apical node negative)  
Dukes C2 (Apical node positive)  
Histologically confirmed liver mets Yes  No  
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Managed Clinical Network for Colorectal Cancer 
Pathology Data 
 
Additional Comments and Notes 
 
 
 
 
 
 
 
 
These data are collected on behalf of the Managed Clinical Network for Colorectal Cancer 
On completion, please forward this form to your local Audit Support Office 
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Managed Clinical Network for Colorectal Cancer 
Oncology Data 
 
Patient Demographic Details  - use patient label if available 
Patient name ......................................................................  
Date of birth .......................................................................  
CHI No  ..............................................................................  
Hospital  .............................................................................  
Name of Consultant Oncologist  ......................................  
Sex Male  Female  
Postcode.............................................................  
Unit No ...............................................................   
 
Date first seen ........./ ........ / .........  
If no treatment:  Patient refused  Patient too frail  Died prior to treatment Inappropriate  
Radiotherapy Primary radical ? Pre-operative? Post operative ?  
Date first seen ............ / ............... /.................  Site of Radiotherapy ............................................  
Type of radiotherapy: Adjuvant preoperative  Adjuvant postoperative  Chemoradiotherapy  
Primary radical  Palliative (totally inoperable)  None-no documented contraindication  
None-documented contraindication  Patient refused treatment   Not recorded  
Date radiotherapy started ............ / ............ /.............. Date radiotherapy completed .. ............ / ............/ .............  
Total dose administered ..................................... cGy Not recorded  
Total fractions given..................................................  Not recorded  
Treatment completed Yes  No  Not recorded  
Specify reason if treatment incomplete ..............................................................................................................   
Chemotherapy 
Type of chemotherapy: Adjuvant  Neoadjuvant  Primary  Palliative  None-no documented  
contraindication  None-documented contraindication  Patient refused treatment  Not recorded  
Date chemotherapy started ............ / ............ /.............. 
Chemotherapy agent: Bolus FUFA over 5 days every 4 weeks  Bolus FUFA weekly   
Intermittently infused FUFA (Bosset)  (+ RT) ? Continuous flourouracil (Lokich)  (+RT)  Bolus FUFA (+RT)  
FUFA infusion (de Gramont)  Capecitabine  Raltitrexed  Not recorded  Inapplicable  
Route of delivery: Intravenous  Portal vein infusion  Oral  Intra-arteria l? Not recorded  Inapplicable  
Treatment completed Yes  No  Date chemotherapy completed ................/ ............ / .............  
Specify reason if treatment incomplete ..............................................................................................................  
Clinical Trials 
Patient entered in clinical trial: Yes  No  Ineligible  Patient refused  Not offered  
No trial available  Not recorded   Trial entry date ............ / ............ /.............. 
Trial entered: QUASAR  CLASSIC  CRO7  EORTC/CITCCG 40983  FOCUS  VICTOR 
 CLOCC  Not recorded  
Other  Please specify ...................................................................  Outwith trial  
If patient is entered in more than one trial please indicate by ticking all relevant boxes. 
Death Details PATIENT HAS DIED Yes  No  
Date of death ............ / ............ /.............. 
Primary cause of death: Colorectal cancer  Other cancer  None cancer death ?Surgical treatment related  
Radiotherapy treatment related  Chemotherapy treatment related  Not recorded   
Other, specify ........................................ 
Additional Comments and Notes may be written on the reverse of this form 
These data are collected on behalf of the Managed Clinical Network for Colorectal Cancer 
On completion, please forward this form to your local Audit Support Office 
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West of Scotland Managed Clinical Network for Colorectal cancer 
Nursing Data 
 
 
 
 
 
Nursing Data 
 
Patient Demographic Details  - use patient label if available 
Forename ..................................................................... 
Surname  ...................................................................... 
Address   ...................................................................... 
....................................................................................... 
....................................................................................... 
 Postcode  ...............................................................  
CHI No ....................................................................  
Unit No ......................................................... 
Date of birth ........... / ........... / ............  
 
Sex Male Female  
 
Hospital of Diagnosis .............................................  
 
Referral 
Previous referral to Cancer Genetic Clinic Yes  No Pt refused Not recorded 
Referred to Stoma Care Nurse?  Yes  No  If yes:   Pre-op Post-op  
Date of referral to Stoma Care Nurse ........... /........... /............  
Primary assessment by Stoma Care Nurse?   Yes No  If yes: Pre-op Post-op  
Date of assessment by Stoma Care Nurse ........... /........... /............  
Stoma site marked pre-operatively by the Stoma Care Yes  No  N/A  
Nurse Specialist or appropriately trained person? 
Referred to Colorectal Nurse Specialist?  Yes  No  If yes: Pre-op Post-op 
Date of referral to Colorectal Nurse Specialist  / /  
Primary assessment by Colorectal Nurse Specialist?  Yes  No  If yes:  Pre-op     Post-op 
Date of assessment by Colorectal Nurse Specialist ........... /........... /............  
MDT  
Nurse Specialist present at pre-treatment  
multidisciplinary team review? Yes  No  N/A  Date ........... /........... /............  
 
Nurse Specialist present at post-operative 
multidisciplinary team review? Yes  No  If yes: Date ........... /........... /............
  
Information and communication  
CNS present when patient is given diagnosis? Yes  No  If yes: Date ........... / ........... /............  
 
Patient given information by the named Nurse Specialist  Verbal Yes  No  Declined  
regarding their disease and treatment ?  Written Yes  No  Declined  
 
Information given relating to stoma and stoma care? Verbal Yes  No  Declined  N/A  
 Written Yes  No  Declined  N/A  
 
Was the patient issued with relevant contact telephone  
numbers to access information, advice and support?   Yes  No   
 
Family History Yes  No  Not recorded  
 
Referral to Cancer Genetic Clinic Yes      No  Pt refused  
 
Comments 
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9.5 Data agreement 
 
 
 
 
 
 
West of Scotland Cancer Network 
 
Data Sharing Agreement 
 
 
 
This document is a formal agreement between the West of Scotland Cancer Network and the recipient(s) of the 
data described herein.  This agreement requires that the data provided are used only for the purposes stated in this 
agreement and that access to these data is restricted only to those persons stated.  Use of these data is conditional 
on adherence to the following: 
 
1. Data provided will, at all times, be used and stored in accordance with local NHS policies and guidance and in 
accordance with the following legislation and guidance: 
 
a. Data Protection Act 1998 
b. Human Rights Act 1998 
c. Common Law Duty of Confidentiality 
d. Freedom of Information (Scotland) Act 2002 
e. Caldicott Guidance 
 
2. Data remain, at all times, the property of the source hospital which reserves the right to withdraw their data at 
any time. 
 
3. Access to data shall be limited to those individuals who require it.  
 
4. Appropriate administrative, technical and physical safeguards will be established to protect the confidentiality 
of data and to prevent unauthorised use or access to it. 
 
5. Publication of results from analyses of these data will require explicit approval of the relevant disease-specific 
MCN Advisory Board or it’s designated group or individual to which these results will be provided in full. 
 
6. The results from the analyses of data will be provided only to stated recipients.   
 
7. Linkage with other data sets described in this agreement should not involve the transfer of MCN data to any 
other party or system unless stated in this agreement. 
 
8. Following completion of the specified work, unless otherwise stated in this agreement, all data supplied must 
be deleted and the MCN Office must be notified in writing that this has been done. 
 
 
Data requested by: 
(please print name, 
designation and 
organisation) 
David S Morrison 
Director 
West of Scotland Cancer 
Surveillance Unit 
Date requested: 
14 March 2008 
 
Main data user and 
contact (name, 
designation, 
organisation and 
location): 
Mr Gary Nicholson 
Surgical Research Fellow 
West of Scotland Cancer 
Surveillance Unit 
1 Lilybank Gardens, Glasgow, 
G12 8RZ 
Contact details: 
 
Email: 
garynicholson@nhs.net 
Tel: 
0141 330 3281 
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The eight variables available for analysis from 1980 onwards. 
Variable N % completeness 
Unique patient identifier 37,966 100 
Sex 37,966 100 
Date of incidence 37,966 100 
Site of cancer 37,966 100 
Health Board of residence 37,966 100 
Local council area 37,964 99.9 
Deprivation category 37,964 99.9 
Date of death 32152 Not applicable* 
* many patients would still be alive 
 
The four additional variables available from 1997 onwards. 
Variable Number of entries % completeness 
Earliest date of surgery 14098 78.9 
Age at surgery 11063 78.5 
Dukes’ stage at diagnosis 14098 100* 
Therapy objectives 14098 83.6 
* This includes “stage not specified” as an entry into the field, hence 100% 
completeness. 
 
From 2001 onwards, the following remaining variables were recorded for all 
patients with COLORECTAL CANCER in the West of Scotland 
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0 50 100
Anastomosis fashioned
Wound infection
Water Soluble contrast enema
Type of admission
TME
Stoma created
Seen by clinical nurse specialist
Name of consultant
Multiple primary tumours
Mode of referral
Mode of presentation 
Mode of 1st treatment
MI post-op
Mechanical bowel prep
Intra-abdominal abscess
Hospital of surgery
Hospital of diagnosis
Grade of operating surgeon
GP referral date
Fistula formation
Family history
Evidence of mets
DVT prophylaxis
DVT
Date seen by stoma nurse
Date of contrast barium enema
Date discussed at MDT
CT pneumocolon
Colonoscopy
Chest X-ray performed
ASA grade
Antibiotic prophylaxis
Anastomotic leak
% completeness
n
a
m
e
 o
f 
fi
e
ld
% completeness for all Fields from 
2001 Onwards
 
Pathology variables and their respective completeness from 2001 to 2005. 
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Table of sites of cancer for all duplicate cases identified 
site of cancer 
ileocaecal valve 
187 12.5 
  
ascending colon 
108 7.2 
  hepatic flexure 40 2.7 
  
transverse colon 
129 8.6 
  splenic flexure 31 2.1 
  
descending colon 
81 5.4 
  
Sigmoid colon (excluding  
272 18.1   
rectosigmoid junction) 
  
Overlapping lesion of colon 
8 0.5 
  
Colon, unspecified 
249 16.6 
  
rectosigmoid junction 
86 5.7 
  Rectal ampulla 311 20.7 
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9.6 OPCS Coding for APE and AR procedures 
 
 
OPCS 
code group Category OPCS definition 
    
H331     1 APE 
ABDOMINOPERINEAL EXCISION OF RECTUM 
AND END COLOSTOMY                            
H332     2 AR 
PROCTECTOMY AND ANASTOMOSIS OF COLON 
TO ANUS                                     
H333     2 AR 
ANT.RESECT.RECTUM AND ANASTOMOSIS OF 
COLON TO RECTUM USING STAPLES               
H334     2 AR 
ANTERIOR RESECTION OF RECTUM AND 
ANASTOMOSIS- NOT ELSEWHERE CLASSIFIED           
H335     3 Hartmann's 
RECTOSIGMOIDECTOMY & CLOSURE OF 
RECTAL STUMP & EXTERIORISATION OF BOWEL          
H336     2 AR 
ANTERIOR RESECTION OF RECTUM AND 
EXTERIORISATION OF BOWEL                        
H338     4 
Excision of rect 
unspecified OTHER SPECIFIED EXCISION OF RECTUM                                               
H339     4 
Excision of rect 
unspecified UNSPECIFIED EXCISION OF RECTUM                                                   
H041     4 Panproctocolectomy PANPROCTOCOLECTOMY AND ILEOSTOMY                                                 
H042     4 Panproctocolectomy 
PANPROCTOCOLECTOMY- ANAST. ILEUM TO 
ANUS AND CREATION OF POUCH- H.F.Q.           
H043     4 Panproctocolectomy 
PANPROCTOCOLECTOMY AND ANASTOMOSIS 
OF ILEUM TO ANUS- N.E.C.                      
H048     4 Panproctocolectomy 
OTHER SPECIFIED TOTAL EXCISION OF COLON 
AND RECTUM                               
H049     4 Panproctocolectomy 
UNSPECIFIED TOTAL EXCISION OF COLON AND 
RECTUM                                   
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H051     4 Total colectomy 
TOTAL COLECTOMY AND ANASTOMOSIS OF 
ILEUM TO RECTUM                               
H052     4 Total colectomy 
TOTAL COLECTOMY AND ILEOSTOMY AND 
CREATION OF RECTAL FISTULA- H.F.Q.             
H053     4 Total colectomy 
TOTAL COLECTOMY AND ILEOSTOMY- NOT 
ELSEWHERE CLASSIFIED                          
H058     4 Total colectomy OTHER SPECIFIED TOTAL EXCISION OF COLON                                          
H059     4 Total colectomy UNSPECIFIED TOTAL EXCISION OF COLON                                              
H101     4 
Excision of sigmoid 
colon 
SIGMOID COLECTOMY AND END TO END 
ANASTOMOSIS OF ILEUM TO RECTUM                  
H102     4 
Excision of sigmoid 
colon 
SIGMOID COLECTOMY AND ANASTOMOSIS OF 
COLON TO RECTUM                             
H103     4 
Excision of sigmoid 
colon 
SIGMOID COLECTOMY AND ANASTOMOSIS- 
NOT ELSEWHERE CLASSIFIED                      
H104     4 
Excision of sigmoid 
colon 
SIGMOID COLECTOMY AND ILEOSTOMY- 
HOWEVER FURTHER QUALIFIED                       
H105     4 
Excision of sigmoid 
colon 
SIGMOID COLECTOMY AND EXTERIORISATION 
OF BOWEL- N.E.C.                           
H108     4 
Excision of sigmoid 
colon 
OTHER SPECIFIED EXCISION OF SIGMOID 
COLON                                        
H109     4 
Excision of sigmoid 
colon UNSPECIFIED EXCISION OF SIGMOID COLON                                            
H091     4 
Excision of left 
hemicolon 
LEFT HEMICOLECTOMY AND END TO END 
ANASTOMOSIS OF COLON TO RECTUM                 
H092     4 
Excision of left 
hemicolon 
LEFT HEMICOLECTOMY AND END TO END 
ANASTOMOSIS OF COLON TO COLON                  
H093     4 
Excision of left 
hemicolon 
LEFT HEMICOLECTOMY AND ANASTOMOSIS- 
NOT ELSEWHERE CLASSIFIED                     
H094     4 
Excision of left 
hemicolon 
LEFT HEMICOLECTOMY AND ILEOSTOMY- 
HOWEVER FURTHER QUALIFIED                      
H095     4 
Excision of left 
hemicolon 
LEFT HEMICOLECTOMY AND EXTERIORISATION 
OF BOWEL- N.E.C.                          
H098     4 Excision of left OTHER SPECIFIED EXCISION OF LEFT 
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hemicolon HEMICOLON                                       
H099     4 
Excision of left 
hemicolon UNSPECIFIED EXCISION OF LEFT HEMICOLON                                           
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9.7 Search strategy for literature review 
CINAHL combined search  
1. cancer.mp. 
2. Calman-Hine.mp. 
3. Specialisation.mp. 
4. Multidisciplinary team.mp. 
5. Managed Clinical Network.mp. 
6. 1 and 2 and 3 and 4 and 5 
7. 1 and 2 
8. 3 and 7 
9. 3 and 4 
10. from 7 keep 1,3,5,8-9,14,17 
 
Outcome of Calman Hine Cinahl  
Library search strategy  
1. exp Neoplasms/ 
2. exp Colon/ 
3. exp Rectum/ 
4. 1 and (2 or 3) 
5. ((colo$ or rect$) adj5 (cancer$ or neoplas$)).mp. 
6. exp Colorectal Neoplasms/ 
7. or/4-6 
8. (managed adj3 network$).mp. 
9. exp "Quality of Health Care"/ 
10. exp Health Care Delivery/ 
11. exp Health Policy/ 
12. exp Practice Guidelines/ 
13. exp Managed Care Programs/ 
14. or/8-13 
15. exp Treatment Outcomes/ 
16. exp Survival/ 
17. exp Cancer Survivors/ 
18. exp Survival Analysis/ 
19. exp Study Design/ 
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20. or/15-19 
21. 7 and 14 and 20 
22. calman hine.af. 
23. 21 or 22 
24. exp Cancer Screening/ 
25. exp Colorectal Neoplasms/pc [Prevention and Control] 
26. or/24-25 
27. 23 not 26 
 
 
HMIC database search  
1. Adenocarcinoma/ or Colorectal Neoplasms/ or management of colorectal 
cancer.mp. 
2. limit 1 to (full text and humans and "review articles") 
3. "Delivery of Health Care"/ or Program Development/ or Scotland/ or managed 
clinical network.mp. or Program Evaluation/ or Managed Care Programs/ 
4. 1 and 3 
5. from 4 keep 18,43,48,57,73,76-77,91,93,100-101,105-106,122-125,134,156 
6. Managed clinical network.mp. 
7. from 6 keep 1,3,5,8,10,12,15-18 
8. from 7 keep 1-10 
9. from 6 keep 1,4,6-8 
10. from 6 keep 1-8 
11. colorectal cancer.mp. or exp colorectal cancer / 
12. exp CANCER SERVICES/ or exp NHS/ or exp INTERPROFESSIONAL 
COLLABORATION/ or exp managed clinical networks/ or exp SERVICE PROVISION/ 
or managed clinical network.mp. or exp SCOTLAND/ 
13. 11 and 12 
14. from 13 keep 8,21,23-25,27,32-34 
 
Initial EMBASE  
1. Adenocarcinoma/ or Colorectal Neoplasms/ or management of colorectal 
cancer.mp. 
2. limit 1 to (full text and humans and "review articles") 
268 
3. "Delivery of Health Care"/ or Program Development/ or Scotland/ or managed 
clinical network.mp. or Program Evaluation/ or Managed Care Programs/ 
4. 1 and 3 
5. from 4 keep 18,43,48,57,73,76-77,91,93,100-101,105-106,122-125,134,156 
6. Managed clinical network.mp. 
7. from 6 keep 1,3,5,8,10,12,15-18 
8. from 7 keep 1-10 
9. from 6 keep 1,4,6-8 
10. from 6 keep 1-8 
 
Outcome of Calman Hine Medline  
Library search strategy  
1. exp Neoplasms/ 
2. exp Colon/ 
3. exp Rectum/ 
4. 1 and (2 or 3) 
5. ((colo$ or rect$) adj5 (cancer$ or neoplas$)).mp. 
6. exp Colorectal Neoplasms/ 
7. or/4-6 
8. exp Cancer Care Facilities/ 
9. exp Guideline Adherence/ 
10. exp Practice Guidelines/ 
11. exp Medical Oncology/st 
12. exp Managed Care Programs/ 
13. (managed adj3 network$).mp. 
14. or/8-13 
15. exp Treatment Outcome/ 
16. exp "Outcome Assessment (Health Care)"/ 
17. exp Survival Analysis/ 
18. exp Survival Rate/ 
19. exp Epidemiologic Methods/ 
20. or/15-19 
21. 7 and 14 and 20 
22. calman hine.af. 
23. or/21-22 
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24. exp *Diagnostic Imaging/ 
25. exp Mass Screening/ 
26. exp *Mass Screening/mt [Methods] 
27. exp *Colonoscopy/ 
28. exp Colorectal Neoplasms/pc [Prevention & Control] 
29. or/24-28 
30. 23 not 29 
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